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"If we stop asking the question 'what breaks tolerance' and begin to focus on the 
vast array of possibilities for each disease, we may begin to understand their 
multigenic nature" (Matzinger, 1998). 
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ABSTRACT 
A Study of the Molecular Immunogenetics of Type 1 Diabetes in Man 
Mohamed Mirza Jahromi 
Type I diabetes is caused by immune destruction of pancreatic p cells. There is 
increasing evidence that genes outside the MHC region contribute to the pathogenesis of 
type I diabetes. Cytokines due to their role in immune regulation seem to play a crucial 
role in the pathogenesis of the disease. Three hundred and eight patients with type I 
diabetes and 150 normal controls were genotyped for polymorphism in the genes for 
IFN-y, IL-4, IL-6, and TGF-PI. All assays employed in this study were PCR based. The 
IFN-y CA repeats was an octa-allelic repeat and the 3 I 3 genotype showed a significant 
association with type I diabetes (p=O.OOO I). The IL-4 C ( -590) T polymorphism did not 
show a significant association with type I diabetes. The GG genotype ofG (-174) C of 
the IL-6 gene polymorphism showed a strong association with the susceptibility towards 
type I diabetes (p= 0.002). The TC genotype of the TGF-P I T (+869) C polymorphism 
also showed a significant association with type I diabetes (p= 0.003). The association of 
the 3 I 3 genotype of the IFNG CA repeats and no association of IL-4 C (-590) T 
polymorphism may support the idea of dominance of the TH I cytokine profile and type 
I diabetes suggesting a cell mediated disease. The IL-6 G ( -174) C result attests an 
existing hypothesis of the important role of IL-6 in the onset of type I diabetes and its 
development. Immunosuppression of the TGF-P I may have been initiated after 
deviation of the THIITH2 cytokine milieu. The GC of the IL-6 G (-174) C and the TC 
of the TGF-PI T (+869) C showed strong association with diabetic nephropathy. 
Haplotype studies showed that cytokine function might be as a result of a cytokine 
network rather than individual cytokines. Further, the genetic susceptibility may be 
influenced not only by genetic composition but by the gender of patients as well as age 
at onset of type I diabetes. In conclusion these results suggest a contribution of the 
IFNG CA repeats, the TGF-p I T ( +869) C, and the IL-6 G ( -174) C to the genetic 
susceptibility of type l diabetes and may have future therapeutical values. 
IV 
,, 
LIST OF CONTENTS ...................................... . Page No 
CHAPTER 1: INTRODUCTION ........................................................ l 
1.1 
1.1.1 
1.1.2 
1.2 
1.2.1 
1.2.1.1 
1.2.1.2 
1.2.1.2.1 
1.2.2 
1.2.2.1 
1.2.3 
1.2.4 
1.2.5 
1.3 
1.3.1 
1.3.1.1 
1.3.1.1.1 
1.3.1.1.2 
1.3.1.1.3 
1.3.1.1.4 
1.3.1.1.5 
1.3.1.1.6 
1.3.1.2 
Categories of immune diseases 
Organ-specific autoimmune diseases 
Systemic autoimmune diseases 
Elements of the immune response 
Lymphocytes 
B cells 
T cells 
T cell receptor 
Major histocompatibility complex 
The structure of the MHC molecule 
Antigen presenting cells 
Monocyte/macrophages 
Dendritic cells 
Cytokines, as molecules which 
phagocytes, and other cells of the body 
Classification of cytokines 
Macrophage-derived cytokines 
Tumour necrosis factor 
Interleukin-1 
Interleukin-6 
Interleukin-15 . 
Interleukin-12 
signal 
Chemokines, IL-8 and the small cytokine family 
T helper 1 cytokines 
V 
between 
2 
2 
2 
3 
3 
4 
4 
8 
9 
12 
16 
16 
lymphocytes, 
18 
20 
24 
25 
25 
26 
28 
29 
30 
32 
1.3.1.2.1 lnterleukin-2 32 
1.3.1.2.2 Interferon-y 33 
1.3.1.3 T helper 2 cytokines 34 
1.3.1.3.1 lnterleukin-4 34 
1.3.1.3.2 Interleukin-1 0 37 
1.3.1.4 T helper 3 cytokine 38 
1.3.1.4.1 Transforming growth factor 38 
1.4 Immunoregulatory mechanisms 44 
1.4.1 Cytokines involved in peripheral tolerance 46 
1.5 Theories of immunity 48 
1.5.1 Autoimmune diseases in light of the "SNS" and "Danger" 
model 48 
1.5.1.1 When there is an unrecognised ongoing infection in the target 
organ 49 
1.5.1.2 Molecular mimicry 49 
1.5.1.3 Bad death 50 
1.5.1.4 Whenever the response is a result, not a cause, of a disease 50 
1.5.1.5 The response switches to a harmful class 51 
1.6 Type 1 diabetes 52 
1.6.1 Classification of diabetes mellitus 52 
1.6.2 Long term complications of diabetes 54 
1.6.2.1 Diabetic nephropathy 54 
1.6.2 .. 2 Diabetic neuropathy 55 
1.6.2.3 Diabetic retinopathy 56 
1.6.3 Mechanisms underlying the anti-~ cell autoimmune response 56 
1.6.3.1 Environmental factors 56 
1.6.3.1.1 Viruses 58 
VI 
1.6.3.1.2 The cow's milk hypothesis 59 
1.6.4 Genetic susceptibility 60 
1.6.4.1 Twin studies 60 
1.6.4.2 Familial clustering 61 
1.6.5 Dissection of the genetic components 63 
1.6.5.1 The MHC genes, the HLA cluster (IDDMJ) 65 
1.6.5.1.1 HLA and cytokines 68 
1.6.5.2 The insulin gene region (IDDM2) 71 
1.6.5.3 Other susceptible genes 73 
1.6.6 Humoral immunity 74 
1.6.6.1 Cytokines involved in humoral immunity 75 
1.6.7 Cellular immunity 76 
1.6.8 Cytokines in autoimmune diseases 77 
1.6.8.1 TH l!TH2 cytokine profile 79 
1.6.9 Cytokine signalling 82 
1.7 Cytokine genes polymorphism 85 
1.7.1 The IL-l gene cluster 85 
1.7.2 The TNF-a and ~ loci 86 
1.7.3 The IFN-y locus 86 
1.7.4 The IL-4 loci 87 
1.7.5 The IL-6 locus 89 
1.7.6 The TGF-~ I locus 89 
1.8 Aims of this study 90 
CHAPTER 2: MATERIALS AND METHODS ..................... 92 
2.1 
2.1.1 
Study subjects 
Patients 
VII 
92 
92 
2.1.1.1 Patients with type I diabetes 92 
2.1.1.2 Long tenn complications of diabetes 93 
2.1.1.3 Familial clustering 93 
2.1.2 Control subjects 93 
2.1.2.1 Nonnal controls 93 
2.1.2.2 Diabetic controls 93 
2.2 Materials 97 
2.2.1 Water 97 
2.2.2 Reagents 97 
2.2.3 Enzymes and buffers 97 
2.2.4 Stock solutions 98 
2.3 Autoclaving 98 
2.4 Genomic DNA isolation from peripheral blood leucocytes 99 
2.4.1 Detennination of DNA concentration and purity 100 
2.5 Linkage markers 101 
2.5.1 Polymerase chain reaction 101 
2.5.2 Microsatellite analysis 104 
2.5.3 Endonuclease restriction enzymes 106 
2.5.4 Amplification refractory mutation system 108 
2.6 Association studies 110 
2.6.1 Case control studies 110 
2.6.2 Family based transmission disequilibrium test 110 
2.7 . Analysis of the IFN-y gene polymorphism 113 
2.7.1 Oligonucleotide design and production 113 
2.7.2 5' -endolabelled amplimer 113 
2.7.3 Agarose gel electrophoresis of the PCR product 118 
2.7.4 Microsatellite analysis of the PCR product 119 
VIII 
2.7.4.1 Gel preparation 119 
2.7.4.2 Pre-run 120 
2.7.4.3 Sample loading and electrophoresis 120 
2.8 Analysis of the IL-4 gene polymorphisms 121 
2.8.1 The C (-285) T polymorphism 121 
2.8.1.1 Analysis of the C ( -285) T polymorphism 121 
2.8.1.2 Agarose gel electrophoresis of PCR products 121 
2.8.1.3 Precipitation of DNA 121 
2.8.1.4 The C (-285) T digestion via Nhel endonulease enzyme 124 
2.8.1.5 Agarose gel electrophoresis of the PCR products following 
digestion 124 
2.8.2 The C ( -590) T polymorphism 126 
2.8.2.1 preparation of DNA and analysis of the C (-590) T polymorphism 126 
2.8.2.2 Agarose gel electrophoresis of the PCR products 126 
2.8.2.3 The C ( -590) T digestion via BsmFI endonuclease enzyme 126 
2.9 Analysis of the IL-6 gene polymorphism 128 
2.9.1 The G (-174) C polymorphism 128 
2.9.2 Agarose gel electrophoresis of the PCR products 131 
2.9.3 The G ( -17 4) C digestion via NI alii endonuclease enzyme 131 
2.10 Analysis of the TGF-P I gene polymorphism 133 
2.10.1 The T (+869) C polymorphism 133 
2.10.2 Agarose gel electrophoresis of the PCR products 136 
2.11 Statistical analysis 138 
2.11.1 Allele and genotype frequencies 138 
2.11.2 Hardy-Weinberg principle 138 
2.11.3 Cytokine profile analysis 139 
IX 
CHAPTER 3: RESULTS .................................................. 140 
3.1 
3.1.1 
3.1.2 
Analysis of the IFN-y locus 
Genotype frequency of the IFNG CA repeats 
Allelic frequency of the IFNG CA repeats 
140 
140 
140 
3.1.3 The impact of gender of patients on genetic susceptibility of the IFNG 
CA repeats 145 
3 .1.4 The impact of age at onset of type I diabetes on the genetic susceptibility 
of the IFNG CA repeats 145 
3.1.5 The role of the IFNG CA repeats in the long tenn complications of 
Diabetes 150 
3.1.6 The familial clustering analysis of the 3 I 3 genotype of the IFNG CA 
3.2 
3.2.1 
3.2.2 
3.2.2.1 
3.2.2.2 
3.2.2.3 
3.2.2.4 
3.3 
3.3.1 
repeats 
Analysis of the IL-4 loci 
The C ( -285) T polymorphism 
The C ( -590) T polymorphism 
Genotype and allelic frequencies of the IL-4 C (-590) T 
polymorphism 
150 
154 
154 
154 
154 
The impact of gender of patients on genetic susceptibility of the IL-4 C (-
590) T 159 
The impact of age at onset of type I diabetes on genetic susceptibility of 
the IL-4 C ( -590) T 159 
The role of the IL-4 C ( -590) T polymorphism on the long tenn 
complications of diabetes 159 
Analysis of the IL-6 locus 166 
Genotype and allelic frequencies of the IL-6 G ( -174) C 
polymorphism 166 
X 
3.3.2 The impact of gender of patients on the genetic susceptibility of the IL-6 
G(-174)C 167 
3.3.3 The impact of age at onset on the genetic susceptibility of the IL-6 G (-
174) c 167 
3.3.4 The role of the IL-6 G ( -174) C polymorphism on long term 
complications of diabetes 175 
3.3.5 The familial clustering analysis ofthe GG of the IL-6 G (-174) C 
polymorphism 
3.4 Analysis of the TGF -PI locus 
3.4.1 The genotype and allelic frequencies of the TGF-P1 T (+869) C 
polymorphism 
175 
179 
179 
3.4.2 The impact of gender of patients on the genetic susceptibility of the TGF-
PIT (+869) c 183 
3.4.3 The impact of age at onset of type I diabetes on the genetic susceptibility 
of the TGF-P I T (+869) C 183 
3.4.4 The role of the TGF-Pl T (+869) C polymorphism on the long term 
complications of diabetes 188 
3.4.5 The familial clustering of the TC genotype of the TGF-Pl T (+869) C 
polymorphism 188 
3.5 Association of cytokine gene polymorph isms with type I diabetes 
3.6 
3.6.1 
3.6.2 
3.6.3 
3.6.4 
3.6.5 
Haplotype analysis of cytokine gene polymorphisms 
The IL-4 C (-590) T vs the IFNG CA repeats 
The IL-6 G ( -174) C vs the IFNG CA repeats 
The IL-6 G (-174) C vs the IL_ 4 C (-590) T 
The TGF-p I T (+869) C vs the IFNG CA repeats 
The TGF-Pl T (+869) C vs the IL-4 C (-590) T 
XI 
193 
193 
197 
201 
205 
209 
3.6.6 The TGF-J31 T (+869) C vs the IL-6 G (-174) C 213 
CHAPTER4:DISCUSSION ...... ........................................ . 217 
4.1 Amplication of cytokine gene polymorphism 220 
4.2 Cytokines as immunogenetic marker for type 1 diabetes 221 
4.2.1 IFN-y, the TH 1 cytokine profile inducer 221 
4.2.2 IL4, theTH2 cytokine profile inducer 223 
4.2.3 IL-6, a multifunctional cytokine released by macrophages 224 
4.2.4 TGF-131, the immunosuppressor cytokine 225 
4.2 Correlation studies between cytokine gene polymorphisms studied in this 
thesis 228 
4.3 Type I diabetes pathogenesis model based on this thesis findings230 
4.4 Conclusion 232 
4.5 Future considerations 236 
CHAPTER 5: REFERENCES ........................................... 238 
XII 
LIST OF TABLES ................................................ Page No 
Table 1.01. Characteristics of cytokines 23 
Table 1.02. Characteristics of type I and type 2 diabetes mellitus 53 
Table 1.03. Summary of human type I diabetes susceptibility loci 69 
Table 2.01 Characteristics of patients with type I diabetes and normal 
Controls 94 
Table 2.02 Patients with the long term complications of diabetes and diabetic 
controls 
Table 2.03 Transmission disequilibrium test 
95 
112 
Table 2.04 
Table 2.05 
Table 2.06 
Table 2.07 
Table 2.08 
Table 2.09 
Table 2.10 
Table 2.11 
Table 3.0 I 
Table 3.02 
The PCR contents for amplification of the IFNG CA repeats 115 
The set of amplimers and PCR condition for amplification of the IFNG 
CA repeats 
The PCRcontents for amplification of the IL-4 gene 
Polymorph isms 
116 
122 
The set ofamplimers and PCR condition for amplification of the IL-4 
loci 
The PCR contents for amplification of the IL-6 G (-174) C 
polymorphism 
123 
129 
The set of amplimers and PCR condition for amplification of the 
IL-6 G ( -174) C polymorphism 130 
The ARMS-PCR contents for amplification of the TGF-~1 T (+869) C 
polymorphism 
The set of amplimers and PCR condition for amplification of 
the TGF-~1 T (+869) C polymorphism 
Different allele size and their CA repeat position 
134 
135 
142 
The genotype of the frequency of the IFNG CA repeats in the patients 
and the normal controls 143 
XIII 
Table 3.03 
Table 3.04 
Table 3.05 
Table 3.06 
Table 3.07 
Table 3.08 
Table 3.09 
Table 3.10 
Table 3.11 
Table 3.12 
Table 3.13 
Table 3.14 
Table 3.15 
Table 3.16 
The allelic frequency of the IFNG CA repeats in the patients and the 
normal controls 144 
The genotype frequency of the IFNG CA repeats with respect to 
gender of the patients and the normal controls 146 
The allelic frequency of the IFNG CA repeats with respect to gender of 
the patients and the normal controls 147 
The genotype frequency of the IFNG CA repeats with respect to age at 
onset of type I diabetes 148 
The allelic frequency of the IFNG CA repeats with respect to age at 
onset of type I diabetes 149 
The genotype frequency of the IFNG CA repeats with respect to the 
long term complications of diabetes 151 
The allelic frequency of the IFNG CA repeats with respect to the long 
term complications of diabetes 152 
TOT for the linkage analysis of the 3 I 3 of the IFNG CA repeats 153 
The genotype and allelic frequencies of the IL-4 C ( -590) T in the 
patients and the normal controls 157 
Comparison between the expected and the observed genotypes of the 
IL-4 C (-590) T according to Hardy-Weinberg principle 158 
The genotype frequency of the IL-4 C ( -590) T with respect to gender 
of the patients and the normal controls 160 
The allelic frequency of the IL-4 C ( -590) T with respect to gender of 
the patients and the normal controls 161 
The genotype frequency of the IL-4 C ( -590) T with respect to age at 
onset of type I diabetes 162 
The allelic frequency of the IL-4 C (-590) T with respect to age at 
onset of type 1 diabetes 163 
xrv 
Table 3.17 
Table 3.18 
Table 3.19 
Table 3.20 
Table 3.21 
Table 3.22 
Table 3.23 
Table 3.24 
Table 3.25 
Table 3.26 
Table 3.27 
Table 3.28 
Table 3.29 
The genotype frequency of the IL-4 C ( -590) T with respect to the 
long tenn complications of diabetes 164 
The allelic frequency of the IL-4 C ( -590) T with respect to the long 
tenn complications of diabetes 165 
The genotype and allelic frequencies of the IL-6 G ( -174) C 
polymorphism 169 
Comparison of the expected and the observed genotypes of the 
IL-6 G ( -174) C according to Hardy-Weinberg principle 170 
The genotype frequency ofthe IL-6 G (-174) C with respect to 
gender of the patients and nonnal controls 
The allelic frequency of the IL-6 G ( -174) C with respect to 
gender of the patients and the nonnal controls 
171 
172 
The genotype frequency of the IL-6 G ( -174) C with respect to 
age at onset of type I diabetes 173 
The allelic frequency of the IL-6 G ( -174) C with respect to age at 
onset of type 1 diabetes 174 
The genotype frequency ofthe IL-6 G (-174) C with respect to the 
long tenn complications of diabetes 176 
The allelic frequency ofthe IL-6 G (-174) C with respect to the long 
tenn complications of diabetes 177 
TOT for the linkage analysis of the GG genotype of the IL-6-
G(-174)C 178 
The genotype and allelic frequencies of the TGF-~1 T (+869) C 
polymorphism 181 
Comparison between the expected and observed genotypes of the 
TGF-~ 1 T (+869) C according to Hardy-Weinberg principle 182 
XV 
Table 3.30 
Table 3.31 
Table 3.32 
Table 3.33 
Table 3.34 
Table 3.35 
Table 3.36 
Table 3.37 
Table 3.38 
Table 3.39 
Table 3.40 
Table 3.41 
The genotype frequency of the TGF-~1 T (+869) C with respect to 
gender of the patients and the normal controls 184 
The allelic frequency of the TGF-~1 T (+869) C with respect to gender 
of the patients and the normal controls 185 
The genotype frequency of the TGF-~1 T (+869) C with respect to age 
at onset of type 1 diabetes 186 
The allelic frequency ofthe TGF-~1 T (+869) C with respect to age at 
onset of type 1 diabetes 187 
The genotype frequency of the TGF-~1 T (+869) C with respect to the 
long term complications of diabetes 189 
The allelic frequency of the TGF-~1 T (+869) C with respect to the 
long term complications of diabetes 
TDT for the linkage analysis of the TC of the TGF-~1-
T (+869) C 
190 
191 
Correlation between the IL-4 C ( -590) T and the IFNG CA repeats 
genotypes 194 
Association of the IL-4 C ( -590) T and the IFNG CA repeats genotype 
frequency with respect to gender of patients with type I 
diabetes 195 
Association of the IL-4 C (-590) T and the IFNG CA repeats genotype 
frequency with respect to age at onset of type 1 diabetes 196 
Correlation between the IL-6 G ( -174) C and the IFNG CA repeats 
genotypes 198 
Association of the IL-6 G ( -174) C and the IFNG CA repeats genotype 
frequency with respect to gender of patients with type 1 
diabetes 199 
XVI 
Table 3.42 
Table 3.43 
Table 3.44 
Table 3.45 
Table 3.46 
Table 3.47 
Table 3.48 
Table 3.49 
Table 3.50 
Table 3.51 
Association of the IL-6 G {-174) C and the IFNG CA repeats 
genotype frequency with respect to age at onset of type I 
diabetes 200 
Correlation between the IL-6 G ( -174) C and the IL-4 C ( -590) T 
genotypes 202 
Association ofthe IL-6 G {-174) C and the IL-4 C (-590) T genotype 
frequency with respect to gender of patients with type I 
diabetes 203 
Association of the IL-6 ( -174) C and the IL-4 C (-590) T genotype 
frequency with respect to age at onset of type I diabetes· 204 
Correlation between the TGF-~1 T (+869) C and the IFNG CA repeats 
genotypes 206 
Association of the TGF-~1 T (+869) C and the IFNG CA genotype 
frequency with respect to gender of patients with type 1 
diabetes 207 
Association of the TGF-~1 T (+869) C and the IFNG CA genotype 
frequency with respect to age at onset of type 1 diabetes 208 
Correlation between the TGF-~1 T (+869) C and the IL-4 C (-590) T 
genotypes 210 
Association of the TGF-~ I T ( +869) C and the IL-4 C ( -590) T 
genotype frequency with respect to gender of patients with type 1 
diabetes 211 
Association of the TGF-~1 T (+869) C and the IL-4 C (-590) T 
genotype frequency with respect to age at onset of type 1 
diabetes 212 
XVII 
Table 3.52 
Table 3.53 
Table 3.54 
Correlation between the TGF -~ 1 T ( +869) C and the IL-6 G ( -17 4) C 
genotypes 214 
Association of the TGF-~ I T (+869) C and the IL-6 G (-174) C 
genotype frequency with respect to gender of patients with type 1 
diabetes 215 
Association of the TGF-~1 T (+869) C and the IL-6 G (-174) C 
genotype frequency with respect to age at onset of type 1 
diabetes 216 
XVIII 
LIST OF FIGURES ................................................. Page No 
Figure 1.0 I Illustration ofCD4 T cell differentiation 6 
Figure 1.02 Illustration of structure ofT cell receptor 7 
Figure 1.03 A simplified map of the MHC region on the short arm of 
chromosome 6 10 
Figure 1.04 Illustration of structure of the MHC I 14 
Figure 1.05 Illustration of structure of the MHC li 15 
Figure 1.06 Illustration of cytokines and their receptor categories 21 
Figure 1.07 Illustration of structure of HLA-DQ molecule and antigen 
Recognition 70 
Figure 1.08 Illustration of intercellular signalling pathways 83 
Figure 1.09 Illustration of a basic model for cytokine action 84 
Figure 2.01 The distribution of the patients with type I diabetes used in this thesis 
with respect to gender and age at onset of type 1 diabetes 96 
Figure 2.02 lllustration of polymerase chain reaction (PCR) 103 
Figure 2.03 Illustration of microsatellite markers 105 
Figure 2.04 Illustration of restriction site polymorphism (RSPs) 107 
Figure 2.05 Illustration of amplified refractory mutation system (ARMS) 109 
Figure 2.06 Illustration of the IFNG CA repeats on the IFN-y gene 117 
Figure 2.07 Illustration of the IL-4 C ( -285) T and the C ( -590) T polymorphisms on 
the IL-4 gene 125 
Figure 2.08 Illustration of the IL-6 G ( -174) C polymorphism on the 
IL-6 gene 132 
Figure 2.09 Illustration of the TGF-~1 T (+869) C polymorphism on the TGF-~1 
gene 137 
XIX 
Figure 3.01 
Figure 3.02 
Figure 3.03 
Figure 3.04 
Figure 3.05 
Figure 4.01 
Photographic representation of the IFNG CA repeats 
Photographic representation of the IL-4 C (-590) T 
Photographic representation ofthe IL-6 G (-174) C 
Photographic representation of the TGF-PI T (+869) C 
141 
156 
168 
180 
Illustration of association of the IFNG CA repeats, IL-4 C ( -590) T, the 
IL-6 G (-174) C, and the TGF-PI T (+869) C polymorphisms with 
type I diabetes 192 
Presentation of the immunogenetic of cytokines in the pathogenesis of 
type I diabetes 233 
XX 
y32r dATP 
J.!L 
J.!M 
APC 
ARMS 
ASA 
BB 
BDA 
bp 
BP 
BSA 
CD 
cDNA 
cM 
CMP 
cpm 
CTLA-4 
DC 
DCCT 
DEC 
DIG 
DN 
DNA 
dNTP 
DNu 
LIST OF ABBREVIATION 
gamma phosphate-32 deoxyadenosine 
Microlitre 
Micromolar 
Antigen presenting cell 
Amplification refractory mutation system 
Allele specific amplimer 
Bio-breeding 
British diabetic association 
Base pair 
Blood pressure 
Bovine serum albumin 
Cluster of differentiation 
Complimentary Deoxyribonucleic Acid 
Centimorgan 
Cows milk protein 
Counts per minute 
Cytotoxic T -lymphocyte-associated antigen-4 
Diabetic complication 
Diabetes control and complications trial 
Dendritic epidermal cell 
Digoxygenin 
Diabetic nephropathy 
Deoxyribonucleic Acid 
2'Deoxyribonucleotide 5' triphosphate 
Diabetic neuropathy 
XXI 
DR 
EAE 
ECM 
EDTA 
EDTA 
ESRD 
g 
GABA 
GAD 
GADA 
GLUT! 
GM-CSF 
HbAlc 
HCI 
HLA 
HSP 
IA2 
IAA 
ICA 
ICAM 
IDDM 
IDF 
IFN 
IFNG 
Ig 
IGF 
IL 
Diabetic Retinopathy 
Experimental allergic encephalomyelitis 
Extracellular matrix 
Ethylene Diamine Tetra Acetic acid 
Ethylene diamine tetra acetic acid 
End-stage renal disease 
Gram 
y amino butyric acid 
Glutamic acid decarboxylase 
Glutamic acid decarbocylase 
Brain type glucose transporter 
Granulocyte/macrophage colony stimulating factor 
Glycated haemoglobin 
Hydrochloric Acid 
Human Leukocyte antigen 
Heat shock protein 
Tyrosene phosphate 
Insulin autoantibodies 
Islet cell antibody 
Intercellular adhesion molecule 
Insulin-dependent diabetes mellitus 
International diabetes federation 
Interferon 
Interferon-gamma gene 
Immunoglobulin 
Insulin-like growth factor 
Interleukin 
XXII 
IMS 
INS 
Kb 
kDa 
L 
M~ 
MCP 
MHC 
MIP 
mmHg 
MODY 
m RNA 
MS 
n 
NaCI 
NC 
NIDDM 
NK 
NOD 
ns 
OD 
PBS 
PCR 
PCR-SSOP 
PDGF 
RFLP 
RSPs 
Industrial Methylated spirit 
Insulin gene 
Kilo-base 
Kilo-dalton 
Litre 
Macrophages 
Monocyte chemotactic peptides 
Major histocompatibility complex 
Macrophage inflammatory protein 
Millimetres of mercury 
Maturity onset diabetes of the young 
Messenger ribonucleic acid 
Multiple sclerosis 
Number of subjects 
Sodium chloride 
Normal controls 
Non-insulin dependent diabetes mellitus 
Natural killer 
Non-obese diabetic 
Not significant 
Optical density 
Phosphate buffered saline 
Polymerase chain reaction 
Sequence specific oligonucleotide probing 
Platelet derived growth factor 
Restriction fragment length polimorphism 
Restriction site polymorphisms 
XXIIJ 
so 
SLE 
SNS 
ssc 
SSCP 
sso 
SSP 
TAP 
TAP 
TBE 
Tc 
TCGF 
TCR 
TOT 
TE 
TEMEO 
TGF 
TH 
TMAC 
TMEO 
TNF 
UK 
USA 
uv 
uv 
V 
vs 
Standard deviation 
Systemic lupus erythamatosus 
Self-non-self 
Standard saline citrate 
Single stranded conformational polymorphism 
Sequence specific oligotyping 
Sequence specific primers 
Transporter associated with antigen processing 
Transporters associated with antigen processing 
Tris-borate acid-ethylenediamine tetra acetic acid 
Cytotoxic T-cell 
T -cell growth factor 
T cell receptor 
Transmission disequilibrium test 
Tris EOT A buffer 
n,n,n " Tetramethylediamine 
Transforming growth factor 
T helper cell 
Tetra-methyl-ammonium chloride 
Tetra-methyl-ethylene-diamine 
Tumour necrosis factor 
United Kingdom 
United states of America 
Ultraviolet 
Ultraviolet 
Volts 
Versus 
XXIV 
VNTR Variable number of tandem repeats 
w Watts 
WHO World health organisation 
Chi square 
XXV 
DECLARATION 
No portion of the work referred to in this thesis has been submitted in support of an 
application for another degree or qualification of this or any other University or other 
institute of learning. 
The following notes on copyright and the ownership of intellectual property rights: 
I) Copyright in text of this thesis rests with the author. Copies (by any process) either in 
full, or of extracts, may be made only in accordance with instructions given by the 
Author and logged in the University of Plymouth Library. Details may be obtained 
from the librarian. This page must be part of any such copies made. Further copies 
{by any process) of copies made in accordance with instructions may not be made 
without the permission (in writing) of the Author. 
2) The ownership of any intellectual property rights which may be described in this 
thesis is vested in the University of Plymouth, subject to any prior agreement to the 
contrary, and may not be made available of use by third parties without the written 
permission of the University, which will prescribe the terms and conditions of any such 
agreement. 
rom1 
3o-to-P-ooo 
XXVI 
ACKNOWLEDGEMENTS 
I would begin with praise and laudation of God who has helped me throughout my life. 
My special gratitude go to my supervisors, Dr AG Demaine and Dr BA Millward, for 
their continual guidance, support, encouragement and giving me the opportunity to 
pursue this study. I am deeply grateful to Dr Demaine for his help, without which this 
work could not have been completed. 
I would like to acknowledge Professor Ian Hutchinson and his group especially Dr V 
Pravica for their cooperation and provision of some control samples for TGF-P I assay. 
Thanks are due to the following: Jane for her assistance and help. Kevin, for his expert 
guidance and for facilitating initial training; Bingmei for her continuous problem 
shooting and guidance. Last but not least I would like to thank Andrea, Anna, Karen, 
Alison, Doha, Debbi, Liz, Derek, John, Hongzing, Martin and Mark. 
I would like lo express my gratitude to my mother Mariam, brothers A. Ghani and 
lbrahim to whom I owe my success. 
Finally, I am deeply indebted to my wife, Farzaneh, for her patience and understanding 
and whose sacrifice and love has made it possible to complete this study. 
XXVII 
PREFACE 
About the Author- I did my BSc at my home country, Bahrain, majoring in Biology 
and Chemistry as a minor at the University of Bahrain. I then joined the quality control 
laboratories in Bahrain Petroleum Company (Bapco) to gain work experience. Within 
less than 3 years I reached the level of quality control laboratory shift supervisor with 
full responsibilities for the Laboratory quality control operation as well as fire and safety 
of the area during the shift. I also was responsible for a group of 6 technicians and 3 
chemists who worked under my supervision. After 5 years working for Bapco I decided 
to leave the Company to continue my studies. From September 1995 to June 1997 I have 
been a MSc student at the University of Manchester. From June 1997 to the present I 
have been a PhD student at the University of Plymouth. 
XXVIII 
PUBLICATIONS 
Abstracts &Presentation: 
Jahromi MM, Millward BA, Demaine AG. Strong Association of the G (-174) C 
polymorphism in the human interleukin-6 promoter region with type 1 diabetes. BDA 
Ann ProfMeet 2000; 17/1: A46, pp 15. 
Jahromi MM, Millward BA, Demaine AG. Investigation of interferon-y and 
interleukin-4 gene polymorphism in type 1 diabetes. Diabatologia 1999; 42/1 (Suppl) 
A90. 
Jahromi MM, Millward BA, Demaine AG. Polymorphisms of interferon-y gene are 
associated with type I diabetes. Diabetologia 1998; 4111: A79. 
Manuscripts arising from this work 
Nicola Cartwright, Andrew Demaine, Mohamed Jahromi, Hilary Sanders, and Edward 
Kaminski. A study of cytokine protein secretion, frequencies of cytokine expressing 
' 
cells and IFN-G gene polymorphisms in normal individuals. J Transplantation 1999; 
68/10: 1546-1552. 
Mohamed M Jahromi, B Ann Millward, Andrew G Demaine. Analysis ofT (+869) C 
polymorphism at. codon I 0 of TGF-P 1gene in type I diabetes pathogenesis (to be 
submitted to Diabetes; 2000). 
Mohamed M Jahromj. B Ann Millward, Andrew G Demaine. A polymorphism in the 
promoter region of the gene for interleukin-6 is associated with the susceptibility to type 
I diabetes (accepted for publication in October 2000; J Interferon and Cytokine 
Research). 
Mohamed M Jahromi. B Ann Millward, Andrew G Demaine. A CA repeat 
polymorphism of the interfron-y gene is highly associated with type I diabetes: IFNG 
and IL-4 gene polymorphism and type I diabetes. J Interferon and Cytokine Research 
2000; 20: 187-190. 
XXIX 
In collaboration with the combined laboratory m Derriford Hospital, Pancreatic 
Research Group of the University of Plymouth as well as Molecular Medicine in 
Edinburgh Royal Infirmary few projects were conducted manuscripts of of which have 
been published or in preparations. 
XXX 
CHAPTER 1: INTRODUCTION 
1 INTRODUCTION 
Immunogenetics is that branch of medical science which deals with the genetics of the 
components which together form the immune system: the major histocompatibility 
complex (MHC), cytokines, cytotoxic T -cells (T c), and autoantibodies. Immunogenetics 
is the study of immunity to diseases and the relationship to the genetic make-up of the 
immune response elements with regard to the pathogenesis of immune regulated 
diseases. 
A major feature of the immune system is its ability to inflict damage upon cells. 
Therefore, it must confine this activity to cells that are a potential threat, such as cells in 
the body that have become infected or neoplastic, whilst remaining unresponsive or 
tolerant to the normal cells of the body. As the regulation of the immune system is very 
important in the context of human disease, a disordered response may result in a 
breakdown of tolerance leading to autoimmune disease or immune deficiency. 
1.1 Categories of immune diseases 
In general, autoimmune diseases can be divided into two categories: organ-specific and 
systemic autoimmune disease. In organ-specific autoimmune disease, the immune 
response is directed towards a target antigen unique to a single organ or gland, so that 
the manifestations are largely limited to that organ. In systemic autoimmune disease, the 
response is directed towards a broad range of target antigens and involves a number of 
organs and tissues (Andre et al., 1996). 
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1.1.1 Organ-specific auto-immune diseases 
Damage to the target organs in organ-specific auto-immunity can occur as the result of 
direct cellular damage by humoral or cell-mediated mechanisms or by stimulating or 
blocking autoantibodies. In this instance, the immune system usually targets discrete 
antigens present on the tissue. Gradually, the cellular structure of an affected organ is 
replaced by connective tissue, hence, the function of the organ declines. Type I diabetes 
mellitus and Hashimoto's thyroiditis are good examples of this type of autoimmune 
disease (Andre et al., 1996). 
1.1.2 Systemic auto-immune diseases 
Autoimmune diseases with systemic manifestations reflect a generalised defect in 
immune regulation that results in hyperactive T-cells and B-cells. Tissue damage is 
widespread, both from cell-mediated immune responses and from direct cellular damage 
caused by autoantibodies or by accumulation of immune complexes. One of the best 
examples of a systemic autoimmune disease is systemic lupus erythematosus (SLE). 
Rheumatoid arthritis and multiple sclerosis (MS) are also important systemic 
autoimmune diseases (Andre et al., 1996). 
1.2 Elements of the immune response 
Functional or structural damage to self-cellular components caused by the immune 
system is not fully understood. Tolerance to self may be broken because normally 
occurring autoimmunity is not controlled, either due to deficient elimination or lack of 
functional inactivation or inhibition of autoreactive lymphocytes in the thymus or in the 
periphery (Kroemer and Martinez, 1992). However, there is no evidence to suggest that 
the initiating events in the immune response are different whether the antigen is self or 
non-self derived. Specific recognition of antigens is dependent on several cells, the 
following are the most important: 
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1.2.1 Lymphocytes 
Lymphocytes are wholly for the specific immune recognition of pathogens, so they 
initiate adaptive immune responses. All lymphocytes are derived from bone-marrow 
stem cells, but T cells then develop in the thymus, while B cells develop in the bone 
marrow. 
1.2.1.1 B cells 
Each B cell is programmed to encode a surface receptor specific for a particular antigen. 
Having recognised its specific antigen, the B cells multiply and differentiate into plasma 
cells, which produce large amounts of the receptor molecule in a soluble form that can 
be secreted, termed as antibody. B cells are essentially little antibody factories (Park and 
Weigert, 1995), able to switch on high-rate synthesis and secretion of antibody 
molecules when stimulated by recognition of the "right" antigen. 
Recognition and response in B cells are perfectly coordinated, because their surface 
antigen-receptor has antibody the same as they will secrete when stimulated. Thus only 
those antibody molecules that are made which can bind to the stimulating antigen and 
help in its disposal will be produced; thus the production of unwanted antibodies is 
avoided. It is the formation of plasma antibody that forms the foundation of the so called 
humoral immune response (McPherson et al., 1999). 
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1.2.1.2 T cells 
Resting T cells look very much like resting B cells, but when they respond the difference 
becomes apparent. T cells have no specificity towards particular antigens. There are 
several different types of T cells, and they have a wide variety of actions. One group 
interacts with B cells and helps them to divide, differentiate and make antibody. Another 
group interacts with mononuclear phagocytes and helps them destroy intracellular 
pathogens. These two groups of cells are called T-helper (THI, TH2) cells which carry 
the CD4 marker and mainly helps or induces immune responses (Chen et al., 1999). A 
third group ofT cells is responsible for the destruction of host cells which have become 
infected by viruses or other intracellular pathogens. This kind of action is called 
cytotoxicity and these T cells carry the CD8 marker and are predominantly cytotoxic 
(Tc). CD4+ T cells recognise antigen in association with the MHC class II molecules, 
whereas CD8+ T cells recognise antigens in association with the MHC class I molecules 
(Croft et al., 1994). 
The T cell receptor has similarities to the antibody molecule, but with important 
differences. Unlike the antibody on the B cell, which can be thought of as a sample of 
what that cell can produce, the T cell receptor can be thought of as a hand reaching out 
to feel the surface of neighbouring cells, with some fingers devoted to contacting MHC 
molecules and others probing for peptide bound to them (Yawaker et al., 2000). 
1.2.1.2.1 T-cell receptor 
The definitive T -cell lineage marker is the TCR. There are two types of TCR: one is a 
heterodimer of two disulphide-linked polypeptides a and p; the other is structurally 
similar, but consists of y and 8 polypeptides . Both receptors are associated with a set of 
five polypeptides, the CD3 complex, and together form the T-cell receptor complex 
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(TCR-CD3). Approximately 90-95% of blood T cells are ap T cells and only 5-10 % are 
y8 T cells. The ap T cells are subdivided into two distinct non-overlapping populations: 
CD4 and CD8 (Housset et al., 1997). 
The CD4 further divides into THI and TH2 subsets. Different factors may be 
responsible for this differentiation. Cytokines, which are produced and secreted by T-
helper cells, might be responsible for the distinction of CD4 differentiation. The two 
subsets of CD4 T cells, THI and TH2 cells, have very different functions: TH2 cells are 
the most effective activators of B cells, especially in primary responses, whereas THI 
cells are crucial for activating macrophages. It is also clear that the two CD4 T-cell 
subsets can regulate each other. Once one set becomes dominant, it is often hard to shift 
the response to the other subset. One reason for this is that cytokines from one type of 
CD4 T cell inhibit the activation of the other. Thus, IL-l 0, a product of TH2 cells, can 
inhibit the development of THI cells by acting on the antigen-presenting cell, whereas 
IFN-y, a product of THI cells, can prevent the activation of TH2 cells (Figure 1.01). 
Such cross-regulatory function of THI and TH2 maintains the balance between 
THliTH2 (Chen et al., 1999). 
As might be expected from their function as highly variable antigen-recognition 
structures, T cell receptors are closely related to antibody molecules in structure 
(Zamoyska, 1998). Like immunoglobulins, TCR are encoded by V, D, and J gene 
segments, which rearrange to form a complete variable-region exon. There are, however, 
important differences between TCRs and immunoglobulins that reflect the unique 
features of antigen recognition by the TCR (Zamoyska, 1998) (Figure 1.02). 
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Figure 1.01: Illustration of CD4 T cell differentiation 
IFN-Y 
TNF-P 
' 
• 
' 
\ 
IL4 
IL-10 
Generation of THl and TH2 cells from naive T cells. Commitment to either subset is 
determined by the microenvironmental conditions that predominate at the time of initial 
stimulation (Adapted from Lafaille, 1998 with modification). 
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Figure 1.02: Illustration of structure ofT -cell receptor 
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The T cell receptor heterodimer is composed of two transmembrane glycoprotein chain 
a and J3. The external portion of each chain consists of two domains, resembling 
immunoglobulin variable and constant domains, respectively (Adapted from Janeway, 
Travers, Walpoert, and Capra, 1999). 
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1.2.2 Major histocompatibility complex 
The molecules that display peptide antigens to T cells are membrane glycoproteins 
encoded in a cluster of genes bearing the cumbersome name of major histocompatibility 
complex. The human :MHC molecules were first discovered as the result of attempts to 
use skin grafts from donors to repair badly burned pilots and bomb victims during World 
War ll (Klein, 1986). The patients rejected the grafts, and eventually genetic 
experiments on inbred mice led to the identification of genes causing the rapid rejection 
of a skin graft between mice that differed only at these genetic loci and at no other. 
Because they control the compatibility of tissue grafts, these genes became known as 
"histocompatibility genes". Later, it was found that several closely linked genes specify 
histocompatibility, which led to the term major histocompatibility complex (Marsh, 
1998"; 1998b). The :MHC is referred to as the HLA in human, as the H-2 in mice, and as 
the RTI in rat (Klien, 1986). 
The function of the :MHC molecules is to bind peptide fragments derived from 
pathogens and display them on the cell surface for recognition by the appropriate T cells 
(Fremont et al. 1996). The consequences of such presentation are almost always 
deleterious to the pathogens. Virus-infected cells are killed, macrophages are activated 
to kill bacteria in intracellular vesicles, and B cells are activated to produce antibody 
molecules capable of eliminating or neutralising extracellular pathogens (Fremont et 
al., 1996). Thus, there is strong selective pressure in favour of any pathogen that can 
mutate its structural genes to escape presentation by the :MHC molecules. 
Two separate properties of the :MHC make it difficult for pathogens to evade immune 
responses in this way. First, the :MHC is polygenic. There are several :MHC class I and 
MHC class 11 genes, encoding proteins with different ranges of peptide-binding 
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specificities. Second, The MHC is highly polymorphic. There are multiple alleles for 
each gene. The MHC genes are, in fact, the most polymorphic genes known. 
1.2.2.1 The structure of the MHC molecules 
The MHC extends over approximately 4 centimorgans of DNA, or about 4 x I 06 base 
pairs, and contains more than 200 genes in humans (Herberg et al., 1998). As work 
continues to define the genes within and around the MHC, both its extent and numbers 
of genes involved are likely to grow. Recent studies suggest that the MHC may span at 
least 7 x 106 base pairs (Herberg et al., 1998). The genes encoding the a chains of MHC 
class I molecules and the a and P chains of MHC class II molecules are within the 
complex. The genes for P2-microglobulin and the variant chain lie on separate 
chromosomes. Figure 1.03 shows the general organisation of these genes in the MHC in 
man. The particular combination of MHC alleles found on an individual chromosome is 
known as a MHC haplotype (Herberg et al., 1998; Marsh, 1998b). 
There are three class la-chain genes in humans, called HLA-A, -B, and -C. There are 
also three pairs ofMHC class II a- and P-chain genes, called HLA DR, -DP, and -DQ. 
However, in many haplotypes the HLA-DR cluster contains an extra P-chain gene 
whose product can pair with the DRa.-chain. This means that the three sets of genes give 
rise to four types ofMHC class II molecules (Herberg et al., 1998; Marsh, 1998). All the 
MHC class I and class II molecules are capable of presenting antigens 
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Figure 1.03: A simplified map of the MHC region on the short arm of chromosome 
6 
Chromosome 6 
q 
Class ll Class ill 
DP DQ DR 21 C4 Bf C2 TNF-a. TNF-~ j 
B2 A2 Bl AI LMP-2,1,7 TAP 82 A2 81 AI 
DP Sub-region DQ Sob-region 
B C X E J 
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' 
'-·-·-·--·---··-·--·-·-··\,\ 
Bl B2 B3 B9 AI \ 
DR Sub-region 
A H G F 
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i 
! 
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1 
on the short arm of the chromosome 6, showing the major genes of class II, m, and I. 
The class II is relatively well studied. Among the genes contained in each sub-region, 
there are some that encode functional molecules (in red) such as DPBl and DPAl, genes 
that are not functioning i.e. pseudogenes or not yet characterised (in green). The DRB9 
gene has not been well studied yet but seems to be able to encode for a non-functionally 
stable protein chain. Transporter associated with antigen processing LMP and TAP are 
all functional and shown in blue and purple colour respectively. 1NF-a. and J3 genes 
among the rest of class m genes are shown next to the genes for class II. The class I 
genes are shown next to class m, and are not been well studied (Williams and Pickup, 
1998; Friday et al. , 1999 with slight modification). 
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toT cells (Fremont et al., 1996). Each protein binds to a different range of peptides, the 
presence of several loci meaning that any one individual is equipped to present a much 
broader range of different peptides than if only one MHC protein of each class were 
expressed at the cell surface (Fremont et al., 1996). 
The MHC class I and MHC class II molecules are cell-surface glycoproteins closely 
related in overall structure and function, although they have different subunit structures. 
Both molecules have two domains that resemble immunoglobulin domains, and two 
domains that fold together to create a long cleft that is the site where peptides bind. 
However, differences in their structures allow them to serve distinct functions in antigen 
presentation, binding peptides from different intracellular sites and activating different 
subsets ofT cells (Smith et al., 1996;Murthy et al., 1997). 
The MHC class I structure is outlined in Figure 1.04. The MHC class I molecules consist 
of two polypeptide chains, an a or heavy chain encoded in the MHC, and a smaller non-
covalently associated chain, ~2-microglobulin, which is not encoded in the MHC (Smith 
et al., 1996). The most remarkable feature of the MHC class I molecules is the structure 
of the a I and a2 domains, which pair to generate a cleft on the surface of the molecule 
that is the site of peptide binding (Smith et a!, 1996; Marsh, 1998b) 
The MHC class II molecules consists of a non-covalent complex of two chains, a and ~, 
both· of which span the membrane (Figure 1.05). The crystal structure of the MHC class 
ll molecule shows that it is folded very much like the MHC class I molecule. The major 
differences lie at the ends of the peptide-binding cleft, which are more open in MHC 
class ll molecules (Murthy et al. 1997; Marsh, 1998b). The main consequence of this is 
that the ends of a peptide bound to an MHC class I molecule are substantially buried 
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within the molecule, whereas the ends of peptides bound to MHC class II molecules are 
not (Murthy et al., 1997). 
A third region of the MHC, denoted class Ill, codes for several molecules having a 
variety of functions, namely complement components (C4A, C4B, factor B and C2), 
tumour necrosis factor (TNF-a and -13). heat shock protein (HSP 70), and 21 
hydroxylase genes (CYP21P and CYP21) (Marsh, 1998b) (Figure 103). The class Ill 
region of the MHC is less polymorphic (Marsh, 1998"; 1998b). 
The two TAP genes( transporters associated with antigen processing) lie in the MHC 
class 11 region in close association with the LMP (subunit of proteasome) genes that 
encode components of the proteasome (Figure 1.03). The gene for tapasin, which binds 
to both TAP and empty MHC class I molecules, lies at the centromeric edge of the MHC 
(Ortmann et al., 1997; Bang et al., 2000; Ferlazzo et al., 2000; Zhang et al., 2000). 
1.2.3 Antigen presenting cells 
T cells do not generally bind to, nor are activated by, peptide antigen in solution, but 
recognise antigen only when it is physically associated with MHC molecules on the 
surface of another cell. The primary function of the MHC is to alert the immune system 
to the presence of pathogens by binding short pathogen-derived peptides and expressing 
them on the cell surface (Braciale et al., 1987, Gerrnain and Margulies, 1993; Bang et 
al., 2000; Zhang et al., 2000). 
Antigen processing refers to the degradation of antigen into peptide fragments which 
become bound to MHC class I or class II molecules. These are critical fragments 
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involved in triggering T cells, the receptors on which recognise sequences of amino 
acids in the MHC groove, rather than the conformational determinants recognised by 
antibodies (Fremont et al., 1996). 
The interaction between T cells and the heterogenous group of cells collectively 
regarded as "antigen-presenting cells" are the most extensively studied example of cell: 
cell interaction in the immune system. It is the first such interaction to occur after 
antigen challenge, and its outcome largely influences the following series of events. If a 
sufficient number of CD4+ T -helper cells are triggered, then activation of B cells or the 
development of cell-mediated immunity almost certainly follows. If T-helper cells did 
not trigger, a form of immunological tolerance can occur, so that no proper immune 
response can take place (Germain and Murgulies, 1993; Bang et al., 2000). 
A wide spectrum or'cells can present antigen, depending on how and where the antigen 
first encounters cells of the immune system. Monocytes/macrophages, B cells, and 
dendritic cells are for all professional APCs (Brodsky and Guagliardi, 1991; Liszewski 
et al., 1996; Zerrahn et al., 1997). 
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Figure 1.04: Illustration of structure of the MHC class I 
c 
?epl de-binding 
cat 
The structure of MHC class I (HLA-A2 ), determined by X-ray crystallography. a) 
shows a molecular graphics, b) show a ribbon diagram, c) looking down on the molecule 
from above, and schematic representation of the molecule (Adapted from Janeway, 
Travers, Walport, and Capra, 1999). 
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Figure 1.05: Illustration of structure of the MHC class ll 
c 
pep!Jde-blndrg 
cl at. 
The structure of :MHC class II (HLADR\ determined by X-ray crystallography. a) 
shows a molecular graphics, b) show a ribbon diagram, c) looking down on the molecule 
from above, and schematic representation of the molecule (Adapted from Janeway, 
Travers, Walport, and Capra, 1999). 
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1.2.4 Monocyte/macrophage 
Macrophages are mature monocytes. Maturation involves an increase in size, number of 
organelles, secretory capacity and phagocytic activity. Class 11 MHC antigens are 
present on some of the monocytes/macrophages and are important in the presentation of 
antigens toT cells (Steimle et al., 1994; Yrlid et al., 2000). 
The most distinguishing feature of monocytes and macrophages is that they possess 
receptors for cytokines such as IL-2, IL-4, IFN-y. The functions of monocyte and 
macrophages can be enhanced by T -cell derived cytokines through their receptors. Such 
activated monocytes and macrophages also produce cytokines themselves, including IL-
12, IL-l, IL-6, and TNF-a., which will be discussed in the forthcoming sections (Chen et 
al., 1999). 
1.2.5 Dendritic cells 
These are called dendritic epidermal T-cells which are a specialised class of y8T-cells 
present in the tissues (Banchereau and Steinman, 1998; Yrlid et al., 2000). Their 
function is to capture antigen and to migrate to the local lymph nodes and spleen, where 
they are particularly active in presenting the processed antigen to T cells (Yrlid et al., 
2000). The mature dendritic cells found in lymphoid tissues are the most potent 
stimulators of naive T cells. This ability is not shared, however, by the immature 
dendritic cells found under most surface epithelia and in most solid organs such as heart 
and kidneys. Dendritic cells arise from myeloid progenitors within the bone marrow, and 
emerge from the bone marrow to migrate via the blood to their peripheral sites (Bang et 
al., 2000). In these sites, they have an immature phenotype t~at is associated with low 
levels of MHC proteins, lacking expression of eo-stimulatory molecules. Thus, they are 
not yet equipped to stimulate naive T cells. However, they are very active in taking up 
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antigen by phagocytosis using receptors such as DEC (dendritic epidermal cell), whereas 
other extracellular antigens are taken up non-specifically by macropinocytosis, a process 
in which large volumes of surrounding fluid are engulfed (Banchereau and Steinman, 
1998; Bang et al., 2000; Yirlid et al., 2000). 
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1.3 Cytokines, as molecules which signal between lymphocytes, 
phagocytes, and other cells of the body 
Cytokines can act on the cells that produce them (autocrine), on other cells in their 
immediate vicinity (paracrine), or on cells at a distance (endocrine) after being carried in 
the blood or tissue fluids. Cytokines comprise a collection of small proteins (-20 kDa) 
which act on a specific receptor; many of these cytokine receptors use a particularly 
rapid and direct signalling pathway. They are involved in signalling between cells during 
immune responses (Bach, 1996; Adorini and Sinigalia, 1997; Rabinovitch, 1998; Yrlid 
et al., 2000). 
The development of an effective immune response involves lymphoid, inflammatory, 
and other hematopoietic cells. The complex interactions among these cells are mediated 
by a group of low molecular weight proteins that are collectively designated cytokines to 
denote their role in cellular and molecular communication. Cytokines assist in regulating 
the development of immune effector cells and some cytokines possess direct effector 
functions of their own. Just as hormones serve as messengers of the endocrine system, so 
cytokines act as messengers of the immune system ((Bach, 1996; Adorini and Sinigalia, 
1997; Rabinovitch, 1998; Yrlid et al., 2000). However, unlike endocrine hormones, 
which exert their effects over large distances, the cytokines generally act locally 
(Fischer, 2000). 
Cytokines are secreted by various cells involved in the immune response and act on 
target cells bearing membrane receptors that are specific for a given cytokine. Binding of 
a cytokine to its membrane receptor transmits a signal into the cell that leads to changes 
in the activation and expression of genes. Cytokines regulate the intensity and duration 
of the immune response by stimulating or inhibiting the proliferation of various cells or 
their secretion of antibodies or other cytokines (Fenton et al., 1992; Bach, 1996; 
Diamond et al., 2000). 
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The action of cytokines is pleotropic; that is, cytokines elicit different biological 
activities at different target cells (Walley and Cookson, 1996; Bach, 1996; Fukaura et 
al., 1996; Adorini and Sinigalia, 1997; Groux et al., 1997; Smith and Bluestone, 1997; 
Yrlid et al., 2000; Fischer, 2000,Diamond et al., 2000). Cytokines' action can also be 
"redundant", that is the action of certain cytokines can be mediated by another cytokine, 
making it difficult to ascribe a given activity to a single cytokine. Adding to the 
complexity of cytokine action, two cytoldnes may exhibit synergy; that is, the combined 
effect of two or more cytokines on a biological activity of an organ is greater than the 
additive effects of the individual cytokines (Warren, 1996). In other cases two cytokines 
might exhibit antagonism, the effects of one cytokine inhibiting the effects of another 
cytokine (Kiniwa et al., 1992; Karlsson and Ludvigsson, 2000). The attributes of 
pleiotrophy, redundancy, synergism, and antagonism permit cytokines to regulate 
biological activity in a co-ordinated interactive way. The actions of one cytokine on a 
responsive target cell generally regulate expression of cytokine receptors and expression 
of new cytokines, which in turn can modulate other cells. Thus, the antigen-specific 
response of a single lymphocyte can influence the activity of a variety of cells necessary 
to generate an effective immune response. For example, cytokines produced by activated 
TH cells can influence the activity of B cells, cytotoxic T -cells, NK cells, macrophages, 
granulocytes, and hematopoietic stem cells, thereby activating an entire network of 
interacting cells (Walley and Cookson, 1996; Bach, 1996; Fukaura et al., 1996; Adorini 
and Sinigalia, 1997; Groux et al., 1997; Smith and Bluestone, 1997; Yrlid et al., 2000; 
Fischer, 2000,Diamond et al., 2000; Karlsson and Ludvigsson, 2000; Fischer, 2000). 
Cytokines act on receptors that can be grouped into equivalent families on the basis of 
their structure (Figure 1.06). These families of cytokines and their receptors are also 
characterised by functional similarities and genetic linkage. For instance, among the 
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hematopoeitins, IL-3, IL-4, IL-5, IL-13 are related structurally, their genes are closely 
linked in the genome, and all are major cytokines produced by TH2 cells (Di Santo et 
al., 1995; Chomarat and Banchereau, 1997; Thompson, 1998). In addition, they bind to 
closely related receptors: the IL-3, IL-4, IL-5, and IL-13 share a common 13 chain 
(Chomarat and Banchereau, 1997; Thompson, 1998). Another subgroup of 
hematopoietin receptors is defined by their use of they chain of the IL-2 receptor; this is 
shared by receptors for the cytokines IL-4, IL-7, IL-9, and IL-15 and is called they 
common chain (Ye) (Di Santo et al., 1995; Chomarat and Banchereau, 1997). 
These specific functional effects depend on intracellular signalling events that are 
triggered by the binding of cytokines to their specific receptors. Cytokine signalling will 
be discussed in section 1.6.6. 
1.3.1 Classification of cytokines 
Cytokines can be divided according to their T -cell of origin. That is, correlating with 
two subunits ofT-helper cells with contrasting and cross-regulating cytokine profiles 
(Mosmann et al., 1986; Bach, 1996; Groux et al., 1997). The TH1 and TH2 patterns of 
cytokine production were originally described in mouse CD4+ T-cell clones (Mosmann 
et al., 1986, Cherwinski et al., 1987) and later in human T-cells (Del Prete et al., 1991). 
20 
CHAPTER 1: INTRODUCTION 
Figure 1.06: illustration of cytokines and their receptor categories 
Representatives of the main families of immunological interest except the interferons 
and their receptors are shown here. Cytokines are in the top row and their receptors 
below (adapted from Janeway, Travers, Walport, and Capra, 1999). 
a) IL-4 
b) IL-4 receptor 
c) TNF 
d) TNF receptor 
e) IL-8 
f) IL-8 receptor 
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Mouse TH1 cells produce IL- 2, IFN-y and TNF-13, also termed lymphotoxin, whereas 
TH2 cells produce IL-4, IL-5, IL-9, IL-10, and IL-13. 
The function of THI and TH2 cells correlates well with their distinctive cytokine 
peptides. TH1-type cytokines (IL-2, IFNy and TNF-13) activate cell-mediated immunity, 
i.e. cytotoxic and inflammatory responses mediated by T-cells, NK cells and 
macrophages. TH2 cell type cytokines (IL-4, 11-5, IL-9, IL-10, and IL-13) activate 
antibody production by B-cells, particularly IgE responses, and enhance eosinophil 
proliferation and function. Importantly, the characteristic cytokine products of TH1 and 
TH2 cells are mutually inhibitory for the differentiation and effector function of the 
reciprocal phenotype. Thus IFN-y selectively inhibits proliferation of TH2 cells 
(Mosmann and Coffman, 1989; Farrar et al., 1993; Grewall and Flavell, 1997; Delvitch 
and Singh, 1997; Rabinovitch, 1998; Suri and Katz, 1999; Proud'homme and Piccirillo, 
2000; Karlsson and Ludvigsson, 2000}, and IL-10 inhibits cytokine synthesis by TH 1 
cells (Fiorento et al., 1989; Bach, 1996;Adorini and Sinigalia, 1997; Rabinovitch, 1998; 
Matzinger, 1998; Kalsson and Ludvigsson, 2000). This cross regulation may partly 
explain the strong biases towards TH1 or TH2 responses during many infections in mice 
and man (Rabinovitch, 1998). THI and TH2 responses are not the only cytokine patterns 
possible. Immature T-cells have been termed THO cells (Mosmann and Coffmann, 
1989}, cells producing large amounts of transforming growth factor- (TGF-) 13 have been 
termed TH3 (Chen et al., 1994; O'Garra et al., 1997; Rabinovitch, 1998; Matzinger, 
1998; _Sedden and Mason, 1999;Proud'homme and Piccirillo, 2000). These cytokines 
and their characteristics are listed in Table 1. 01. 
However, Clerici and Shearer defined cytokines on the basis of the response they 
modulate rather than on the cell type that produces them. Thus type 1 cytokines (IFN-y, 
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Table 1.01: Characteristics of cytokines 
TNF-P 
TGF-Pl 
25 
25 
6p 
19q 
TH2 T cells, B cells 
T cells, chondrocytes, monocytes Powerful immunosuppressant, inhibits cell 
The major sources of major cytokines, in light of this thesis, with characteristics, target and principal effects are listed. Some cytokines have several 
sources and most cytokines act on more than one cell types (Derynck et al 1987; Male, Cook, Owen, Trowsdale, Champion 1996; Roitt, Brostoff, Male 
1998; Janeway, Travers, Walport, Capar 1999). 
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IL-2, TNF-P, and IL-12) primarily stimulate cell mediated immunity; type 2 (IL-4, 11-5, 
IL-9, IL-10, and IL-13) primarily induce humoral immunity and diminish cellular 
immunity (Clerci and Shearer, 1994). 
On the other hand, TGF-P triggers the IgA isotype switch (Stavnezer et al., 1997), and 
can help to shut down a THl response (Seder et al., 1998). In addition to cytokines that 
influence B cell maturation but are not involved in isotype switching are IFN-y, IL-l, IL-
2, IL-5, IL-6, IL-12, and IL-15 which are also involved in humoral immunity. In this 
thesis cytokines are classified on the basis of their origin of secretion. The biological 
actions of some cytokines that have been studied are as follows: 
1.3.1 Macrophage derived 
Cytokines that are primarily derived from macrophages are effective in promoting the 
cellular infiltration and damage to resident tissue, characteristics of the inflammatory 
response. The sequence of events leading to the activation of the cytokine cascade in the 
early stages of acute inflammation includes the recruitment of T and B cells by the 
release of cytokines by macrophages. Both proinflammatory (IL-l, IL-6, and TNF-a.) 
and anti-inflammatory IL-ra are cytokines secreted by macrophages. 
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1.3.1.1 Tumour necrosis factor (TNF) 
TNF comprises two proteins of 17 and 25 kilodaltons (kDa) that are primarily derived 
from mononuclear phagocytes (TNF-a) and lymphocytes (TNF-13) respectively (Beuller 
and Cerami 1989; Zhang and Tracey, 1998). In addition to mononuclear phagocytes, 
TNF-a may be produced by neutrophils, activated T or B cells, NK cells, endothelial 
cells, and smooth muscle cells. Furthermore, many cytokines including ll..,-1, ll..,-13, 
granulcyte-macrophage colony stimulating factor (GM-CSF), and interferon may also 
induce transcription of the TNF gene. The genes coding for TNF-a and -13 are located in 
the human MHC. TNF loci have been shown to be extremely polymorphic (Zhang and 
Tracey, I 998). Recent studies have shown that TNF polymorphisms are associated with 
increased susceptibility to autoimmune disease. TNF microsatellite alleles (TNF a2, b3, 
d2) are significantly associated with susceptibility to SLE, RA, and type 1 diabetes. 
These TNF Polymorphisms have also been shown to be associated with RA in an age 
and gender dependent manner (Hajeer et al., 1997). Certain TNF polymorphisms are 
more frequent in female than in male patients (Ha jeer et al., I 997). These differences are 
more obvious in patients stratified according to age at onset. Gender and age at onset 
may be important factors in the immunogenetic studies of autoimmune disease. 
Cytotoxic effect of TNF -a in the destruction of 13 cell in diabetic patients has been 
intensively studied (Soldevila et al., 1990; Soldevila et al., 199I; Pociot et al., 1993). 
1.3.1.2 Interleukin (IL) -1 
The ll..,-1 family represents three peptides (ll..,-1a, ll..,-113, and ll..,-1 receptor antagonist 
(IL-1ra or IL-y) (Oppenheim et al., 1986, Dinarello et al., 1993). One of the most 
prominent biologic activities of ll..,- I is its ability to activate lymphocytes. T -helper cell 
activation requires the interaction of antigen-MHC complex with the TCR. However, an 
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additional non-cognate signal ts also required for optimal T -cell activation and 
proliferation, which is generally provided by IL-l. 
IL-l ra is secreted naturally in inflammatory responses. Its production is up-regulated by 
many cytokines IL-4, IL-13, transforming growth factor (TGF-P), and IL-l itself. 
Alleles of the IL-l ra genes are associated with several autoimmune and inflammatory 
diseases, where they seem to have a role in the severity of the diseases rather than in 
susceptibility to the disease itself. 
Several polymorphisms have been identified in the IL-l genes. Hexa-allelic intron 5 
microsatellite or hexa-allelic intron 6 tandem repeat polymorphisms were found in the 
IL-l a gene (Danarello, 1991 ). There are contradicting reports about their association 
with autoimmune diseases (Eisenburg et al., 1990; Re et al., 1994). 
IL-l ra has been shown to be polymorphic in intron 2 (Danis et al., 1995). Its 
relationship with different autoimmune diseases has also been investigated. 
Finally, another interesting bi-allelic polymorphism in the IL-l gene is based on a C ~ 
T transition in exon IB of the IL-IRT I gene. It is associated with susceptibility to type I 
diabetes (Pociot et al., 1994, Bergholdt et al., 1995). Polymorphisms of IL-IR IT gene 
have not been reported to date and only limited sequence information concerning this 
gene is available. 
1.3.1.3 lnterleukin (IL) ~6 
Mononuclear phagocytic cells are probably the most important source of IL-6. 
However, IL-6 is also produced by T and B cells, fibroblasts, keratinocytes, hepatocytes, 
neuroglial cells, and bone marrow stromal cells (Akina et al., 1993). Its synthesis is 
induced by IL-l, IL-2, and INF-y; however, it is inhibited by IL-4 and IL-13. An 
important biological activity of IL-6 is its ability to stimulate the final stages of B cell 
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maturation. IL-6 shares several activities with IL-l, including the induction of pyrexia 
and the acute phase response. IL-6 may have anti-viral activity and a capacity, shared 
with INF-y, to induce class I J\1HC expression. Like IL-l and TNF, IL-6 may display 
anti-tumour effects. Finally, IL-6 is a neutrophils activator and synergies with other 
cytokines to support bone marrow stem cell maturation. 
Interleukin- (IL-6) is a pleotropic cytokine that recently has been reported in different 
autoimmune diseases (Foulis et al., 1987, Hivano et al., 1989, Ohno et al., 1993, Peters 
et al., 1998, Fishman et al., 1998, Autsushi et al., 1999; Femandez-Real et al., 2000). 
Interleukin-6 may take part in the destruction of pancreatic J3 cells. The role of IL-6 in 
type 1 diabetes has been studied in vitro or in animals (Cavallo et al., 1991, Jiang and 
Woda, 1991, Cambell et al., 1991, Ohno et al., 1993). IL-6 along with IFN-y have been 
reported in the late stage of insulitis of recently diagnosed patients with type 1 diabetes 
mellitus who died shortly after diagnosis ( Foulis et al., 1987). However, IL-6, IL-4 and 
IL-l 0 have not been detected in recently diagnosed patients with type 1 diabetes 
(Cavallo et al., 1991, Hussain et al., 1996) or in prediabetes ( Hussain et al., 1996). 
Urinary IL-6 ts known as a useful indicator of mesangial proliferative 
glomerulonephritis, especially IgA nephropathy (Shikano et al., 1999). Urinary and 
protein levels of IL-6 have been reported in diabetic nephropathy (Shikano et al., 1999). 
Recently, it has been reported that a polymorphism in the 5' flanking region of the IL-6 
gene alters the transcriptional response to stimuli such as endotoxin and IL-6 (Fishman 
et al., 1998). 
In addition to its role in acute response, IL-6 has been recently shown to be released by 
adipose tissue, and release is greater in obese subjects (Mohamed-Ali et al., 1997). 
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Furthermore, IL-6 increases in parallel to glucose and insulin levels in the interstitial 
fluid of subcutaneous adipose tissue (Orban et al., 1999). This increase suggests that IL-
6 might modulate adipose glucose metabolism (Orban et al., 1999; Clarke and 
Mohamed-Aii, 2000). 
1.3.1.4 Interleukin (IL) -15 
IL-15 is a 14-15 kDa peptide that has activity similar to that of IL-2. This molecule has a 
predicted tertiary structure similar to that of IL-2 and has been shown to act as a potent 
growth factor for activated T- and NK cells (Grabestein et al., 1994). Its potential role in 
regulation, proliferation of human NK cells has been investigated (Warren et al., 1996; 
Warren et al., 1996; Carson et al., 1997; Lin et al., 1997). 
The IL-2 receptor system plays a pivotal role in regulatory and effector functions of the 
immune response. Disorders of this system have been observed in association with a 
broad array of human diseases (W aldmann, 1993 ). Several diseases are associated with 
high serum level of the IL-2Ra subunit (CD25) which may not only be due to IL-2 but 
also IL-15 stimulation. This fact was investigated by Treibar-Held and eo-workers on 
native human peripheral blood mononuclear cells who found that IL-15 stimulated more 
IL-2Ra than IL-2. The production of IL-15 by macrophages, and possibly other cell 
types, in response to environmental stimuli and infectious agents suggests that IL-15 
may play a role in protective immune responses, allograft rejection, and pathogenesis of 
autoimmune diseases (Kennedy and Park, 1996). 
The IL-15 gene has been mapped to chromosome 4 region q25-35. It is 14968 bp in 
length and consists of6 exons (Krause et al., 1996). IL-15 and IL-15 receptor expression 
was measured in retinal pigment epithelial cells (RPE) and shown to play an important 
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role in ocular immune and inflammatory responses by stimulating infiltrated T cells and 
RPE cells via paracrine and autocrine loops, respectively (Kumaki et al., 1996). 
IL-15 stimulates the proliferation of y8 T cells (Nishimura et al., 1996) as well as the 
CD8+ T cell-mediated response (Kohn & Kasper, 1996). It has been shown that IL-15 is 
a tumour promoting factor for human non-hemapoietic cells. IL-15 may play an 
important role in T cell-mediated human renal rejection (Pavlakis et al., 1996) as well as 
a role in the host response to HIV infection (Seder et al., 1995). Interleukin 15 may also 
play an important role in autoimmune diseases. Increased expression of IL-15 has been 
found in autoimmune diseases (Kirmann et al., 1996; Ajjan et al., 1997). IL-15 has been 
shown to recruit and activate T cells into the synovial membrane, and may contribute to 
the pathology of Rheumatoid arthritis (Mclnnis et al., 1996). 
To date no polymorphism has been reported in the IL-15 gene although its serum level 
and expression has been investigated in different autoimmune diseases including type 1 
diabetes (Hussain et al., 1996). 
1.3.1.5 Interleukin (IL) -12 
IL-12 is a mononuclear phagocytic cell-derived peptide originally described as NK 
stimulatory factor (Bellone & Trinchieri, 1994). It is a heterodimer composed of 
unrelated subunits. The larger subunit (p40) is homologous to the soluble receptor for 
IL-6, whereas the smaller subunit (p35) is homologous to both IL-6 and GM-CSF. 
IL-12 is predominantly derived from monocytes and macrophages, but also from B cells 
and connective tissue type mast cells. It exerts its effects on resting and activated T cells 
and NK cells by enhancing IFN-y and TNF-a. production (Adorini et al., 1995). 
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IL-12 suppresses the synthesis of immunoglobulin E by IL-4 stimulated human T cells 
(Kiniwa et al., 1992). IL-12 has the capacity to induce TH1 CD4+ cells and its potential 
role in the mediating TH1 cell-mediated autoimmune diseases has made it an attractive 
target for immunointervention (Adorini et al., 1995). Although IL-12 plays a very 
important function in immune regulation and TH1 cell mediated autoimmunity its 
genetic structure is not well known and to date there is no reported polymorphism in the 
IL-12 gene. 
As type 1 diabetes is postulated to be a TH1 cell mediated auto-immune disease, IL-12 
may play an important role in the development of the disease. Szelawska and colleagues 
have shown that IL-12 is involved in the pathogenesis oftype 1 diabetes. 
1.3.1.6 Chemokines (IL-8 and the small cytokine family) 
The chemokines are a small chemotactic cytokine family ofstructurally and functionally 
related proteins that include at least 14 distinct members (Oppenheim et al., 1991, 
Horuk, 1994, Baggioliolini et al., 1994; Terun, 2000). In addition to mononuclear 
phagocytic cells, chemokines are secreted by T cells, NK cells, neutrophils, 
keratinocytes, hepatocytes, fibroblasts, endothelium, and epithelial cells. The peptides 
are small (8-1 0 kDa) secreted proinflammatory cytokines that exhibit between 20-50 % 
homology in their amino acid sequences (Baggioliolini et al., 1994; Nelsson et al., 
1998). The chemokines are characterised by the presence of four conserved cysteine 
residues and are subdivided into two families on the basis of positioning of these 
cysteines. The C-X-C subfamily is located on chromosome 4q, and its members are 
characterised by the separation of the first two cysteines by a variable amino acid. The 
C-C subfamily has the first two cysteine residues adjacent to each other, and its genes 
are located on chromosome 17q. These two families may be distinguished by their 
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primary target cells: the C-X-C subfamily primarily targets neutrophils, and the C-C 
family targets monocytes and T cells. Recently, a new family of chemokines, which 
lacks the first and third C, has been identified and is referred to as the "C family" 
(Nelson et al., 1998; Terun, 2000). 
IL-8 is the most extensively studied member of chemokine superfamily (Leonard et al., 
1990, Oppenheim et al., 1991, Horuk, 1994, Nelson et al., 1998). IL-8 is primarily 
derived from mononuclear phagocytes and endothelial cells but also from T cells, 
eosinophils, neutrophils, fibroblasts, keratinocytes, hepatocytes and chondreocytes. IL-8 
synthesis may be induced by IL-1, TNF, and viruses. IL-8 on a molar basis is one of the 
most potent chemoattractants for neutrophils. It also stimulates polymorphonuclear 
neutrophils degranulation, the respiratory burst, and adherence to endothelial cells 
through CD11b/CD18. Other members of chemokine family-including platelet factor-4, 
macrophage inflammatory protein (MIP)-1a., and neutrophil-activating protein-2 share 
to a lesser extent a capacity to activate polymorphonuclear neutrophils. Other members 
of the chemokine C-C family, including RANTES, MIP, and monocyte chemotactic 
peptides (MCP)-1 and MCP-3 have unique contributions towards allergic inflammation 
(Baggiolini et al. 1994; Nelson et al. 1998), leading to the promotion of the infiltration 
into tissues of a range of leukocyte cell types including effector T cells. Further, tissue 
phagocytes initiate host responses in tissues, and their numbers are soon augmented 
through the action of chemokines, which recruit large numbers of circulating phagocytic 
and immunocompetent cells to sites of infection and tissue damage. Why there are so 
many chemokines is not yet known; neither is the exact role of each one in host defence 
and in pathological responses (Leonard et al., 1990, Nelson et al., 1998, Ward et al., 
1998; Terun, 2000). Recently, however, polymorphic variants in the IL-8 (Emi et al., 
1999) and RANTES peptides (Al Sharif et al., 1999, Hajeer et al., 1999) have been 
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characterised which could be used in the investigations of the role of chemokines in the 
pathogenesis of different diseases. 
1.3.2 T helper 1 (TH1) cytokines 
1.3.2.1 Interleukin (IL) -2 
IL-2 is 15.5 kDa glycoprotein originally called T cell growth factor (TCGF). It is 
produced by CD4+ THl cells and some CD8+ T cells. Stimulation ofT -cells by antigen 
in the presence of IL-l induces the simultaneous secretion of IL-2 and the expression of 
high affinity IL-2 receptors (Taga and Kishimoto, 1995). The binding of secreted IL-2 to 
its receptor on T cells induces clonal IL-2 production and IL-2R expression for T cells to 
proliferate and assures that only T cells specific for the antigen inciting the immune 
response will be activated. 
IL-2R consists of three chains, IL-2a., IL-2(3, and L-2yc, (Minami et al., 1993). One of 
the IL-2 receptor chains (ye) is found to be common between different cytokines, IL-4, -
5, -7, -9, -13, and IL-15 (Waldmann, 1991; Taniguchi et al., 1993; Santo et al., 1995). 
This phenomenon plays a critical role in the interaction between the latter cytokines and 
their receptors, which acts as a major factor in the development and regulation of the 
hematopoietic system (Santo et al., 1995). The high serum level of IL-2R in most 
diseases is perhaps due to this fact. Absence of ye chain is responsible for one form of 
X-linked severe immunodefficiency (Ciark et al., 1995). 
With regard to the importance of IL-2 in the regulation of the immune system, little is 
known about polymorphism in its gene although a microsatellite marker has been 
identified (Denny et al., 1997). 
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1.3.2.2 Interferon (IFN) -y 
Interferon-y is produced by T- and NK cells. IFN- y is a cross regulator between TH1 
and TH2 CD4+ cells. It down-regulates Th2 cell activity and also possesses many 
stimulatory activities. IFN-y is considered by many to be the most important cytokine 
responsible for activation of macrophages. Although IFN-y is a member of cell-mediated 
cytokines it plays an important role as a pro-inflammatory cytokine. Interferon-y is a 
potent immunoregulatory molecule with additional anti-proliferative effects (Farrar et 
al., 1993). IFN-y stimulates antigen presentation and cytokine production by monocytes 
and stimulates monocyte effector functions including adherence, phagocytosis, 
secretion, the respiratory burst, nitric oxide production, and anti-tumour activity. The 
net result is the accumulation of macrophages at the site of the cellular immune 
responses, and their activation of macrophages makes them capable of killing 
intracellular pathogens. As discussed later, IFN-y has been proposed as an inhibitor of 
allergic responses through its ability to inhibit IL-4 mediated effects on B cells, hence, 
inhibit IgE secretion and expression of low-affinity IgE receptors. 
Interferon-y is located on chromosome 12 (Overbach et al., 1981; Weissman, 1981 ). 
However, IFN-y is quite unrelated to other IFNs and human IFN-y contains three introns 
and repetitive DNA sequence which is not highly polymorphic (Patrick et al., 1982). The 
cytokine IFN-y, alone or in combination with IL-l, TNF-a 113 or both and/or IL-6 was 
suggested to be cytotoxic to beta cells (Meuller et al. 1995; Rabinovitch et al., 1996). 
This has been shown subsequently to be the case in rat, mouse, and human pancreatic 
islets in vitro (Nagota and Yoon, 1992; Bradley et al., 1992; Eduard et al., 1993; Kelso, 
1995; Peterson and Haskins, 1996; Miner and Craft, 1998), at least in part via generation 
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of nitric oxide (Craft and Swain, 1995; Peterson and Haskins, 1996). IFN-y is a product 
ofT cells and NK cells, possesses unique immunomodulatory properties, and can affect 
nonlymphoid tissues as well. In addition to the direct effect on beta cells, IFN-y may 
play a role in the pathogenesis of type 1 diabetes for the following reasons. IFN-y 
upregulates MHC class I (Nicholson and Kuchroo, 1996), class 11 (Soldevila et al., 1990; 
Soldevila et al., 1991; Meuller et al., 1996; Wilson et al., 1998), and adhesion molecules 
(Meuller et al., 1997; Szelachowska et al., 1998) on various cells, including pancreatic 
beta cells. It may also modulate the processing of exogenous (MHC class 11) antigens by 
human monocytes (Nadler et al., 1994). Transgenic mice expressing IFN-y by pancreatic 
p cells develop autoimmune diabetes (Sarvetnick et al., 1990; Ciampolillo et al., 1993; 
Rabinovitch et al., 1995), and postnatal anti- IFN-y treatment prevents pancreatic 
inflammation in this model (Wogensen et al., 1994). Antibodies to IFN-y also protect 
against diabetes development in NOD mice (Campbell et al., 1991; Debrays-Sachs et al., 
1991; Rabinovitch et al., 1995; Almawi et al., 1999), and in BB rats (Nicholetti et al., 
1990; Almawi et al., 1999). Finally, IFN-y is expressed in late-stage insulitis in patients 
with a recent-onset oftype 1 diabetes (Foulis et al., 1991; Rabinovitch et al., 1995). The 
reported actions if IFN-y are consistently diabetes promoting, and, therefore, the IFN-y 
gene (IFNG) is an obvious candidate gene for conferring susceptibility to type 1 
diabetes. 
1.3.3 T helper 2 (TH2) cytokines 
1.3.3.i Interleukin (IL) -4 
IL-4 was originally identified as a B-cell growth factor, obtained from the optimal 
stimulation of B cells by antigen (Coffman et al., 1986; Paul, 1987). In addition to T-
helper cells, IL-4 may be derived from cytotoxic T cells, mast cells, and basophils. 
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Furthermore, IL-4 induces the immunoglobulin isotope switch from lgM to IgE 
(Coffman et al., 1986). IgE production occurs after the IL-4 mediated initiation of 
transcription of IgE heavy chain transcripts. The presence of the signal triggers the 
expression of the CD40 molecule and leads to genomic splicing and synthesis of lgE 
transcripts. The additional presence of B cell-activating cytokines, including IL-2, IL-5, 
and IL-6 synergises IL-4 to increase the secretion oflgE (Vercelli et al., 1993). 
In addition to the effect on B cells, IL-4 is a growth factor for T cells (TH2) and 
suppresses TH1 activity. IL-4 activates cytotoxic T cells as well as NK and LAK cells. It 
has some macrophage-activating activities, enhancing the expression ofMHC class I and 
11 molecules, leukocyte function associated antigen-!, and low affinity IgE receptors 
(Paul et al., 1991). 
In contrast to these proinflammatory effects on monocytes, IL-4 inhibits antibody-
dependent cellular cytotoxicity, inhibits the expression of Fey receptors, down-regulates 
production of nitric oxide, IL-l, IL-6, and TNF -a. while stimulating the production of 
IL-lra (Fenton et al., 1992). 
Apart from the latter characteristics ofiL-4, it plays a critically important role in allergic 
diseases through its ability to induce the differentiation of IL-4-producing T helper cells. 
IL-4 along with IL-13 (has approximately 30% homology to IL-4 and shares much of 
IL-4's biologic activities on mononuclear phagocytic cells and B cells), and IFN-y play 
crucially important roles in allergic and inflammation. IFN-y acts as an inhibitor of 
allergic responses through its ability to inhibit IL-4-mediated expression of low affinity 
IgE receptors and isotope switch to IgE. The capacity of T cell clones to support lgE 
production is inversely proportional to their IFN-y production, and clones producing 
both IL-4 and IFN-y will support IgE production only in the additional presence of anti-
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IFN-y antibodies (Romagnani, 1990; Vercelli et al., 1993). Additional cytokines that 
have been reported to inhibit ITA induced IgE production are IL-12, IL-8, and TGF-~ 
(Kiniwa et al., 1992; Gauchat et al., 1992). However, it should be noted that at least one 
study has found no correlation between IL-4 expression and serum IgE levels (Van der 
Pouw-Kraan et al., 1994). 
Genetic markers within the IL-4 encoded region (Sq31-33) have been shown to be linked 
to total serum lgE concentration (Marsh et al., 1994; Xu et al., 1995). Since IL-4 has 
been located in that region, it could be a candidate for the reported genetic linkage. 
Consequently, there have been a number of studies investigating IL-4 gene 
polymorphisms with raised serum IgE levels. Several polymorphisms in the IL-4 gene 
have been identified and have been shown to be associated to lgE concentration (Borish 
et al., 1994; Song et al., 1996; Walley and Cookson, 1996; Dreckback et al., 1997; 
Beghe et al., 1999). Song and his eo-workers have analysed the sequence of "allele 2", 
which was reported to exhibit higher transcriptional activity than all of the other IL-4 
alleles. 
Administration of IL-4 to NOD, non-obese diabetic mice for a period of 14 weeks, 
starting at 6 weeks of age, a marked reduction of diabetes incidence was observed 
(Rapport et al., 1993). Mueller and colleagues (Mueller et al., 1996) generated NOD 
mice in which IL-4 was expressed in the pancreas. Although peri-insulitus was observed 
in NOD-IL-4, it never progressed to insulitis and all mice were protected from diabetes. 
Moreover, sublethally irradiated NOD-IL-4 transgenic recipients, but not their non-
transgenic litterrnates, were protected from diabetes when injected with splenocyes from 
diabetic NOD mice. However, in eo-transfer experiments, they did not protect NOD-
SCID recipients from diabetes caused by splenocyte transfer from diseased NOD donors 
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(Mueller et al., 1997). An intriguing result was observed when NOD-IL-4 mice were 
crossed with NOD-TCR transgenic mice specific for a pancreatic antigen. While neither 
the NOD-IL-4 nor the NOD-TCR transgenic mice developed diabetes, NOD-IL-4-TCR 
transgenic mice developed diabetes with a higher frequency than non-transgenic NOD 
mice (Mueller et al., 1997). Thus, in this restricted T cell repertoire model, pancreatic 
expression of IL-4 has a deleterious effect on the development of diabetes. 
Recently, however, Leech and colleagues showed that a significant drop in secretion of 
IL-4 and IL-10 in type I diabetes (Leech et al., 1999). The increase in IL-4 and IL-l 0 
production in recently in vivo activated T cells in newly diagnosed diabetic subjects may 
represent an attempt at immunoregulation of active insulitis (Leech et al., 1999). 
1.3.3.2 Interleukin (IL) -10 
IL- 10 has a predominantly anti-inflammatory effect. IL-l 0 or cytokine inhibitory factor 
was initially identified in mice, in which it is a product of TH2 cell that inhibits both 
THI proliferation and production ofiFN-y and IL-2 (Fiorentino et al., 1989). Subsequent 
studies have extended these activities to man and have shown that IL-l 0 is also a 
product of other cells, B cells, mast cells, and mononuclear phagocytic cells. IL-l 0 
contributes to isotype switching to IgG I and IgG3 (Briere et al., 1994). IL-l 0 also 
functions as a growth factor for cytotoxic T cells. Thus, IL-l 0 inhibits cytokines 
associated with cellular immunity and allergic inflammation while stimulating cytotoxic 
immune responses. The kinetics of IL-l 0 production differs from those of other 
cytokines (Yassel et al., 1992). The appearance of IL-l 0 thus correlates with and may 
contribute to the down-regulation of the pro-inflammatory cytokines which may be a 
signal for IL-10 synthesis (Wanidworanun et al., 1993; Eskada et al., 1997). 
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TNF-a. secretion is a potent stimulator for IL-10 secretion. These studies suggest a 
hoineostatic mechanism whereby an inflammatory stimulus induces TNF-a. secretion, 
which in turn stimulates IL-l 0 secretion, which acts as a negative feedback for TNF-a. 
secretion. 
Interleukin-1 0 is an important regulatory cytokine whose involvement extends into 
diverse areas of the human immune system. Recent studies have shown elevated serum 
levels of IL-l 0 in several auto-immune diseases; such changes may have a genetic 
background. Genetic influence on IL-l 0 production is an area that is currently being 
studied. To date there are few reports about polymorphisms in the IL-l 0 gene (Eskada et 
al., 1997; Turner et al., 1997; Hobbs et al., 1997). Some of these polymorphisms have 
been associated with autoimmune diseases (Eskada, 1997). 
1.3.4 T-helper 3 (TH3) cytokine 
A third type ofT cell has been identified following oral immunisation with ovalbumin 
(OVA) (Del Prete et al., 1991; Chen et al., 1994; Rabinovitch, 1998; Chen et al., 1998; 
Suri and Katz, 1999; Prud'homme and Picirrollo, 2000). TH3 secretes large amounts of 
TGF-P but low amounts ofiL-4, IL-10, and IFN-y. 
1.3.4.1 Transforming growth factor (TGF) -P 
In view of the vast literature on TGF-P biology, and the publication of recent reviews 
(Derynck and Choy, 1998; Letterio et al., 1998; McCarthy et al., 1998), only the most 
salient points will be mentioned here. TGF-P is a family of polypeptide growth factors 
that has a fundamental role in growth and differentiation. TGF-P is synthesised as an 
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inactive precursor that requires proteolytic cleavage, in a high salt and low pH 
environment to become active. Activation can occur in macrophages (Nunes et al., 1995) 
which are present in inflammatory lesions. 
The TGF-13 superfamily consists of more than 25 molecules isolated from a number of 
species (Kitamura and Suto, 1997). The main subgroup includes three mammalian 
isoforms termed TGF-131, TGF-132, and TGF-133. Differential expression of these 
isoforms may be critical during embryogenesis, carcinogenesis, and in chronic fibrotic 
diseases (Border, 19948 ). The three isoforms are 60-80 % homologous with virtually 
indistinguishable biological activities (Ohta et al., 1987). They are structurally similar 
and act through the same receptors to stimulate a wide variety of cellular responses 
(Basile, 1999). The TGF-131 is produced by many cell types, usually in its latent form, 
but the highest amounts are found in human platelets and mammalian bone (Fontana et 
al., 1992). Antigen specific T cells and activated macrophages produce both active and 
latent TGF-131 (Kehrl et al., 1986). Chen et al. report that THO, THI, and TH2 clones 
can all be induced to secrete TGF-131 through cytotoxic T -lymphocyte-associated 
antigen 4 (CTLA-4). Clearly, TGF-131 production cannot be considered a feature unique 
to a subset of TH cells. At this point, the persistence of TGF-131 production by 
THO/TH1/TH2 clones is unclear, and the significance of this observation in terms of 
immunoregulation has not been defined. However, it seems that CTLA-4, acting partly 
or primarily through TGF-131, counterbalances CD28 eo-stimulation of TH cells (Chen 
et al.,· 1998). The TGF-131-producing phenotype was enhanced by adding II...-4 to 
cultures, or by neutralising THI cytokines with anti-IFN-y plus anti-IL-12 antibodies. 
The presence of IL-l 0 in cultures also favoured TGF -131 production. In addition, Sed er 
et al. reported that TGF-131 strongly stimulated its own production (Seder et al., 1992). 
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From this study it appears that ITA, ll.-10, and TGF-Pl promote differentiation ofTGF-
PI-producing T cells, while IFN-y and/or ll..-12 have the opposite effect. However, from 
the literature, it does not appear that either IT..-4 or ll..-10 is essential for inducing TGF-
p 1 production in T cells, while IFN-y does not necessarily prevent its production. 
Notably, these regulatory T cells can be generated in ll.-4 knockout mice (Seder et al., 
1992). Moreover, memory T cells can produce TGF-P 1 upon activation independently of 
exogenous cytokine stimulation (Seder et al., 1992). 
Since TGF-P 1 protected efficiently against antigen-induced EAE (Chen et al., 1994) 
and various other autoimmune diseases, it is of great interest to learn more about the 
conditions leading to the generation of TGF-P 1. Receptors for TGF-P 1 are present on 
virtually all cells, and it mediates a wide range of biologic activities. In general, it is an 
important stimulant fodibrosis, including formation of the extracellular matrix. TGF-P 1 
has been invariably associated with a decrease in immune responses and improvement of 
autoimmune conditions (Kuru villa et al., 1991; Racke et al., 1991; Karpus and 
Swanborg, 1991; Thorbecke et al., 1992; Ruscetti et al.. 1993; Groux et al., 1995; Poerie 
et al. 1996; Santambrogio et al. 1997). In contrast to these immunosuppressive effects, 
TGF-P is a chemoattractant for macrophages and supports the a isotype switch to IgA 
by B cells (Sonoda et al., 1989; Stavnezer et al., 1997). TGF-P 1 knockout mice do not 
survive because of diffuse inflammation of numerous organs by mononuclear cells 
(Shull et al., 1992). In allergic inflammation the expression of TGF-P1 may be 
associated with the fibrosis observed in long-standing asthma and the subendocardial 
fibrosis associated with the hypereosinophilic syndrome. TGF-P 1 may lessen allergic 
inflammation through a capacity to inhibit E gremlin transcription and IgE synthesis in 
ITA-treated human B cells and through inhibition of mast cell proliferation. Recently, 
' 
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Han's group showed that TGF-~1 prevents spontaneous autoimmune diabetes and 
recurrent diabetes in syngeneic islet-transplanted NOD mice (Han et al., 1996). 
A considerable amount of evidence supports the pathogenic role of TH 1 cells and related 
cytokine production in type 1 diabetes, and this topic has been recently reviewed 
(Delovitch and Singh, 1997; Rabivitch, 1998; Suri and Katz, 1999; Prud 'homme and 
Picirrollo, 2000). In an islet antigen-specific TCR transgenic model, adoptive transfer of 
TH1 cells induced diabetes rapidly in recipients, whereas transfer of TH2 cells did not 
induce diabetes (Kaltz et al., 1995). In NOD mice, gene therapy with a vector encoding a 
soluble IFN-y receptor/ IgG fusion protein (Prud'homme and Young, 1999), or null 
mutation of the IFN-y receptor (O'Garra et al., 1997) protect from autoimmune diabetes. 
IL-12 administration provokes disease in NOD mice, while diabetes is prevented with 
IL-12 antagonists (Trembleau et al., 1995; Trembleau et al., 1997). Expression of IFN-y 
or IL-4 in the ~-islet cells of transgenic mice either promotes or prevents the onset of 
type 1 diabetes, respectively (Delovitch and Singh, 1997, Grewall and Flavell, 1997; 
Rabinovitch, 1998; Suri and Katz, 1999; Prud'homrne and Piccirillo, 2000). 
Administration of IL-4 by protein injection (Delovitch and Singh, 1997; Rabinovitch, 
1998; Suri and Katz, 1999) or gene therapy (Chang and Prud'homme, 1999) is also 
protective. However, islet-reactive TH2 clones injected into NOD-SCID mice can 
induce insulitis and diabetes (Pakala et al., 1997). Thus, the concept that TH2 cells are 
unequivocally protective is not entirely satisfactory. It is possible that the 
immunoprotective effect of IL-4 is mediated indirectly by induction of TGF-~ 1 (King et 
al., 1998; Moritani et al., 1998), as well as by the injection of TGF-~ 1 -producing T -cell 
clones (Han et al., 1996) or gene therapy with latent TGF-~ 1 -encoding vector (Piccirillo 
et al., 1998). However, locally produced TGF-~1 in transgenic mice can induce chronic 
pancreatitis and fibrosis (Sanvito et al., 1995). 
41 
CHAPTER 1: INTRODUCTION 
Interestingly, Han and colleagues found that a protective regulatory T cell clone 
(responsive to self-:MHC class 11 determinants) produced substantial amounts ofTGF-~ 1 , 
IL-10, and IFN-y, and that the suppressive activity could be abrogated by anti- TGF-~ I 
antibodies, but not by anti-IL-l 0 antibodies (Han et al., 1996). Evidently, simultaneous 
production of TGF-~1 and the inflammatory cytokine IFN-y can occur in regulatory 
clones, and the latter cytokine does not stimulate inflammation in that context (Zekzer et 
al., 1997). 
Further, oral administration of insulin induces TGF-~1-producing protective cells 
against diabetogenic factors (Polanski et al., 1997; Maron et al., 1998). Diabetes in 
Bb/Wor rats was prevented by injection of peritoneal exudate cells incubated with TGF-
~ I and islet cells (Keovary, 1994). 
Glucose intolerance is the hallmark of diabetes mellitus. Several studies have shown that 
high glucose induces increase in TGF-~ 1 (Wolf et al., 1992; Bollineni and Sholey, 1993; 
Nakamura et al., 1993; Shankland ans Sholey, 1994; Ziadeh et al., 1994; Moitani et al., 
1998). Glomerular TGF-~lmRNA expression measured by northern blot analysis after 
12-15 weeks of diabetes was increased 2-3 fold in diabetic rats compared to non-diabetic 
rats (Bollineni and Sholey, 1993; Nakamura et al., 1993; Shankland ans Sholey, 1994; 
Ziadeh et al., 1994). An increase in TGF-~ 1mRNA was detected after 24 h of ttie 
induction of diabetes (Ziadeh et al., 1994). Plasma level of TGF-~ 1 in diabetic rats was 
three times higher than in non-diabetic rats (Nakamura et al., 1993). The increase of 
glomerular TGF-~ 1mRNA expression in diabetic rats was attenuated by insulin 
treatment (Bollineni and Sholey, 1993; Ziadeh et al., 1994). Elevation of urinary TGF-
42 
CHAPTER 1: INTRODUCTION 
131 has been reported in patients with diabetes mellitus, with or without renal 
insufficiency (Kapoor et al., 1997; Fagerudd et al., 1997). 
Further, autoimmune diabetes in NOD mice could be prevented by transgenic paracrine 
TGF -131 in the islet compartment through protection against CD4 ( +) and CD8 ( +) 
(Pankeycz et al., 1992; Han et al., 1996; Zekzer et al., 1997; Han et al., 1997). 
All of these findings strongly support a causative role of high glucose increasing the 
TGF-131 levels. An increase in TGF-I31 concentration has been proposed to be a factor for 
the excessive production of extracellular matrix (Ziyadeh et al., 1994; Border and Noble, 
1994; Sharma et al., 1997) proteins seen in diabetes (Bollineni and Reddi, 1993; 
Bollineni and Sholey, 1993; Ziadeh et al., 1994; Sharma et al., 1997). TGF-I31 stimulates 
glucose uptake by enhancing the expression of Glut 1 in mesangial cells, which leads to 
intracellular metabolic abnormalities in diabetes (Inoki et al., 1999). 
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1.4 Immunoregulatory mechanisms 
Autoimmunity, that is, immune reactivity against self, is a normal part of the immune 
system. What causes autoimmunity to progress to autoimmune disease, with functional 
and structural damage to self-cellular components, is not fully understood. Tolerance to 
self may be broken because normally occurring autoimmunity is not controlled, either 
due to deficient elimination or lack of functional interactaction/inhibition of autoreactive 
lymphocytes in the thymus or in the periphery (Kreomer and Martinez, 1992). 
An antigen, typically soluble proteins or glycoproteins are taken up by APC, for 
example, tissue macrophages, dendritic cells, or B-cells by binding to antigen receptors 
on the APC. The antigen/receptor complexes are internalised into the endosomal 
compartment where the antigen is cleaved by sequential proteolysis and trapped in the 
antigen-binding groove of MHC class 11 molecules found in the endosomes. When the 
endosomes fuse with the cell membrane, the antigen peptide!MHC class 11 molecule 
complex is presented on the surface of the cell. The presented antigen!MHC class 11 
complex can be recognised by specific T -helper cells carrying the appropriate T-cell 
receptor. 
Antigen recognition in the absence of secondary signals usually gives rise to tolerance to 
the presented antigen. Secondary signals to elicit an immune response include soluble 
factors and specific cell surface antigens. Soluble secondary signals encompass certain 
cytokines which are non-immunoglobulin signal proteins synthesised by immune and a 
number of non-immune cells when appropriately stimulated. Thus, the cytokine ll...-1 is 
produced mainly by activated macrophages but also by many other cells (Dinarello, 
1994) and provides an important activating signal particularly to resting T -cells by 
binding to specific cell surface receptors. Several cell surface expressed receptor/ligand-
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pairs increase the adhesion between the APC and antigen recognising cells; for example, 
lymphocyte function associated antigen 1 (LEA 1} that binds to inter-cellular adhesion 
molecules 1,2, and 3 (ICAM 1-3), LEA-3 binding to CD2 on T-cells and NI< cells, CD8 
expressed by cytotoxic T -cells binding to the MHC class I and CD4 expressed on T-
helper cells binding to the MHC class 11 molecules on the APC (Dustin and Springer, 
1991). 
When the antigen is recognised by the T -helper cell in the context of appropriate cell 
adhesion and soluble secondary signals, the T-cell is activated primarily via the 
production of a number of cytokine genes. The synthesis and release of cytokines 
mediate leukocyte chemotaxis, endothelial activation, and differentiation of recruited 
leukocytes, and many other biological activities. Interferon-gamma (IFN-y) positively 
feeds back on macrophage IL-l and tumour necrosis factor alpha (TNF-a.) secretion, 
whereby the immune response is amplified. Together, IL-l, TNF-a., and IFN-y are 
central mediators of the acute phase response of inflammation, infection and tissue 
trauma, and have overlapping, but also distinct, biological effects. 
Thus, the early phase of the immune response is characterised essentially by interaction 
between one APC and one antigen recognising cell, which will lead to high 
concentrations of cytokines with paracrine effects on the immediate environment, and 
endocrine actions on more remotely situated tissues. Late stages of the immune response 
are ch!lracterised by build-up of an inflammatory reaction encompassing most active 
immunocompetent cells, the secretion of cytokines, proteases, free oxygen and nitric 
derived radicals, and other immune mediators. 
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1.4.1 Cytokines involved in peripheral tolerance 
Immunosuppressive cytokines participate in creating a state of tolerance. In the NOD 
mouse model for insulin-dependent diabetes, transfer of a certain insulin-specific T -cell 
clone can prevent the destruction of pancreatic p cells by autoreactive T cells (Han et al. 
1996). This suggests that insulin-specific T cells can suppress the activity of other 
autoaggressive T cells in an antigen-dependent manner. They do this by homing to the 
islet, where they react with insulin peptides presented on the P cells. This stimulates the 
secretion of cytokines, prominent amongst which ts TGF-P, a known 
immunosuppressive cytokine (Chen et al., 1994; Rabinovitch, 1998; Chen et al., 1998; 
Suri and Katz, 1999; Prud'homme and Picirrollo, 2000). There are interesting hints that 
such cells naturally affect the course of the immune response that causes human 
diabetes. P-cell destruction in humans occurs over a period of several years before 
diabetes is manifest, yet when pancreas was transplanted from an identical twin into his 
or her diabetic eo-twin, they were destroyed within weeks (Kida et al., 1998). This 
suggests that, in the normal course of the disease, specific T cells protect the p cells from 
attack by effector T cells and the disease therefore progresses slowly. It might be that 
after the host islets have been destroyed, these protective mechanisms decline in activity, 
but that the effector cells responsible for p cell destruction do not (Kida, 1999; Graves 
and Eisenbarth, 1999). 
Furthermore, experimental allergic encephalomyelitis (EAE) is normally caused by THl 
cells that produce IFN-y in response to myelin basic protein. In mice fed with this 
protein, CD4+ T cells that produce cytokines such as TGF-P I and IL-4 are found in the 
brain instead. TGF-P, in particular, suppresses the function of inflammatory TH I 
lymphocytes. In both of these cases, the protection seems to be tissue-specific rather 
than antigen-specific. Thus, feeding with insulin protects against diabetes, yet insulin is 
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not thought to be the target of autoimmune attack on the 13 cells. Likewise, feeding with 
myelin basic protein will protect against EAE elicited by immunisation with other brain 
antigens (O'Garra et al., 1997). Systemic administration of TGF-131 in mice infected 
with L. amozonia led to increased production of IL-4 and decreased synthesis of IFN-y 
(Barral-Netto et al. 1992). TGF-131 may favour TH2 development by attenuating IL-
12RI32 expression (Szabo et al., 1997). IL-12 signal transduction, and cytokine 
signalling will be discussed in section 1.6. 9 (Bright and Stiram, 1998). This ultimately 
reduces IL-12 responsiveness in T cells (Gorham et al., 1998), and results in decreased T 
cell proliferation and IL-12-induced IFN-y production, increase T cell apoptosis, and 
suppressed THI-mediated responses (Szabo et al., 1997; Gorham et al., 1998). 
An anergic CD8+ T -cell islet-infiltrating clone that releases an inhibitory factor (IL-X) 
able to block IL-2 and IL-4-dependent proliferation of T cell, abrogates diabetogenic 
autoimmunity in an accelerated NOD model (Diaz-Gallo et al., 1992). Furthermore, it 
was shown that this soluble factor was neither IL-l 0 nor TGF-13. These data, together 
with the aforementioned studies, would support the existence of cytokine driven 
immunoregulatory which may participate in self tolerance. 
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1.5 Theories of immunity 
Innate immunity is the system of cells and molecules that make up the body's first line 
of defence against pathogens. In other words, the immune system may be the ultimate 
controller of adaptive immune responses through its regulation of the eo-stimulatory 
molecules necessary for T and B cell responses (Janeway, 1989; Janeway, 1992), which 
leads to an expansion of the longstanding self-non-self (SNS) model of immunity. 
According to the expanded SNS model the definition of non-self now includes not only 
the foreign molecules recognised by B and T cells, but also those recognised by the 
innate immune system (both by cells, such as macrophages and dendritic cells, and by 
humoral molecules such as those of the complement cascade) (Fearon and Locksley, 
1996). 
The Danger model (Matzinger, 1994) suggests that immune responses are initiated by 
tissue injury, not by the recognition of non-self. Looking at primitive systems dealing 
with tissue injury aids finding the origin of immunity. In many cases there may be 
nothing wrong with the immune response. The primary cause is in the presentation of 
antigen and the activation of APCs (Matzinger, 1994). 
1.5.1 Autoimmune diseases in light of the "SNS" and "Danger" models 
In any autoimmune disease there are two important questions: a) what initiates the 
destructive response? b) What maintains it? Matzinger has classified autoimmune 
diseases into five categories according to the type of immune responses (Matzinger, 
1998). The immune response in each case is explained in light ofboth the SNS and 
Danger models. 
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1.5.1.1 When there is an unrecognised ongoing infection in the target organ 
In this category there is not true autoimmunity and there is nothing wrong with the 
immune response. The effector cells are clearing the pathogens, however, they damage 
the target organ in the process. Helicobacter Pylori (Frobes et al. 1994), a bacterium in 
upper gastrointestinal tract, turns out to be a common cause of peptic ulcers that were 
thought to be due to autoimmunity mimic which this category. Mouse Theiler's virus, 
which also infects the brain, can closely mimic MS (Miller et al., 1997). 
1.5.1.2 Molecular mimicry 
Molecular mimicry describes cross reaction of self-tissue with an environmental antigen. 
It has often been suggested that a reaction to a self antigen might be initiated by a cross-
reactive environmental antigen (Steinman and Conlon, 1997). In this type a cell 
normally expresses only a subset of its potential peptide!MHC complexes and a change 
in the cell might allow the expression of a peptide that is normally hidden, leading to 
autoimmunity (Cobbold et al., 1992). 
Once tolerance is broken, the SNS models, original and expanded model, have no 
problem with the maintenance of the response. In the belief that, once initiated, an 
immune response continues until the target antigen is cleared, there is no way to stop the 
autoimmune response. 
T and B cells are probably functioning normally to clear pathogen. For example, in type 
1 diabetes the islets are not efficient at tolerating themselves (Von Herrath et al., 1996). 
Individuals with certain alleles of MHC and of tissue specific self antigens will be 
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susceptible to immune damage by crossreactions with environmental pathogens 
(Vidovic and Matzinger, 1988; Matzinger, 1998). Recurring infections will cause 
chronic and/or progressive disease (Matzinger, 1998). 
1.5.1.3 Bad death 
This category is unique and a direct prediction of the Danger model, based on the 
assumption that normal, programmed, cell death does not activate APCs but the cells 
that are stressed in a certain way and the cells that die abnormally send signals which 
can initiate an immune response (Matzinger, 1998). In this category of autoimmune 
disease, as in previous categories, the immune response is normal. What is abnormal is 
the way in which a cell dies and activates local APCs. 
For example, in SLE, the autoantibody response seems to be directed against DNA, but 
where does all this antibody come from? It could come from poorly handled cell death 
which has occurred due to mutation in one of the immune response elements which lead 
to a general defect in T cell tolerance (Vyce and Kotzin, 1998). Nevertheless, the SNS 
models have no other explanation for the role of such defect in one of the immune 
response elements. The Danger model does have an alternative solution where the alarm 
signals activate local APCs, and initiate a response to exposed self antigens captured by 
those APCs (Matzinger, 1998). 
1.5.1.4 Whenever the response is a result, not a cause, of a disease 
This category is a subset of the "bad death" category, described by Livia and Anthony 
Rosen, 1999. The idea was that the disease is unrelated to the immune system. The 
immune response is triggered by the damage and points to the relevant antigens. Rosen's 
idea grew from their study of patients with SLE and with Scleroderma, another 
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connective tissue disease in which a number of autoantibodies appear (Rosen, et al. 
1997; Casciola-Rosen, et al., 1997). They suggested that Scleroderma may not be an 
autoimmune disease. The damage is not due to antibodies but perhaps the immune 
system reacting to the released antigens by producing autoantibodies. These antibodies 
do not influence the course of the disease, though they might help clean up the mess, and 
give insights into the molecules involved (Matzinger, 1998). 
1.5.1.5 The response switches to a harmful class 
The antibodies and cytokines released during an immune response are highly potent 
molecules that can wreak enonnous havoc, and some tissues are more sensitive to 
certain cytokines than others. For example, in diabetes the response could be directed 
against a self component, perhaps as a cross-reaction only made by individuals with 
certain l\1HC haplotypes, or strictly against a pathogen (in which case the autoantibodies 
would be pointers, as in Sclerodenna). In either case, it could be a response made by 
many individuals without destroying their islets. The problem in diabetes may be that the 
response is shifted to a class that destroys the islets, which are sensitive to TNF-13 and 
IFN-y but not to the cytokines made by responses of a different class, such as a TH2 or 
TH3 (Chen et al., 1997). 
This category of autoimmune disease does indeed involve a defect in the immune 
response. It could be a defect in the tissue itself, in a neighbouring cell, in a regulatory 
cell that resides in it, in the signal sent and/or received by APCs, or in the immune 
history ofthe individual, etc. In short, the defect could be anywhere (Matzinger, 1998). 
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1.6 Type 1 diabetes 
Type 1 diabetes is an autoimmune disease characterised by T lymphocyte-mediated 
destruction of insulin producing p cells of the pancreatic islet of Langerhans. According 
to the International Diabetes Federation (IDF) and the World Health Organisation 
(WHO) there were 30 million people with diabetes in 1985. Today, the figure is an 
estimated 143 million. By 2025 there are expected to over 300 million diabetic patients 
worldwide (IDF, 1997). The incidence of type 1 diabetes is from about 5 to 43 per 
100,000 births per year in Caucasians of European descent (Green et al., 1992; Kavonen 
et al. 1993; Buzzetti et al., 1998). It has clearly been established that diabetes is not a 
single disease but a genetically heterogenous group of disorders with glucose intolerance 
as a common feature. The concept of genetic heterogeneity, i.e. that different genetic 
and/or environmental factors can result in similar phenotypes, has significantly altered 
the genetic analysis of this common disorder. It is now apparent that diabetes and 
glucose intolerance are not diagnostic terms but simply describe symptoms and/or 
laboratory abnormalities which can have a number of distinct aetiologies (Graves and 
Eisenbarth, 1999; Friday et al., 1999). 
1.6.1 Classification of diabetes mellitus 
According to the modified WHO criteria, diabetes mellitus can be classified into two 
main categories: Insulin dependent diabetes mellitus, type 1 diabetes or IDDM and non-
insulin dependent diabetes mellitus (NIDDM) or type 2 diabetes. Apart from glucose 
intolerance, diabetes is associated with certain conditions and syndromes such as 
pancreatic disease, endocrine problems, certain drug or chemical-induced conditions, 
abnormalities of insulin or its receptors, or certain genetic syndromes and other 
syndromes which are out of the scope of this thesis (NDDG, 1979; WHO, 1980; WHO, 
1985). Distinguishing features ofthese two categories are listed in Table 1.02. 
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Table 1.02: Characteristics of type 1 and type 2 diabetes mellitus 
Characteristics 
Age of onset 
Nature of onset 
Genetic predisposition 
Secondary environmental 
factors 
B-cell autoimmunity 
Insulin secretion 
Body habitus 
Symptoms at onset 
Long-term complication 
Insulin dependency 
Type 1 Diabetes Mellitus 
Generally in pre-adolscent 
or adolescent; may appear 
at any age 
Often sudden 
Related to specific lll..A 
factors DR3, DR4, DQB 
Viruses, toxins 
Present in initial episode 
Type 2 Diabetes Mellitus 
Typically older than 35 
years; may appear at any 
age 
Slow, insidious 
Strongly familial; unrelated 
tolll..A 
Obesity 
Not present 
Generally absent or reduced Reduced in amount with 
insulin resistance 
Thin, can appear cachectic Usually normal or obese, 
50% obese 
Poyuria, polydipsia, weight Often none, 'or mild ; no 
loss, hunger; ketoacidosis ketoacidosis 
common 
Retinopathy, nephropathy, Similar to Type 
neuropathy; onset after 5 complications 
years 
Absolute Occasionally 
1 
Table indicates features of the major types of diabetes mellitus. 
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1.6.2 Long term complications of diabetes 
The pathogenesis of long-term complications of diabetes remains a subject for debate, 
with the genetic hypothesis and the metabolic hypothesis each receiving support and 
criticism. It has been assumed by some that a genetic predisposition must be necessary 
(Deckert, 1960; Bennett, 2000), although the Diabetes Control and Complications Trial 
(DCCT) results strongly support the over-riding importance of hyperglycaemia for the 
specific complications (DCCT, 1993). Evaluation of the incidence of microvascular and 
macrovascular complications in diabetes secondary to acquired pancreatic disease is of 
interest because it may shed light on the relative contributions of heredity and 
hyperglycaemia. Experimental pancreatectomy is associated with development of 
vascular changes similar to those found in spontaneous genetic diabetes (Dulin et al., 
1983). Recent work in diabetic microvascular complications in man supports the idea 
that genetic factors are important agents for these complications (Tiengo et al., 1988; 
Heesom et al., 1997; Pociot et al., 1998; Chowdhury et al., 1998, Bennett, 2000). 
1.6.2.1 Diabetic Nephropathy 
Diabetic nephropathy is characterised by thickening of the glomerular basement . 
membrane, expansion of mesangial matrix with an altered composition of extracellular 
matrix (ECM), such as the accumulation of fibronectin and collagen, and increasing 
degrees of nodular or diffuse glomerular sclerosis and interstitial fibrosis. Kidney 
changes related to diabetes involve alterations of the glomerular capillaries and 
associated arterioles that lead to changes in filtration, proteinuria, and eventually 
impaired renal function (Border et al. 1998). Nephropathy is a serious late complication 
of diabetes. The disease can be diagnosed clinically with the fulfilment of additional 
criteria including the presence of diabetic retinopathy, and no clinical or laboratory 
evidence of kidney or urinary tract disease other than glomerulosclerosis. Only 20-40 % 
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of patients with type 1 diabetes will develop nephropathy (Krolewski et al., 1985; 
Kofoed-Enevoldsen et al., 1987; Yokoyama et al., 1994). Besides poor glucose control, 
genetic susceptibility seems to be an important pathogenic factor. However, once 
developed, this subgroup of patients with type 1 diabetes demonstrates a mortality rate 
40 times that of the background population and a higher mortality than type 1 diabetes 
patients without nephropathy (Borch-Johnsen and Kreiner, 1987). Patients with 
nephropathy also suffer from an extremely high prevalence of other diabetic 
microvascular complications, invariably retinopathy and neuropathy (Jensen et al., 
1987). Therefore patients with diabetic nephropathy are characterised to be at extremely 
high risk for severe micro- and macrovascular problems. Diabetic nephropathy is now 
the most common and important cause of end-stage renal disease (ESRD) in the United 
States and Europe (Breyer, 1992; Striker et al., 1993; Pociot et al., 1998; Bennett, 
2000). 
1.6.2.2 Diabetic Neuropathy 
Peripheral and autonomic nerves are significantly affected by the abnormal metabolism 
of type 1 diabetes, resulting in pathological change, functional disturbance and clinical 
morbidity. Diabetic neuropathy is the clinical expression of structural and biochemical 
alterations to peripheral somatic or automatic nerve fibres (Sima, 1992; Nathan, 1993). 
Changes in nerve electrophysiology, such as decreased sensory and motor nerve 
conduction velocity, can be detected even in newly diagnosed diabetic patients. 
However, nerve function often improves after hyperglycaemia is corrected by treatment. 
These observations suggest that the changes in nerve function may be secondary to 
metabolic changes in the nerve, such as changes in myelin lipid composition, reduction 
in tissue myoinositol, increased sorbitol, and increased glycosylation of neural proteins. 
Neuropathies are more likely to develop if blood glucose levels are poorly controlled. 
55 
CHAPTER 1: INTRODUCTION 
On average the onset of symptoms occurs 10 to 20 years after diabetes has been 
diagnosed. However, some caution should be used in relating hyperglycaemia to diabetic 
somatic and autonomic neuropathy, because alcohol consumption may be common in 
these individuals. Therefore, the true pathogenic mechanism(s) of neuropathy in diabetic 
patients with pancreatic disease is difficult to define (Zeigler, 2000). 
1.6.2.3 Diabetic Retinopathy 
Diabetic retinopathy involves both morphological and functional changes in the retinal 
capillaries, including basement membrane thickening, loss ofpericytes, increased 
permeability and vascular dysfunction (Bennett, 2000). Long-term studies have shown 
that after 20 years of diabetes, 90 % of patients will have evidence of retinopathy (KI ien 
et al., 1984, Bloom et al., 1994, Anonymous et al., 1998, Klein et al., 1998). Incidence of 
retinopathy is correlated with the duration of the hyperglycaemia (Tiengo et al., 1988). 
Factors that have been associated with the development and progression of diabetic 
retinopathy include gender, HLA type, age at onset, duration of disease, degree of 
metabolic control, presence and treatment of hypertention and relation to puberty 
(Kohner et al., 1996). 
1.6.3 Mechanisms underlying the anti-13 cell autoimmune response 
It is well established that type 1 diabetes results from destruction of pancreatic 13-cells by 
the autoimmune mechanisms in which both environmental and genetic factors are 
involved (Kida et al., 1998;Graves and Eisenbarth, 1999). 
1.6.3.1 Environmental factors 
Several lines of evidence point to a major role of environmental factors in the 
pathogenesis of type 1 diabetes. First, more than 70% of identical twins are discordant 
for the disease, and it is quite unlikely that this is all due to differential somatic 
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rearrangement of TCR. Second, disease frequency varies enormously from country to 
country (Diabetes Epidemiology Research International Group, 1988; Leslie and Elliott, 
1994). These differences cannot simply be explained by ethnic genetic differences since 
migrants from countries with a low frequency of type 1 diabetes to countries with a high 
frequency are more susceptible than their compatriots (Patrick et al., 1989; Leslie and 
Elliott, 1994). Intriguingly, northern countries are more exposed to the disease than 
southern countries (Diabetes Epidemiology Research International Group, 1988; Leslie 
and Elliott, 1994); it will be critical to discover the factor(s) responsible for this 
North/South gradient. Finally, disease incidence is on the increase in most countries 
(IDF, 1997) strongly pointing to an environmental influence; this holds true even in 
areas with a distinct genetic background such as Sardinia, where the incidence has 
increased dramatically, to values much higher than those in surrounding regions 
(Songini and Mountoni, 1991; Leslie and Elliott, 1994). 
Not only do environmental factors seem to influence the onset of type 1 diabetes but 
they may also alter the course of the disease. These factors can be shared by the whole 
population (climate factor, hygiene, etc.), or by a given family (e.g. eating habits), or be 
specific to the individual (e.g. foreign travel and sexual partners) (Buzzetti et al., 1998; 
Knip and Akerblom, 1999). 
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1.6.3.1.1 Viruses 
A viral origin of type 1 diabetes was the first etiological hypothesis (Harris, 1898; 
Jenson et al., 1980; Patterson et al., 1981; Jenson and Rosenburg, 1984; MacDonald et 
al., 1987; Yoon and lhrn, 1990; Munoz and Figueredo, 1992 ; Yon-Herrath et al., 1998), 
but the data on which it was based are more complex than initially thought and must 
now be interpreted in light of data on the autoimmune pathogenesis of the disease. 
Nonetheless, the viral origin of type I diabetes remains a central point in the aetiology of 
the disease. 
Jt has been known for some time that mumps, rubella, and coxasackie B viruses (Jenson 
et al., 1980; Notkins and Yoon, 1984; Parkkonon et al., 1992; Pato et al., 1992; Yon 
Herrath et al., 1998) can infect islet cells in vitro and in the pancreas in vivo. This 
evidence has been derived from studying children with acute onset early childhood 
diabetes, but there is not enough clarity about the potential association of viral infections 
with most cases of autoimmune diabetes (Harris, 1898; Jenson et al., 1980; Patterson et 
al., 1981; Jenson and Rosenburg, 1984; MacDonald et al., 1987; Yoon and lhm, 1990; 
Cambell and Harrison, 1990; Munoz and Figuerodo, 1992; Batch, 1994, Leslie and 
Elliott, 1994; Yon-Herrath et al., 1998). Further, immunologically mediated damage can 
occur after the causative viral infection has been cleared and viral "footprints" are no 
longer detectable in the affected organ. The concept that viruses can cause the disease 
continues as a distinct possibility, especially with the inclusion of recent observation. A 
more mechanistic understanding of events leading to virally mediated type I diabetes 
has evolved from studies using animal models (Ohashi et al., 1991; Yon-Herrath et al., 
1994, Forster et al., 1995;Yon Herrath et al., 1998). 
There are two major processes through which VIruses can activate potentially 
autoreactive lymphocytes without directly destroying the pancreas and/or islets through 
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activation involving inflammatory cytokines (Tough et al., 1996). The other is the 
concept of "molecular mimicry". In this instance, autoreactive lymphocytes are directly 
"cross activated" because they recognise both viral and self determinants (Oidstone, 
1987; Barnett and Fujinami, 1992; Leslie and Elliott, 1994; Von Harrath et al., 1994; 
Baum et al., 1996; Von Herrath et al .. 1996; Von Harrath and Oldstone, 1996; Von 
Harrath et al., 1998). 
1.6.3.1.2 The cows' milk hypothesis 
The theory that diabetes incidence is affected by infant diet was stimulated by 
Scandinavian studies showing correlation between the decline in breast-feeding and 
increase in diabetes in diabetes incidence (Borch-Johnson et al., 1984; Pozzilli, 1999). It 
was suggested that exposure to certain cows' milk proteins (bovine serum albumin, 
casein, or P-lactoglobulin) at an early age interrupted the normal development of 
tolerance to these common dietary antigens (Pozzilli, 1999; Graves and Eisenbarth, 
1999). This theory was strengthened by the observation that there were antibodies in 
diabetes patients which reacted with both a BSA peptide and with islet-cell antigens 
(Karjalainen et al., 1992; Nonis and Pietropaolo, 1999; Pozzilli, 1999; Graves and 
Eisenbarth, 1999). While it is true that reduction in breast feeding often leads to 
exposure to potential diabetogens in cows' milk-based formula, this may occur 
concomitantly with introduction of other foods in the infant diet (Graves and Eisenbarth, 
1999). Numerous subsequent case control studies gave conflicting results about the 
association between breast-feeding and type 1 diabetes, but a meta-analysis of these 
studies indicated a significant but moderate effect of exposure to breast-milk substitutes 
or cows' milk-based substitutes (Nonis and Scott, 1996; Graves and Eisenbarth, 1999). 
However, recall bias as well as differential participation rates by case controls may have 
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affected these studies, and the relatively weak associations observed may have had 
methodological explanations (Graves and Eisenbarth, 1999). 
In summary, despite the conflicting data in this field, the underlying message is that 
exclusive breast-feeding for at least 4 months would be an easy way to reduce the risk of 
type 1 diabetes (Pozzilli, 1999). 
1.6.4 Genetic susceptibility 
Genetic susceptibility to type 1 diabetes appears to be inherited as a polygenic trait 
(Kida, 1988; Buzzetti et al., 1998; Friday et al., 1999; Graves and Eisenbarth, 1999; 
Todd, 2000). The presence of specific "genes disease" can be on the basis of two main 
observations: 
1.6.4.1 Twin studies 
Twin-studies generally provide an idea of which genetic or environmental factors are· 
dominantly involved in the development of the disease. The concordance rate for type 1 
diabetes between identical twins is estimated to be 35-50%, being significantly lower 
than that in dizygotic twins (Barnett et al., 1981; Olmos et al., 1988; Atkinson and 
Maclaren, 1994; Lorenzen et al., 1994; Todd and Farrall, 1996; Buzzetti et al., 1998; 
Hawa et al., 2000). Nevertheless, the concordance in identical twins does not reach 
100%, underlining the importance of environmental factors, whether they be nutritional 
factors to which an individual was exposed early in life, such as cows' milk (Cavallo et 
al., 1996; Szopa et al., 1993; Leslie and Elliott, 1994; Graves and Eisenbarth, 1999), or 
viral infection (Szopa et al., 1993; Von Herrath et al., 1998). However, two significant 
factors should be taken into consideration: 
• Identical twins may be genetically different for certain genes because of postzygotic 
events. The TCR and immunoglobulin (lg) molecules result from both random and 
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ordered recombination of the genes encoding them and may differ between identical 
twins (Tonegawa, 1993; Buzzetti et al., 1998; Friday et al., I999; Todd, 2000). For 
example, a study in twins affected by multiple sclerosis (MS) indicates that the 
expressed TCR repertoire differs within twin pairs discordant for the disease but not 
within concordant pairs (Utz et al., I993). 
• It is agreed that monozygotic twins are predisposed to type I diabetes more than 
dizygotic twins and non-twin siblings. The concordance rate for the disease is 
significantly higher in monozygotic twins possessing a susceptible ill...A type of 
DR3/DR4 than those not possessing it (Wolf et al., I983; Thompson et al., I988; 
Buzzetti, I998; Graves and Eisenbarth, I999; Todd, 2000; Puglies and Eisenbarth, 
2000). Therefore the genetic component may be responsible for the susceptibility to 
type I diabetes. 
1.6.4.2 Familial clustering 
Epidemiological studies support the hypothesised genetic predisposition to development 
of diabetes with strong evidence for familial clustering of the disease. The overall risk 
for developing type I diabetes in North American Caucasian sibling, parents, and 
offspring of individuals with type I diabetes ranges from I% to I5% (Wagenger et al., 
I982; Warram et al., I984; Warram et al., I988; Bleich et al., I993; Warram et al., I994; 
Buzzetti, I998; Friday et al., I999; Todd, 2000; Puglies and Eisenbarth, 2000) as 
compared to less than 1% for individuals without affected relatives, and 1.2/1000 of the 
general population (LaPorte et al., 1995). It is interesting that an increased risk for type 
1 diabetes seems to be present also in first degree relatives of individuals with type 2 
diabetes mellitus (Groop et al., 1986; Landin-Olsson et al., 1992; Tuomi et al., 1993; 
Rewers et al., 1995; Zimmett et al., 1994; Turner et al., I997). Specific ill...A haplotypes 
may account for the susceptibility to both type I and type 2 diabetes mellitus. This latter 
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finding is supported by the occurrence of 13-cell humoral autoimrimnity in 10-33% of 
Caucasian adult onset diabetic patients not treated with insulin (Groop et al. 1986; 
Landin-Olsson et al., 1992; Tuomi et al., 1993; Rewers et al., 1995). Therefore some 
forms of type 2 diabetes manifest a similar genetic susceptibility and immunologic 
abnormalities to those characteristics of type 1 diabetes. 
Siblings sharing identical HLA haplotypes have a 3 or more times higher risk of the 
disease (Cavender et al. 1984; Todd, 1997; Graves and Eisenbarth, 1999;Todd, 2000). 
Furthermore, studies conducted in the United States of America and Scandinavia have 
shown that the offspring of parents with type 1 diabetes have a higher risk for 
progression to the disease if the father, rather than the mother, is affected by the disease 
(Tillil and Kobberling, 1987; Warram et al., 1988; Dahlquist et al., 1989; Alien et al. 
1991; Dahlquist et al., 1991; Tuomelehto et al., 1992; Buzzetti et al., 1998). The risk is, 
in fact, 1/40 among offspring of father's with type 1 diabetes and 1/60 of offspring of 
type 1 diabetic mothers (Nepom, 1995). Different explanations have been proposed for 
this finding: 
• Spontaneous abortion by diabetic mothers of foetuses that might develop type 1 
diabetes (Graves and Eisenbarth, 1999). 
• Ml!-temal environmental factors determine the foetus' level of tolerance to islet 
autoimmunity (Warram et al., 1984; Graves and Eisenbarth, 1999). 
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• There is a paternal transmission of HLA DR3/X category of patients suggesting a 
HLA-associated genetic heterogeneity linked to chromosome Xp in type I diabetes 
(Vadheim et al., 1986; Cucca et al., 1998). 
1.6.5 Dissection of the genetic components 
According to the above evidence type I diabetes appears to have a genetic component. 
Segregation analysis of the genetic component of type I diabetes indicates that the 
disease cannot be categorised as a classic recessive, dominant, or intermediate 
inheritance. There are three main differences with respect to Mendelian diseases: 
• Type I diabetes caused as a result of the interaction between environmental agents 
and different genetic factors (Von Herrath et al., 1998; Pozzilli, 1999). 
• More than one gene is involved in the pathogenesis of the disease, the disease is 
polygenic rather than monogeneic (Buzzetti et al., 1998; Friday et al., 1999; Todd, 
2000; Puglies and Eisenbarth, 2000). 
• The genes responsible for the disease do not represent rare variants or a rare 
mutation, but are polymorphic genes presenting different allelic variants, each with a 
frequency greater than I% in the general population and which differ from among 
each other in some functional characteristics. Although it has been suggested that 
multiple genes play a role in disease susceptibility, until recently only two genetic 
regions had consistently shown linkage to, and association with, type I diabetes in 
man. To identify the susceptible genetic region the abbreviation /DDM and a 
number, e.g. IDDMJ, IDDM2, etc, with the number usually reflecting the order in 
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which such genetic region was reported. Of these, by far the greatest effect is 
encoded by the l\.1HC region on chromosome 6p21.3I (IDDM 1) (Marton et al., I983; 
Todd, I994; Buzzetti, I998; Friday et al., I999; Graves and Eisenbarth, I999; Todd, 
2000; Pugliese and Eisenbarth, 2000). To a lesser degree, the insulin gene (INS) 
region on chromosome IIpi5.5 (JDDM2) seems to be associated (Spielman et al., 
I993; Lucassen et al., I993; Metcalfe et al., I995; Buzzetti, I998; Graves and 
Eisenbarth, I999; Friday, et al., I999; Todd, 200;Pugliese and Eisenbarth, 2000). 
The contribution of these two loci to familial inheritance is approximately 42% for 
IDDMJ and IO% for IDDM2 (Davies et al., I994; Friday et al., I999). There are two 
main hypotheses about genetic susceptibility of type I diabetes with regard to the 
l\.1HC and non-MHC loci. The first theory results from genome-wide scans for type I 
diabetes susceptibility genes and have excluded other genes with an equally strong 
effect to the l\.1HC (Concannon et al., I998; Mein et al., I998). On the other hand, 
many other studies demonstrate a strong association of non-MHC loci to type I 
diabetes (Buzzetti et al., I998; Friday et al., I999; Kida, I999; Todd, 2000; Pugliese 
and Eisenbarth, 2000). 
Further, Verdaguer and colleagues have explained how non-MHC-linked 
polymorphisms can override the susceptibility to type I diabetes provided by pathogenic 
l\.1HC haplotypes, and demonstrated that protective non-MHC genes may selectively 
target specific lymphoid cell types in complex autoimmune responses (Verdaguer et al., 
1999). 
Relationships between many other non-l\.1HC genes and a susceptibility to type 1 
diabetes has been proposed. An up to date, comprehensive list of the known susceptible 
gene regions is shown in Table I.03. 
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1.6.5.1 The MHC genes, HLA cluster (IDDMJ) 
Many factors may combine the risk of progression to type I diabetes. These include a 
family history of diabetes, genotype (HLA haplotype), environmental factors, residual 
insulin secretory capacity islet cell antibody (ICA) on the islet sections, and antibodies 
reacting with characterised islet autoantigens (Pietropaolo and Eisenbarth, I994; Tisch 
and McDevitt, 1996). The presence or absence of the others may modify the prognostic 
significance of any of these risk factors (Bingley, I996). With respect to genotype, 
polymorphic variants of the class 11 antigens DQ and DR are recognised as the major 
contributing genes to HLA-linked susceptibility to autoimmune diab.etes (Trucco, I992; 
Conrad et al., I994; Aitman and Todd, I995; She and Marron, I998). This hypothesis is 
supported by transracial studies that have consistently shown the influence of HLA 
genotypes on the risk of developing diabetes (Aitman and Todd, 1995), and the observed 
conservation of the MHC class 11 effect in both human and murine autoimmune diabetes 
(Owerbach and Gabbay, I996). 
The association of type I diabetes with HLA antigens has been known for many years. 
Indeed, 90-95% of Caucasian patients with type I diabetes, compared to 45-55% of a 
control population, possess the HLA DR3 or DR4 or both antigens. However, 
individuals with heterozygosity for DR3/4 appeared to be the most susceptible to 
progression to type I diabetes (Wolf et al. 1983; Thompson et al., I988). In contrast, 
expression of the HLA-DR2 allele is associated with protection from developing type 1 
diabetes (Erlich et al., 1991; Graves and Eisenbarth, I999). 
Studies involving a variety of racial and ethnic groups have revealed that the presence of 
a specific human DQI3 chain variant encoding a neural amino acid (alanine, valine, or 
serine) other than an aspartic acid residue at codon 57 (non-Asp-57) is strongly 
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associated with type I diabetes {Todd et al., 1987; Todd et al., 1988; More! et al., 1988; 
Khalil et al., 1990). In contrast, a negatively charged aspartic acid at position 57 of the 
DQP chain (Asp-57) appears to confer resistance to type I diabetes (Trucco, 1992; 
Leslie and Elliott, 1994; Todd, 1997). 
Apart from the importance of DQP non-Asp-57 in disease susceptibility, the Arg-52 
amino acid residue of the DQa chain also was shown to be important in the 
susceptibility to the disease {Khalil et al., 1990). These two disease associated HLA 
polymorphisms represent a refinement of the type I diabetes relative risk assessments 
for the HLA-DR3 and HLA-DR4 disease associations. Because of linkage 
disequilibrium, the class II MHC extended haplotype inherited with the HLA-DR3 allele 
includes DQa alleles with the Arg-52 polymorphism and the HLA-DR4 haplotype 
associates with non-Asp-57 DQP alleles. A question subsequently raised is whether 
HLA DQa (52)-Arg and DQP (57)-non-Asp are simply the genetic markers for the 
group of people with a risk of type I diabetes; or whether the changes in the chemical 
structure of HLA DQa and P-chains are directly involved in initiation of the 
autoimmune responses against pancreatic p cells. The latter possibility by a study of the 
three-dimensional structure of the MHC class 11 molecule. The MHC class 11 molecule 
consists of 2 a helices and I P-sheet (Brown et al., 1988; Todd, 1997). The amino acid 
residue 52 of the a-chain and amino acid residue 57 of the P-chain are located at the 
tolerance of the alpha helices. The substitution of the amino acids at these residues of the 
a- and P-chains is thought to alter the three dimensional structure of the HLA class 11 
molecule. This makes it easier for helper T-cells to recognise an antigen peptide sitting 
on a P-sheet together with the MHC class II antigen which initiates the immune 
responses of the MHC class 11 of helper T-cells against the pancreatic P-cells {Figure 
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1.07). Regarding the HLA-DQa chain, a substitution of its residue 52 being modally 
serine with argenine (DQA1 •0301) predisposes to type 1 diabetes through the different 
ethnic groups including Caucasian, black and Japanese populations (Khalil, 1990; 
Buzzetti et al., 1993; Rowe et al., 1994; Sanjeevi et al., 1995; Leech et al., 1995; Nepom 
and Kwok, 1998). Recently, some other polymorphic amino acid variations in HLA-DQ 
and HLA-DR are suggested to be involved in susceptibility to type 1 diabetes; DQ-69 
(Leu) (Sanjeevi et al., 1995; Nepom and Kwok, 1998), DQ-47(Giy) (Buyse et al., 1994; 
Zamani and Cassiman, 1998), and DR 71(Lys) (Harfouch-Hammound et al., 1996; 
Zamani and Cassiman, 1998). 
HLA-DQ8 and HLA-DQ2 have been associated with the predisposition to type 1 
diabetes (Thorsby and Ronningen, 1993). These DQ molecules occur in linkage 
disequilibrium with DR4 and DR3, respectively (Thorsby, 1995). Epidemiological 
studies have shown that· individuals carrying the extended haplotype DR4/DQ8 and 
DR3/DQ2 give the highest predisposition to type 1 diabetes. Several autoantigens have 
been implicated in the aetiopathology of this disease, and these include insulin, GAD 65, 
Hsp60, and IA-2 among others. Most of the efforts have focused on GAD 65 and insulin 
with some work being done on the tyrosine phosphate, IA-2 (Herman et al., 1999; 
Graves and Eisenbarth, 1999). 
67 
C~Rl:ThiTRODUCTION 
1.6.5.1.1 HLA and cytokines 
One of several possible mechanisms for the HLA-disease association is HLA-related 
polymorphism of cytokine expression. However, with the exception of TNF, no 
evidence has been found for a relationship between Ill.,A alleles and cytokine 
expression. This may be because cytokine responses to commonly employed mitogens 
are neither antigen nor HLA dependent, and responses to recall antigens are dominated 
by the effect of prior antigen exposure. The effect ofHLA on secretion level ofTNF-a!P 
and IFN-y has been studied since 1990 (Soldevila et al., 1990; Sachs et al., 1990; 
Soldevila et al., 1991 ). Recently, however, the association of HLA polymorphism to 
IFN-y production has become a well documented issue (Petroviski and Harrison, 1997; 
Weigle and Romball, 1997; Rabinovitch, 1998; Perry et al., 1999). Various authors have 
reported the association between the elevation of TNF-a and IFN-y production to 
polymorphisms in the HLA- DR and DQ haplotypes, whereas, TNF-P production 
differs. This is at first surprising, given that TNF-a and -P genes are adjacent on the 
MHC whereas the IFN-y gene is located on chromosome 12. A possible explanation is 
that the TNF-a and IFN-y genes have a common regulatory factor (Petroviski and 
Harrison, 1997). 
It is not known whether the association between HLA class 11 alleles and diabetes 
susceptibility is the result of linkage disequilibrium with other as yet uncharacterised 
loci, or is a direct result of the gene products themselves. However, given the 
involvement of class 11 in peptide presentation to T cells and subsequent immune 
regulation, it is a likely possibility thai their involvement in initiating autoimmune 
disease is direct (She, 1996), for example by recognition and presentation of self-
peptides, or by altering the developing T cell repertoire and influencing in the production 
ofiFN-y, a major diabetogenic cytokine (Rabinovitch, 1998). 
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Table 1.03: Summary of human type 1 diabetes susceptibility loci 
Locus Chromosome Candidate genes 
Location 
IDDMl 6p21.3 HLA-DR/DQ 
IDDM2 llp15.5 ·ms VNTR 
IDDM3 15q26 ? 
IDDM4 Ilql3.3 "MDUI, ZFMl, RT6, ICE,LRPS, FADD,CD3 
IDDMS 6q25 MnSOD 
IDDM6 18q12-q21 JKOKJdd),Z]{f236 
IDDM7 2q31-q33 NEUROD 
IDDM8 6q25-27 ? 
IDDM9 3q21-25 ? 
IDDMIO 10pll-q11 ? 
IDDMII 14q24.3-q31 ENSA, SEL-1L 
IDDM12 2q33 CTLA-4 
IDDMI3 2q34 IGFBP-2, IGFBP-5, NEUROD, HOXD8 
IDDMIS 6q21 ? 
IDDM17 10g25 ? 
The IDDM nomenclature is assigned to a locus after linkage has been formally 
demonstrated, replicated, and confirmed in at least three different studies (For 
details refer to Buzzetti et al., 1998; Friay et al., 1999; Pugliese and Eisenbarth, 
2000). 
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Figure 1.07: Dlustration of structure of HLA-DQ molecule and antigen 
recognition 
This figure illustrates the process of antigen presentation by APC using HLA-DQ-a. and 
-~ chains which are directly involved in initiation of the autoirnmune responses against 
pancreatic ~-cells (Adapted from Kida et al., 1999 with slight modification). 
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1.6.5.2 The insulin gene region (IDDM2) 
It has previously been demonstrated that the chromosomal region encoding the insulin 
gene in locus IIq15.5 confers susceptibility to type I diabetes (Bell et al., I984; Julier et 
al., 199I; Metcalfe et al., I995; Metcalfe et al, I996). This locus is a 20 kb region 
including the structural genes for tyrosine hydroxide, insulin-like growth factor n 
(IGFII) and insulin. 
Further studies restricted the susceptibility to a region of 4.I kb containing a cluster of 
highly associated polymorphisms (Lucassen et al. I993; Owerbach and Gabbay, I993), 
one or more of which could be responsible for the (IIq I5.5) type I susceptibility. 
Finally, Bennett et al, by "cross-match" haplotype analysis, mapped the IDDM2 within 
the VNTR at the 5' end of the insulin gene (Bennett et al. 1995). The polymorphism 
results from a variable number of tandemly repeated (VNTR) 14 bp oligonucleotides 
located at 363 nucleotides from the transcriptional start site. Alleles of VNTR are 
grouped into three classes according to their lengths (number of repeats): class I with an 
average of 570 bp, class 11 with an average of 1200 bp, and class Ill with an average of 
2200 bp (Lucassen et al., 1993). 
The class I VNTR allele from a parent to offspring is related to the number of repeats 
(Bennett et al., 1995). IDDM2 mapped to the VNTR minisatellite region by a genome 
wide scan of affected sib-pair families is estimated to account for I 0% of family 
clustering of the disease (Davies et al., 1994). It is strongly suggested that the 
susceptibility gene to type I diabetes in IDDM2 is the VNTR locus itself (Owerbach and 
Gabbay, 1993; Bennett et al., 1995; Undlien et al., 1995), although it has not been 
proven definitely (Doria et al., 1996). 
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Homozygosity for short class I VNTR confers a two fold increase in type 1 diabetes risk 
(Pugliese et al., 1994), while class Ill VNTR alleles are dominantly protective (Pugliese 
et al., 1994; Pugliese et al., 1997). The VNTR locus is known to regulate the 
transcription and expression of the insulin gene in the pancreas. The class Ill VNTR 
alleles, protective for type 1 diabetes, are associated with lower levels of steady-state 
expression of insulin mRNA in human pancreas in vivo (Bennett et al., 1995; Vafiadis et 
al., 1996) and in vitro (Kennedy et al., 1995). However, it seems difficult to find a link 
between the lower mRNA levels of insulin in the pancreas and the protective effect of 
class Ill VNTR against type 1 diabetes in reference to the autoimmune mechanisms 
directed to pancreatic cells. It has been found that insulin is expressed in the human 
thymus (Pugliese et al., 1997; Vafiadis et al., 1997). More interestingly, class Ill VNTR 
alleles are found to be associated with 2-3 fold higher levels of insulin mRNA 
expression in the thymus than class I VNTR alleles (Pugliese et al., 1997; Vafiadis et al., 
1997). 
The INS VNTR locus is close to the IGF-II gene. IGF-11 is known to promote T cell 
survival preventing apoptosis, and also has an immunomodulatory activity 
(Polychronakos et al., 1995; Metcalfe et al., 1995). Furthermore, IGF-11 is the dominant 
thymic peptide of the insulin-superfamily sharing a high homology to proinsulin and 
therefore may help induce immune tolerance to proinsulin by negative selection of T 
cells in the thymus (Green et al., 1993). It is to be noted that the class I VNTR is highly 
associated with the higher steady-state levels of IGFII mRNA expression in human 
placenta, showing that the VNTR may act as a long range control element affecting the 
expression of both insulin and IGF-II (Paquette et al., 1998). Inconsistently, no 
associations of INS VNTR variations with IGF-II expression are found in the human 
foetal pancreas and thymus (Vafiadis et al., 1998). 
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1.6.5.3 Other possible genes 
IDDMJ and IDDM2 are the major susceptibility genes for type I diabetes, and the 
contribution of these two loci to familial inheritance is approximately 42% for IDDM 1 
and I 0% for IDDM2 (Davies et al., 1994; Friday et al., I999; Todd, 2000). As a result of 
genome wide searches, relationships between many other non-:MHC genes and 
susceptibility to type I diabetes have been proposed (Table I.03). Some of them have 
been confirmed by subsequent studies, but others have not. The /DDM/2 region, 
includes a gene for CTLA-4 (cytotoxic T-lymphocyte associate-4), that maps to the long 
arm of chromosome 2 (2q33) (Donner et al., I997). As CTLA-4 is a T cell receptor 
which negatively regulates T cells and induces apoptosis ofT cells. It is of interest to see 
if the polymorphisms of CTLA-4 are involved in the development of autoimmune 
diseases caused by a lack of negative selection of T cells, namely apoptosis of 
autoreactive T cells, in the thymus. The polymorphisms of the CTLA-4 gene are 
reported to be linked to and associated with type I diabetes (Nistico et al., I996; Donner 
et al., I997; Marron et al., I997), but a recent family-association study showed no 
association of CTLA-4 polymorphisms with type 1 diabetes (Owerbach et al., 1997). A 
recent genome-wide search for type I diabetes susceptibility genes in 356 affected 
sibpair families from the UK (Warren I) suggests that chromosome I6q22-q24, 
chromosome IOp13-qi1, chromosome I4p12-q2I, and chromosome I9p13-q13 may be 
potential susceptibility candidates genes for type 1 diabetes, outside the HLA region 
(Bain et al., I990; Todd, I997; Mein et al., 1998; Todd, 2000). 
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1.6.6 Humoral immunity 
Organ specific autoantibodies, such as anti-thyroglobulin antibodies are often detected in 
patients with type I diabetes (Kaino et al., 1994). The autoantibodies specifically 
directed to pancreatic ~ cells are known to be present in the circulating blood of patients 
with type I diabetes and, furthermore, to emerge before the clinical onset of the disease. 
These comprise islet cell antibodies {ICA), insulin autoantibodies {IAA), and some 
others, such as autoantibodies against tyrosine phosphate {IA2), and membrane 
glycoprotein (Giima 38) (Baekkeskov et al., I990; Aanstoot et al., 1996; Graves and 
Eisenbarth, 1999). Today, these antibodies are not believed to be directly involved in the 
destruction of pancreatic ~ cells but to be secondary immunological phenomena 
subsequent to destruction of pancreatic ~ cells (Graves and Eisenbarth, 1999). 
Some studies have shown that administration of the autoantigens GAD or insulin, 
prevent or slow down the development of diabetes, which suggests that these 
autoantigens play a key role in the development of the autoimmune response and 
destruction of pancreatic ~cells (Tisch et al., 1994). 
Such antibodies may be detected in a prediabetic stage several months or years prior to 
the clinical onset of type I diabetes. In a study, changes in ICA were noticed before and 
after the onset of type I diabetes in a 9 year old girl. ICA was already positive after I2 
months before the clinical onset of the disease and its titre increased steeply thereafter 
reaching its peak at the time of its clinical onset. The changes in ICA titres were 
inversely correlated with insulin secretion and glucose tolerance expressed by HbA I c 
(Kida et al., 1994). Autoantibodies are, therefore, very good predictors of the 
development of type I diabetes in high risk populations, particularly when in high titre. 
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It has been reported that almost all subjective autoantibody positive develop type 
diabetes within S years, if they were positive for 3 auto-antibodies (Verge, 1996). 
Although diagnosis of type I diabetes rests on the detection of humoral antibodies 
detected against beta-cell antigens, it is now recognised that initiation of beta-cell 
autoimmunity is a T -cell mediated process (Wegman et al., 1996). This conclusion is 
based on evidence of cellular infiltration (insulitis) in the islets of NOD mice long before 
the development of overt diabetes, T -cell adoptive transfer experiments and isolation of 
islet specific T -cell clones. However, the sequence of development of autoantibodies can 
be revealing in terms of the primary initiating targets of the immune response. Until 
recently, it was thought that GAD might be the primary antigen to be recognised, but 
now attention is shifting towards insulin (Eisenbarth, 1994). 
1.6.6.1 Cytokines involved in humoral immunity 
At least two cytokines contribute to B cell maturation in the bone marrow; the lymphoid 
stem cell growth factors IL-7 and IL-11. Once B cells egress from the bone marrow, 
isotype switching, the activation of mature B cells, and their final differentiation into 
plasma cells are processes that are under T -cell control (Finkelman et al., 1990). 
Switching mechanisms involve at least two factors: T ceii-B cell cognate interactions 
and secretion of interleukin molecules (Cyster et al., 1994). These interleukins make 
accessible the S' switch regions of the heavy chain DNA sequence so that they, E, or a 
genes can be transcribed. Contact signals provided by the T cells are triggered through 
the CD40 ligand on the surface of the B cells by the CD40 ligand on T cells (Cyster et 
al., 1994). Cytokines that trigger the isotype switch include IL-4 and IL-13, which 
induce switching to the IgE isotype (Vercelli et al., 1993; Borish and Rosenwasser, 
1996). There are many reports that categorise cytokines of TH2 origin as mediators of 
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humoral immunity. However, there are cytokines of macrophage or THl origin that take 
part in humoral immunity. For example, TGF-13, which triggers the IgA isotype switch. 
IL-10 contributes to the generation oflgG isotypes. Other cytokines that influence B-cell 
maturation but are not involved in isotyp~ switching are IFN-y, IL-l, IL-2, IL-5, and the 
recently described B-cell growth factors IL-4, IL-6, IL-12, and ILlS (as discussed 
earlier) are also involved in humoral immunity. 
1.6. 7 Cellular immunity 
It is believed that cellular immunity plays a primary role in the destruction of pancreatic 
13-cells. Infiltration of pancreatic islets, known as "insulitis" or "insulinitis" is found in 
patients with type I diabetes. lmmunostaining of biopsies of pancreatic islets from 
patients with type I diabetes reveals that most of the infiltrating T cells are CDS+ and a 
few are CD4+ cells (Itoh et al., 1993). Conversely, in NOD mice, which are an animal 
model of type I diabetes, most of the infiltrating lymphocytes on pancreatic islets are 
CD4+ cells and approximately I 0% are CDS+ cells (Ito et a!, 1996). The CD45RB low T 
cells are predominant among CD4+ cells infiltrating a pancreatic islet in NOD mice 
(Shimada et al. 1996). The balance between THI and TH2 is thought to be involved in 
cellular immunity, leading to destruction of the pancreatic 13 cell (Rabinovitch, 1994). A 
shift of THI/TH2 balance towards THI dominance seems to be closely related to 
cellular autoimmunity against pancreatic 13 cells in patients with type I diabetes and 
animal models of diabetes. There is a sex difference in the incidence of diabetes in NOD 
mice, providing a clue for understanding the underlying basis for autoimmunities to 
pancreatic 13 cells in man. 
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More mRNA for TH1 cytokines than for the TH2 seemed to be produced by T cells 
infiltrating the pancreatic islets in female NOD mice that are diabetes-prone. The 
opposite was fewer for male NOD mice, which are more diabetes resistant (Fox and 
Danska, 1997; Hirai et al., 1998). CD45Rblow CD4 splenocytes produce more TH2 
cytokines when NOD mice are young. They seem to produce more TH1 cytokines just 
before the onset of diabetes (Shimada et al., 1996). Female NOD mice have more 
CD45Rblow CD4+ splenocytes (considered to be the memory/activated cells) and ·more 
CD4+CD25+splenocytes (considered to be activated cells) than male NOD mice (Hirai 
et al., 1998). Administration of peptides of insulin or GAD decreases THI cytokine 
production while TH2 cytokines production increased in NOD mice, associated with the 
prevention of diabetes in this model (Muir et al., 1995; Sai et al., 1996). These findings 
indicate that dominance of TH1 to TH2 plays a primary role in initiation of the 
autoimmune responses against pancreatic ~ cells leading to its destruction in NOD mice. 
1.6.8 Cytokines in autoimmune diseases 
Several clinical and experimental observations suggest that autoimmune diseases 
develop as a result of abnormalities in the immune response mediated by T cells and T 
cell-derived cytokines (Paul and Seder, 1994; O'Garra et al., 1997; King and Sarvetnick, 
1997). Evidence is accumulating in both experimental animal models and human 
pathological conditions to suggest that the relative contribution of either TH1- or TH2-
dominated reactions can determine the development of a particular autoimmune 
response (Liblau et al., 1995). In most cases, it appears as a consequence of the 
development of self-reactive CD4+ TH 1 cells (reviewed in King and Sarvetnick, 1997). 
The frequently proposed counter-regulatory or protective role of TH2 cells is still not 
clearly established, since TH2 clones can induce autoimmune diseases such as EAE and 
type 1 diabetes under some circumstances (O'Garra et al., 1997). Moreover, in NOD 
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m1ce eo-transfer of islet-reactive TH2 clones with diabetogenic THI clones is not 
protective, and in this strain IL-4 knockout does not exacerbate the disease (Suri and 
Katz, 1999).Recently some authors have proposed that immuno-protectio~ although 
related in some way to IL-4 production, is mediated by different (non-TH2) subsets of 
THO, THI, and TH2 clones can all be induced to secrete TGF-131-producing regulatory 
T cells (TH3) (Del Prete et al., 1991; Chen et al., 1994; O'Garra et al., 1997; 
Rabinovitch, 1998; Matzinger, 1998; Sedden and Mason, 1999; Proud'homme and 
Piccirillo, 2000). 
There is a strong association between infection and the onset of autoimmunity, 
suggesting that infectious agents, genetic factors and environmental factors, might cause 
a breakdown in tolerance that will progress to an autoimmune disease. Diseases such as 
type I diabetes, autoimmune thyroiditis (Graves' disease and Hashimoto's thyroiditis) 
and so forth are examples of such chronic syndromes. Much interest has gone into the 
analysis of their pathogenic mechanisms, and there is now a consensus that these 
diseases are due to a complex interaction between genetic and environmental factors, 
with more knowledge of the former (Foldmann 1989; Buzzetti et al, 1998; Graves and 
Eisenbarth, 1999; Friday et al., 1999; Kida, 1999). 
An essentially random process of gene rearrangement generates antigen receptors on the 
surface of lymphocytes. Consequently, individual lymphocytes have no inherent 
capacity to make the distinction between what is self and what is foreign, and clones 
with self-reactive antigen receptors are generated. Although the initiating event(s) 
remains poorly defined, certain genes have been considered as prerequisite for allowing 
the autoimmune response to occur. Among these, prime consideration has been given to 
the immunologically relevant genes, i.e. Ig, TCR, and those encoded within the MHC. 
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However, there is increasing evidence that the genes coding for cytokines and their 
receptors may be involved in controlling the normal and aberrant immune response. 
Recent studies have shown that certain cytokine genes are polymorphic and these 
genetic variants may have a functional role (Tax, et al., 1995; Song et al., 1996; 
Rosenwaser, 1997; Gurjit, et al, 1997; Awad et al., 1998; Yamada et al., 1998; Perry et 
al., 1999; Dizier et al., 1999; Yamada et al., 1999; Bathgate et al., 2000; Aziz et al., 
2000). Further, cytokine and/or receptor genes are found in areas where susceptibility 
genes have been mapped. To date, very little is known about cytokine gene 
polymorphism and susceptibility to type I diabetes as well as the long-term complication 
of diabetes. 
1.6.8 THlffH2 cytokine profile 
One of the most important points in understanding the cause of autoimmune disease is to 
determine the basis for THlffH2 differentiation in response to antigen. The most critical 
element in determining TH differentiation is the cytokine milieu in which the T cell is 
activated. The major determinant of THI differentiation has been shown to be IL-12. 
Thus, IL-12 induces, in a dose-dependent fashion, increasing concentrations of INF-y 
and decreasing concentrations of IL-4 in the responding TCR lymphocytes (Manetti et 
al., 1993). IL-12 mediated IFN-y may be required for the full expression of the THI 
phenotype (Schmitt, et al., 1994). IL-4, on the other hand, is the major inducer of TH2 
activation (Abehsira-Ama et al., 1992). This has been best established in transgenic mice 
in which the concomitant exposure of the animal to IL-4 and the relevant antigen 
induces, in a dose-dependent fashion, increasing production of IL-4 in the responding T 
cells. In summary, elevation of THl cytokines or reduction of TH2 cytokines are 
followed by THI CD4+ activation. Processes mediated by TH2 cells would be 
accelerated by TH2 cytokines and attenuated by responses of THI type. This cross-
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regulation may partly explain the strong biases towards TH1 and TH2 responses during 
many infections and autoimmune diseases. It may not be the perfect profile model for 
demonstrating autoimmune mechanisms, however, it is the only one available now 
(Matzinger, 1998; Rabinovitch, 1998). 
Type 1 diabetes is a disease that develops in genetically susceptible individuals due to a 
breakdown of self-tolerance that results in destruction of the insulin producing f3-cells. It 
is characterised by lymphocytic infiltration of the pancreatic islets of Langerhans that 
eventually, cause the specific destruction of insulin producing f3-cells (Bedossa et al., 
1989; Mandrup Poulsen et al., 1989; Castano and Eisenbarth, 1990; Foulis et al., 1991; 
Meuller et al., 1995; Robinovitch et al., 1996). Several factors may contribute to the 
destruction of pancreatic f3 cells, including the profile of the cytokines secreted by TH1 
and TH2 subsets ofT-helper cells (CD4+), macrophage antibodies against the islet f3 
cells and cytotoxic T-cells. 
Disrupted immune regulation and the balance ofTHI to TH2 cells have been postulated 
to be crucial in the pathogenesis of type I diabetes (Kelso, 1995; Nicholson and 
Kuchroo, 1996). Cytokines, due to their nature, could be considered to be one of the 
most favourable agents in the latter process, as they are crucially important in the 
regulation and maintenance of immune responses (Fitzpatrick and Kelso, 1998). 
Thl cells secrete interleukin (IL)-2, interferon (IFN)-y, and tumour necrosis factor (TNF)-~ 
whereas TH2 cells secrete IL-4, IL-5, IL-l 0, and IL-13. Both types ofT -helper cells secret 
IL-3 TNF-a, and granulcyte macrophage colony stimulating factor (GM-CSF). 
Previous studies have shown that CD4+ T cells play a primary role in the pathogenesis of 
the disease. For instance, purified CD4+ splenocytes from diabetic NOD mice or a single 
CD4+ T cell clone can transfer diabetes into immunodeficient NOD-scid recipients 
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(Christianson et al., 1993; Peterson and Haskins, 1996). In contrast, CD 8+ T cells are 
dependent on a signal from CD4+ cells before they can destroy pancreatic 13-cells 
(Nagota and Yoon, 1992; Bradley et al., 1992; Edouard et al., 1993; Rabinovitch, 1998 ). 
It is apparent that the ratio of TH1/TH2 cells can have an important role in the initial 
stage of the aberrant immune response. These reports suggest that THO cells can be as 
prevalent as TH1 or TH2-Iike cells after naive CD4 activation, that the relative levels of 
autocrine IL-4 and IFN-y are important to the lack of commitment, and that not all cells 
are predestined to have THI or TH2 phenotypes early in the response (Craft and Swain, 
1995). Previous studies have shown that during the pre-diabetes stage of the disease 
there is an imbalance ofTH1/TH2 cells due to an increase in number of uncommitted T 
cells. This could be due to abnormal secretion of either IFNG or the cytokine IL-4. 
It is becoming clear that the ratio of TH IITH2 cells can have an important role in the 
initial stage of the aberrant immune response. It has been suggested that uncommitted 
THO cells can be as prevalent as TH1 or TH2 cells, and this may be due to the abnormal 
levels of autocrine IL-4 and IFN-y (Craft and Swain, 1995; Nicholson and Kuchroo, 
1996). An imbalance of TH1 and TH2 cells due to an increase in number of 
uncommitted T cells has been demonstrated during the prediabetes stage of the disease. 
Upon secretion of IL-12 from macrophages, THO produces IFN-y, which acts as a 
positive feed back to. deviate the TH1/TH2 balance towards TH1 dominance 
(Szelachowska et al., 1997; Miner and Croft, 1998). 
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1.6.9 Cytokine signalling 
Cytokines have pleiotropic and overlapping effects. Cells of different types, stages of 
activation and differentiation may utilise distinct signalling pathways, leading to the 
hope that tissue- and disease-specific intervention strategies based on tissue-specific 
cytokine action may be developed (Diamond et al. 2000). 
Many cytokine receptors signal by rapid pathway using receptor-associated tyrosine 
kinases of the Janus Kinase family (JAKs), so-called because they have two symmetrical 
kinase-like domains, and thus resemble the two-headed mythical Roman god Janus. 
These kinases then phosphorylate cytosolic proteins called signal transducers and 
activators of transcription (STATs). Phosphorylation of STAT proteins leads to their 
homo- and heterodimerisation; ST AT dimers can then translocate to the nucleus, where 
they activate various genes (Figure 1.08). The proteins encoded by these genes 
contribute to the growth and differentiation of particular subsets ofT cells (Liu et al., 
1998, Leonard and 0' Shea, 1998). 
In this pathway, gene transcription is activated very soon after the cytokine binds to its 
receptor, and specificity is achieved by using different combination of JAKs and STATs. 
This signalling pathway is used by most of the cytokines that are released by T cells in 
response to antigen. Although cytokines are not in themselves antigen-specific, their 
effects can be targeted in an antigen-specific manner by their directed release in antigen-
specific cell-cell interactions and their selective action on the cell that triggers their 
production (Liu et al., 1998; Leonard and O'Shea, 1998; Diamond et al., 2000). Figure 
1.09 shows a basic model for cytokine action. 
Most work on cytokine signalling in P-cells has been performed with IL-l and studies 
are summarised in the following. For comprehensive reviews see (Sandlers et al., 1991; 
Corbett and McDaniel, 1992). 
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Figure 1.08: Illustration of intercellular signalling pathways 
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The intercellular signalling pathways activated by IFN-a are illustrated diagramitacally. 
IFN-a binding aggregates the two subunits of the receptor. This lead to activation and 
polyphorylation of two Jak kinases, Jakl and Tyk2, which then phosphorylate Statl and 
Stat2. These two transcription factors from a complex with a DNA-binding protein 
called p48 (Adapted from Roitt, Brostoff, and Male, 1998) 
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Figure 1.09: Dlustration of a basic model for cytokine action 
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A simple model for cytokine activation of a cell is shown, (the structures illustrated are 
based on those of the IL-6 receptor). Cytokine binds to its receptor on the cells and 
induces dimerisation or polymerisation of receptor polympeptides at the cell surface. 
This causes activation of intercellular signalling pathways, resulting in the production of 
active transcription factors which migrate to the nucleus and bind to the enhancer region 
of gene induced by that cytokine (Roitt, Brostoff, and Male, 1998). 
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1.7 Cytokine genes polymorphism 
Most studies to date have been performed in vitro or in animal models such as the rat 
(Rabinovitch et al., 1996; Szelachowska et al., 1997; Kallmann et al., 1997) which may 
not be representative of type I diabetes in man. Evidence from present studies in man on 
the state of cytokines in the pathogenesis of type I diabetes is incomplete. However, the 
role of cytokine genes and type I diabetes susceptibility can be summarised as 
following: 
1.7.1 The IL-l gene cluster 
The genes encoding IL-a and -~ and IL-l ra as well as the two receptors for IL-l binding 
(IL-RTI and II) have been mapped to the long ann of the human chromosome 2 and 
located to the IDDM7 susceptibility locus in humans (Copeman et al., 1995). Several 
polymorphisms have been investigated for their association with type I diabetes in case-
control studies. 
No association has been found between type I diabetes and a hexa-allelic intron 6 
tandem repeat polymorphism of the IL-l a gene (Copeman et al., 1995). In contrast, the 
13.4 kb IL-l 8* I allele of a diallelic polymorphism due to a silent T to C transition in 
ex on 5 of the IL-~ gene was found to be significantly associated with type I diabetes in 
familial cases. The strongest association was found in patients with type I diabetes not 
carrying the classic HLA DR3 or DR4 haplotypes (Pociot et al., 1992; Pociot et al., 
19941). Interestingly, patients and control subjects carrying type I diabetes associated 
IL-l ~ had higher LPS stimulated IL-l ~ secreted from isolated PBMNC compared with 
patients homozygous or heterozygous for the allele not associated with type I diabetes 
(Pociot et al., 1992; Pociot et al., 19941). 
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The All A I genotype of the penta-allelic 86 bp tandem repeat polymorphism in intron 2 
of the ILIRa gene was also found to be significantly associated with type I diabetes, 
most strongly in familial cases (Pociot et al., 19941). Homozygous IL-IRa was 
significantly associated with lower circulating levels of IL-l Ra compared to 
heterozygous individuals (Mandrup-Poulsen et al., 1994). 
Finally, the genotype frequencies of a biallelic polymorphism based on a C ~ T 
transition in exon lB of the IL-1RTI gene were found to be significantly different in 
patients with type I diabetes compared to healthy controls (Pociot et al., 19941; Metcalfe 
et al., 1995). 
1. 7.2 TNF-a and 13 loci 
The gene for TNF-a is located to the MHC class Ill region on the short arm of 
chromosome 6. There is strong linkage disequilibrium between the TNF locus and the 
MHC class Il susceptibility loci. However, when patients who are identical for HLA 
DR3/4 haplotypes are compared there appears to be an independent contribution to type 
1 diabetes susceptibility from the TNFa2 microsatellite allele (Pociot et al., 1993). 
1.7.3 The IFN-y locus 
The IFNG is a single copy gene that contains three introns and four exons encoding a 
polypeptide of 166 amino acids, 20 of which constitute the signal peptide (Gray arid 
Goedel, 1982; Taya et al., 1982}, and has been assigned to chromosome 12q24.12 (Trent 
et al. 1982). A CA repeat polymorphism in the first intron of the INF-y gene was 
reported to be associated with type 1 diabetes in Japanese population of patients (Awata 
et al., 1994). This association was confirmed in a Spanish (Gallart et al., 1998) and 
Finnish, but not in a Danish population (Pociot et al., 1997). Previous studies have 
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suggested that the polymorphism in IFNG may be related to the secretion of the protein 
(Parvica et al., 1999). 
1.7.4 The IL-4locus 
The human IL-4 gene possesses 4 exons and 3 introns localised on the long arm of 
chromosome 5 on bands q23-31 together with the genes for IL-3, IL-5, IL-9, IL-13, and 
GMCSF (Arai et al., 1989). Binding sites on the IL-4 promoter region were shown to be 
critical for its gene regulation. A C to T transition at -285 bp in the promoter region 
(Song et al., 1996) and another C ( -590) T counting from the first A TG codon (Arai et 
al., 1989) polymorphism have been claimed to be associated with high IgE production 
(Walley and Cookson, 1996). 
Two nucleotide substitutions were identified in allele 2. The first polymorphism is a C to 
T transition at -285 position. The second polymorphism, which is unique to allele 2, is 
an A to G transition at -81. Another polymorphism in the IL-4 promoter region is a C to 
T change at -590 counting from the first ATG codon, which has been investigated for its 
association with different autoimmune diseases (Walley and Cookson, 1996; 
Rosenwaser, 1997; Vandenbroeck et al., 1997; Beghe et al., 1999). Recently, a mutation 
in a sub unit of the IL-4 receptor has been reported which may predispose to allergic 
diseases by altering the signalling of the receptor (Hershey et al., 1997; Rosenwaser, 
1997). 
87 
CHAPTER 1: INTRODUCTION 
1.7.5 The IL-61ocus 
To date there is no genetic study that confirms the role of IL-6 in the pathogenesis of 
type I diabetes. In fact, there has been no report on the association of a polymorphism in 
the human IL-6 gene to autoimmune disease. Recently, however, a single base change 
variation at position -174 in the 5' region of the human IL-6 gene (Yakusha et al., 1987) 
was characterised and its association to systemic-onset juvenile chronic arthritis has 
. been investigated (Fishman et al., 1998). The association of the IL-6 G ( -174) C with 
insulin sensitivity with regard to white blood cell count in type two diabetes has been 
studied (Femandez-Real et al., 2000). 
The G ( -174) C polymorphism in the IL-6 gene has been found to be associated with 
different transcription rates. Specially, subjects with the CC genotype showed lower 
plasma IL-6 levels compared with GC or GG subjects (Fishman et al., 1998). 
1.7.6 The TGF-13tlocus 
The gene for TGF-131 is on chromosome 19q13. TGF-131 gene comprises of7 exons and 
8 introns with 390 amino acids (Derynk et al., 1987). Inter-individual variations in the 
TGF-I31 gene sequence might be associated with different effects of TGF-131 cellular 
functions (Cambien et al. 1996). Several polymorphisms have been reported in the TGF-
131 gene (Cambien et al., 1996; Langdahl et al., 1997; A wad et al., 1998). 
Pociot" et al 1998 have studied a C (76) T in ex on 5 resulting in a change from threonine 
to isoleucine in the position 263 of the peptide and a deletion of C in the intron sequence 
eight bases prior to exon 5. They have reported no association between the two TGF-131 
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sequence variations with type 1 diabetes. However, a significant association was found 
in patients with diabetic nephropathy and C (76) T in exon 5 (Pociot et al., 1998). 
Recently, A wad and colleagues reported a T ( + 869) C and a G ( + 915) C in exon 1 of 
the TGF-P 1 gene which lead to a Leucine ~ Proline and Arginine ~ Proline 
substitution, respectively, in codons 10 and 25 of the TGF-P 1 signalling sequence (Awad 
et al. 1998). These two polymorphisms have been associated with the concentrations of 
circulating TGF-P 1 protein (Awad et al., 1998; Bathgate et al., 2000; Aziz et al., 2000). 
The genetic susceptibility of the latter also have been well studied in different organ 
transplantation (Awad et al., 1998; Bathgate et al., 2000; Aziz et al., 2000). Recently, 
however, the association ofT (+ 869) C has been investigated in other diseases and 
related to the circulating TGF-P protein (Yamada et al., 1998; Yamada et al., 1999). 
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1.8 Aims of this study 
The aim of this study is to investigate the role of cytokine gene polymorphisms in the 
susceptibility to type 1 diabetes and the long term complications of diabetes. 
To date little is known about cytokine gene polymorphisms in this disease. However, it 
is becoming clear that the polymorphism in these genes can modulate their function. 
Therefore, polymorphism of cytokine genes could have a dramatic effect on the 
regulation of the immune system, hence the pathogenesis of the disease. 
In the present study three hundred and eight patients with type 1 diabetes and one 
hundred and fifty healthy Europid controls were genotyped for polymorphism in the 
genes encoding for key cytokines from TH1, TH2, TH3 cell, and macrophage origin. 
The objectives of the project will be: 
• Since IFN-y and ll...-4 play a critical role in the initiation of TH1 and TH2 cytokine 
profile, respectively, the status ofTHIITH2 cytokine milieu will be studied. 
• For the first time the association of the IL-6 G {-174) C polymorphism with type 1 
diabetes will be studied. 
• The immunosuppression and control on the TH1ffH2 cytokine profile has been 
under debate for a long time and has mostly been attributed to ll...-4. The association 
of the TGF-P 1 gene polymorphism with type 1 diabetes will clarify this issue, and 
also be the first report of genetic susceptibility to type 1 diabetes. 
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• In order to confirm the results of case control studies, familial clustering of the 
marker gene for the cytokine gene polymorphisms will be studied. 
• To examine the impact of cytokine gene polymorphism in patients with type 1 
diabetes with regard to age at onset and gender of patients, the susceptibility 
cytokine genes polymorphism with regard to the forementioned factors will be 
assessed. 
Ultimately these results will provide an insight into the role of cytokine gene 
polymorphism in this disease. It may possibly allow new preventative regimes to be 
derived for the treatment of this disease and its complications. 
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2 MATERIALS AND METHODS 
2.1 Study subjects 
2.1.1 Patients 
2.1.1.1 Patients with type 1 diabetes 
Three hundred and eight unrelated British Caucasoid patients with type I diabetes as, 
defined by the National Diabetes Group I979, who had attended the diabetic clinic at 
Derriford Hospital, Plymouth (Dr B. A. Millward) were studied. Local ethical committee 
approval had been obtained. At presentation the ages ranged from I to 52 years (mean ± 
SD = I5.3± 9.9 years). The duration of diabetes in the patients ranged from less than I to 
more than 72 years (mean ± SD =2l.l± I6.3 years). Although age is a continuous 
variable, the patients studied were divided into three groups depending on the age at 
onset of type I diabetes. There are definite peaks of incidence of type I diabetes shown 
to exist at different ages (National Diabetes Data Group, 1979; Williams and Pickup, 
I998), which are determined as follows: 
• <I 0 years pre puberty at onset of the disease 
• I 0-20 years time of puberty at onset of disease 
• >20 years post puberty at onset of the disease 
The characteristics of the patients are presented in Table 2.01. 
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2.1.1.2 Long term complications of diabetes 
In order to study the possible impact of cytokine profiles in the long term complications 
of diabetes, i.e. retinopathy, nephropathy, and neuropathy, one hundred and twenty three 
patients with type 1 diabetes with long-term complications were included in the patients 
with type I diabetes (Table 2.02). 
2.1.1.3 Familial clustering 
Fifty-three multiplex families were used in this study. The families were obtained from 
the BDA-Warren Repository, UK. The classification of the families is as follows: each 
family has at least two children with type 1 diabetes, at least one child being diagnosed 
with type 1 diabetes before the age of seventeen, and both parents are alive (Bain et al., 
1990). 
2.1.2 Control subjects 
2.1.2.1 Normal controls (NC) 
One hundred and fifty cord blood samples were taken following normal healthy obstetric 
deliveries at Derriford Hospital, Plymouth. None of the subjects had a personal or family 
history of type 1 diabetes or any other autoimmune disease. 
2.1.2.2 Diabetic controls 
A group of patients with type 1 diabetes who have no documented long term diabetic 
complications after at least 20 years of duration of diabetes have been used as controls in 
the studies of long term diabetic complications (n=33) (Table 2.02). 
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Table 2.01: Characteristics of patients with type 1 diabetes and normal controls 
Patient Male: Female Age at onset of diabetes Duration of diabetes 
Subgroup n mean ± SD/years mean ± SD/years 
(range) (range) 
Total 140 : 168 15.3± I 0.0 21.1±16.3 
(0-52) (1-72) 
< I 0 years 45 : 54 5.9 ± 2.6 20.3±16.0 
(1-9) (2-72) 
10-20 years 58 52 14.1±3.1 21.5±15.9 
(10-20) (2-72) 
>20 years 46 : 42 30.2±6.9 24.6±16.7 
(21-52) (2-67) 
NC 61 89 
The patient subgroups are expressed as mean ± Standard deviation together with the 
range in brackets. All patients had type I diabetes as defined by the National Diabetes 
Data Group. 
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Table 2.02: Patients with the long term complications of diabetes and diabetic 
controls 
Long term complications of diabetes 
No. % 
Diabetic control (DC) 3 3 I 0. 7 
Diabetic nephropathy (DN) so 16.2 
Diabetic neuropathy (DNu) 42 13.6 
Diabetic retinopathy (DR) so 16.2 
DC= patients who have had diabetes for at least 20 years but remain free of retinopathy 
and proteinuria. 
DN= patients with nephropathy defined as patients who had diabetes for more than 1 0 
years with persistent proteinoria over 12 months in the absence or haematoria or 
infection. 
DNU= patients with overt neuropathy defined as loss of ankle jerks, sensations of pain, 
foot ulcer and/or autonomic neuropathy. 
OR= patients with retinopathy defined as more than S blots or blots per eye. Hard or soft 
exudates, new vessels or flourescein angiographic evidence of maculopathy or previous 
laser treatment for preproliferative or proliferative retinopathy. 
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Figure 2.01: The distribution of patients with type 1 diabetes used in this thesis 
with respect to their gender and age at onset of type 1 diabetes 
60 
50 
0/o 40 
30 
20 
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>10yr 10 to 20 yr >20yr 
I--- Total ---- Male -- Female I 
This figure illustrates the frequencies gender of the patients with respect to age at onset 
oftype 1 diabetes. Both male and female groups of patients with type 1 diabetes were 
distributed almost equally according to age at onset of type 1 diabetes. 
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2.2 Materials 
2.2.1 Water 
Double distilled water was prepared using Barnstead thermoline (Triple Red Limited, 
Oxford, UK), and used in all stock preparations. Sterile water (Baxter Healthcare, 
Thetford, UK) was used in PCR reaction solutions and oligonucliotide digest solutions. 
2.2.2 Reagents 
All reagents used tn this study were of analytical grade or equivalent. Acetic acid, 
disodium ethylene diamine tetra-acetic acid, glycerol, hydrochloric acid, magnesium 
chloride, orthoboric acid, sodium chloride, sodium citrate, sodium dodecyl sulphate, 
Sodium hydroxide, sucrose, Tris (hydroxymethyl) amenomethane and Tween 20 were 
purchased from BDH Laboratory Supplies-Merck Ltd (Poole, UK). Choloroform, 
ethanol, and M were purchased from Rathburns Ltd (Walkerburn, UK). Ammonium 
persulphate, ethidium bromide, and xylene cyanol purchased from Sigma Chemicals 
(Poole, UK). 
2.2.3 Enzymes and buffers 
• Endonuclease restriction enzymes: Nhel, BsmFI, and Nlaiii were purchased from 
New England Biolab, Herts, UK. 
• Tag polymerase and super Tag buffer were purchased from HT Biotechnology, 
Cambridge, UK. 
• Deoxynucleoside 5'-triphosphates (NTPs) and T4 polynucleotide kinase (T4 PNK), 
and y 32P was purchased from Pharmacia Biotech, Herts, UK. 
• 50 x 30 cm filter paper was purchased from Heto Laboratory Equipment, Surrey, 
UK. 
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• Ultra pure agarose was purchased from Life Technologies, Paisly, UK. 
• TEMED and formaldehyde were ordered from Sigma Chemicals, Poole, UK. 
Sequage/™Cocentrate, Diluent, and Buffer were purchased from Biorad, Herts, UK. 
2.2.4 Stock solutions 
• Iris/borate electrophoresis buffer (TBE) 
1 Ox solution: 0.89 mM tris base, 0.89 mM boric acid, 2mM EDT A (pH8.0) 
• Ethidium bromide 
10 mg/ml 
• Xylene cyanol track dye/loading buffer 
0.25% w/v xylene cyanol, 10% v/v glycerol in 10xTBE 
• Sodium chloride/sodium citrate, SDS 
20xsolution: 3M NaCI, 0.3 M tris-sodium citrate 
• TE (Tris-EDT A) 0.1 
10 mM Tris, pH 7.6, 0.1 mM EDTA pH 8.0 
2.3 Autoclaving 
To prevent bacterial infection all solutions, glassware, and plasticware used in this study 
were autoclaved at 121 oc under 15 psi for 30 minutes in a steam autoclave (Prior Clave 
Limited , London, UK). 
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2.4 Genomic DNA isolation from peripheral blood leukocytes 
Ten to 15 m! of peripheral blood venous blood was collected into 5% disodium ethylene 
diamine tetra-acetic acid (Na2EDT A), and stored at -20°C in polypropylene containers 
prior subsequent DNA extraction. 
For DNA extraction a Nucleon®BACC (blood and cell culture) genomic DNA extraction 
kit was used (Scotlab Ltd, Coatbridge, UK). The manufacturer's protocol was followed 
with a slight modification, as below. 
The kit reagents supplied (Reagents A & B, sodium perchlorate, Nucleon® resin) were 
used. 
The peripheral blood was thawed at room temperature, and an aliquot of 1 0-15 m! 
transferred to a 50 ml Falcon tube (Phillip Harris Scientific, Cardiff, UK). To the sample 
a 4x volume of Reagent A (10 mM Tris-HCL, 320 mM sucrose, 5mM MgCb, 1% Triton 
X-100, pH 8.0) was added and mixed on a Luckham R100/TW Rotatest shaker for 4 
minutes. After centrifugation at 1300 g for 4 minutes on a MSE Mistral 1000 (MSE 
Scientific Instruments, Leicester, UK), supernatant containing lysed red cells was 
separated from the pellet and discarded. 
The pellet was resuspended in 2 ml Reagent B (40 mM tris-HCI pH 8.0, 60 mM EDTA, 
150 mM NaCI, I% SDS) and incubated at 37°C for 15 minutes, enabling nuclear 
membrane disruption to occur. The suspension was transferred to a 15ml falcon tube 
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(Phillip Harris Scientific, Cardiff, UK), and SOO ~J,l of sodium perchlorate added and 
mixed by inversion. 
Three ml of chloroform ( -20°C) (Rathburn Ltd, Walkerburn, UK) was added and mixed 
to emulsify the 2 phases, which were separated by centrifugation at 1300 g for 3 
minutes. The aqueous phase containing the DNA was carefully transferred to a fresh 
tube ensuring that the interphase with silica resin and the underlying organic phase was 
not disturbed. The solution was centrifuged for I minute at 1300g to pellet any residual 
silica and after centrifugation, the supernatant was transferred to a clean IS ml falcon 
tube and twice the amount by volume of I 00% ethanol ( -20°C) (Rathburn Ltd, 
Walkerburn, UK) was added to it to precipitate out the DNA. The IS ml falcon tube was 
inverted for several times and resulting "DNA strand" was hooked out using a sterilised 
glass pipette with a sealed tip was used to hook out the precipitated DNA which was 
washed in 70% ethanol, dissolved in SOO !J.l of sterile water. To ensure that all of the 
DNA went into solution, the sample was kept at 4°C over 24 hours. 
2.4.1 Determination of DNA concentration and purity 
To ensure that the DNA was in a homogenous solution the samples were stored at 4°C 
over 24 hours before taking an optical density reading (OD). Five !J,l of stock DNA was 
mixed with 49S!J,l ofTE buffer in a l.S ml microcentrifuge tube. OD's were taken at 260 
nm and 280 nm and compared with a TE reference sample using optically matched 
quartz cuvettes employing a Cecil spectrophotometer (Cecil Instruments Limited, 
Cambridge, UK). The concentration (!J.g/!J,l) of the DNA in the stock solution was 
determined by multiplying the absorbance reading at 260 nm by a factor of five. The 
purity of DNA was assessed using the ratio of Ods at A.260 nm/A.280 nm. DNA yields 
100 
CHAPTER 2: MATERIALS AND METHODS 
ranged from between 200J.!g and 250J.!g DNA per 10 ml blood. DNA stocks were stored 
in the DNA Bank of the Molecular Medicine Laboratory. An aliquot of DNA samples 
were diluted accordingly to give a concentration between 50-150 ng/J.ll for use in PCR 
amplification as will be described in subsection 2.6.1. 
2.5 Linkage markers 
2.5.1 Polymerase chain reaction 
It is possible to obtain large quantities of a particular DNA sequence merely by selective 
replication. The method for selective replication is called the polymerase chain reaction 
(PCR). The development of the PCR, which allows sequences of DNA to be amplified 
easily, has revolutionised genetic mapping. It is a cell-free method of DNA cloning. The 
technique was first described in its initial format in 1971 (Kleppe et al. 1971) and over 
the next twenty six years, appreciation of its potential became widespread (Mull is and 
Faloona, 1987; Saiki et al. 1988). To permit such selective amplification, some prior 
DNA sequence information from the target sequences is required, enabling the 
construction of two oligonucleotide primers, usually about 20 nucleotides in length, 
from each end of the target DNA sequence. Such so-called amplimers, when added to 
denatured genomic DNA, will bind specifically to complimentary DNA sequence 
immediately flanking the desired target region. They are designed so that, in the 
presence of a suitably heat-stable DNA polymerase and DNA precursors (the four 
deoxynucleoside triphosphates, dTP, dCTP, dGTP, dTTP), they can initiate the synthesis 
of new DNA strands which are complimentary to the target DNA segment 
PCR is a chain reaction because newly synthesised DNA strands will act as templates for 
further DNA synthesis in subsequent cycles. Starting with a mixture containing as little 
as one molecule of the fragments of interest, repeated rounds of DNA replication 
increase the number of molecules exponentially. After about 30 rounds of DNA 
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synthesis, the PCR product will include, in addition to the starting DNA, about I 07 
copies of the specific target sequence, an amount which is easily visualised as a discrete 
band of specific size when submitted to agarose gel electrophoresis. An outline of the 
polymerase chain reaction is shown in Figure 2.02. A heat stable DNA polymerase is 
used because the reaction involves sequential cycles composed of three steps: 
• Denaturation- typically at about 93-95°C for human genomic DNA. 
• Annealing- at temperatures usually from 48 to 65°C, depending on the Tm of the 
expected duplex (the annealing temperature is typically about 5°C below the 
calculated Tm). 
• Elongation (DNA synthesis)- typically about 70-74°C. 
All PCR reactions implemented in this study were run in PTC-200 Thermocycler (MJ 
Research, Essex, UK). 
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Figure 2.02: Illustration of polymerase chain reaction (PCR) 
A: First cycle 
Oligonuceotides 
amolimer ••• 
••• 
B: Second / 
·-· :r 
• 
• 
DNA sequence to be 
amplified 
Denaturation, annealing 
---· ~ 
DNA • 
• 
replication • • y · 
• 
C: 20-30 
Polymerase chain reaction (PCR) for amplification of particular DNA sequences. 
Ampli.mers (red) that are complimentary to the ends of the sequence of interest (black) 
are used in repeated rounds of denaturation, annealing, and DNA replication. Copies of 
the target sequence are shown in green. The number of copies of the target sequence 
doubles in each cycle of replication, eventually overwhelming any other sequences that 
may be present (Adapted :fromHartl and Jones, 1998 with slight modifications). 
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2.5.2 Microsatellite analysis 
Short tandem repeat polymorphisms (STRPs) or microsatellite markers are polymorphic 
genetic markers. Such markers were first described in 1982 (Hamada et a!, 1982). 
Microsatellites consist of short sequences, typically 1 to 4 bp in length, that is tandemly 
repeated several times, and often characterised by many alleles. The most useful repeat 
element is the (CA)n repeats are often polymorphic if they exceed 12 repeats, although 
runs of single A's and T's are common as they represent 0.3 % of the genome. 
Microsatellites are repeated frequently, 10 to 60 times, and can readily be amplified by 
PCR. They are widely dispersed throughout the genome being found on average every 6 
kb and because they have many alleles they are very informative (Weber and May 
1989). An example of use of CA repeat marker is shown in Figure2.03. 
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Figure 2.03: Illustration of microsatellite markers 
0 ~I c I c I c I c I c I c I c I c I c I c I c I c I G G G G G G G G G G G G ... 
=f l g I ~ c I c I c I c I c I c I c I c I c I ... I G G G G G G G G G 
B 
This figure illustrates typing of a CA repeat polymorphism that has two alleles as a 
result of variation in the number of the CA. In this figure the C= CA and G= GT. On the 
autoradiograph each allele is represented by a major upper band and two minor ' shadow 
bands' . Individual 1 has genotype as 1 I 3 (according to this study nomenclature) 
(Adapted from Strachan and Read, 1996 with slight alteration) 
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2.5.3 Endonuclease restriction reaction 
Restriction Site Polymorphisms (RSP)-RSPs are polymorphisms resulting in alleles 
possessing or lacking a specific restriction site. Such polymorphisms can be typed using 
an endonuclease restriction enzyme, which signifies the polymorphic allele by cutting 
the PCR products into different sized fragments depending upon the polymorphism. The 
RSP is an alternative to RFLP, a technique which was typed by using Southern blot 
hybridisation (Southern, 1975). Amplimers for RSPs are designed using sequences 
which flank the polymorphic restriction site, amplifying from genomic DNA, then 
cutting the PCR product by an appropriate restriction enzyme and separating the 
fragments by agarose gel electrophoresis (Figure 2.04). 
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Figure 2.04: Illustration of restriction site polymorph isms (RSPs) 
ATGCTGCTCAGGATCCTAGG 
Tl1b bl1b~ I~Jtbld+ ~ldJ~I~d b 
Sstl V ATGCT~ITCAGGATCCT AGG 
~1~~1~~1b~~d!~d~l~J! 
TCAGG TCCTAGG 
lb~J b~ I~J b l~.f bbl 
_ ... 
--• 
--la 
1 2 1 I 2 
This figure illustrates restriction site polymorphisms which cut PCR product with a 
suitable restriction enzyme eg Sst1 V that cuts A and Tin ATCAGG sequence. Allelel 
is cut into a and b fragments as result of restriction reaction and allele 2 has no cutting 
site, a+b; so genotype for an individual with such alleles is 1 I 2 (Adapted from Strachan 
and Read, 1996 with slight modifications) 
107 
CHAPTER 2: MATERIALS AND METHODS 
2.5.4 Amplification refractory mutation system (ARMS) 
Amplification refractory mutation system (ARMS) is an improved PCR technique which 
permits rapid analysis of any known mutation in genomic DNA. This system allows 
genotyping solely by inspection of reaction mixtures after agarose gel electrophoresis. It 
will clearly distinguish heterozygous from homozygous forms of the allele. The ARMS-
PCR system was introduced to molecular biology in 1989 ( Newton et al. 1989). The 
system requires neither restriction endonuclease enzyme digestion, allele specific 
oligonucleotides (ASO) as conventionally applied, nor sequence specific analysis of 
PCR. This is the PCR equivalent of the allele-specific hybridisation which is possible 
with ASO probes. In the case of allele specific hybridisation, alternative ASO probes are 
designed to have differences in a central segment of the sequence (to max1m1se 
thermodynamic instability of mismatched Duples). However, in the case of allele-
specific (ARMS) PCR, ASO amplimers are designed to differ at the nucleotide that 
occurs at the extreme 3' terminus. This is so because the DNA synthesis step in the PCR 
reaction is crucially dependent upon the correct base pairing at the 3' end (Figure 2.05). 
This method can be used to type specific alleles at a polymorphic locus, particularly to 
detect a specific pathogenic mutation. 
108 
CHAPTER 2: MATERIALS AND METHODS 
Figure2.05: Illustration of ARMS-PCR 
Allele A DNA 
5' A 3' 
---.-. -·-·-·- ·-·-·-·-·-·-·-·-·-·-·-·- ·-·-·-·- ·-·-·-·- ~ 
ASA-A ~ -·-·-·- · - ·-·----------------- ---- - --- - - -~--- 5' 
3' T 5' 
A SA-C 
--0 T No amplification 3' 5' 
AlleleCDNA 
5' c 3' 
~ -- - - - - --- - -·-·- · - ·-· - · - · - - - - - · - - - ·-·-· -·- · - · - · - · -·~- - -
~ -----------------------------------..:.:.;,=. ...... ASA-C 5' 
3' 
----'9 No amolification 
G 
AS A-A 
3' 5' 
ASA-A: allele specific amplimer-"A" allele 
ASA-C: allele specific amplimer-"C" allele 
This figure illustrates correct base pairing at 3' end of PCR amplimers (Adapted from 
Strachan and Read, 1996 with slight modification). 
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2.6 Association studies 
Association studies, either in the form of a "case-control" or "family-based TOT" 
(transmission disequilibrium test), have proved to be the most useful approaches 
(Cierget-Oarpoux, 1998). These methods of association studies will be explained in the 
following subsections. 
2.6.1 Case control studies 
There are two types of case-control studies: the prospective cohort study and cross-
sectional study. Cohort studies suffer from having to follow patients up for many years 
and are difficult to fund, and so cross-sectional studies are generally accepted as good 
study designs. Cross sectional case-control studies are performed by comparing the 
frequency of marker alleles, typically from a selected candidate gene, in a group of 
affected individuals (cases) to the frequency of marker alleles in a group of unaffected 
individuals (controls). An allele at a gene of interest is associated with the disease if it 
occurs at a significantly higher frequency among cases compared to control subjects, p= 
:::; 0.05. The statistical analysis is the 2x2, 3x2, and 8x2contingency table, where 
applicable, and chi square test, x2 In general, it is preferable to select a functional 
polymorphic marker from a candidate gene which is believed to be implicated in disease 
pathology. Therefore, markers, for RSPs and ARMS, are typically bi-allelic as opposed 
to microsatellite. 
2.6.2 Family based transmission disequilibrium test 
The transmission disequilibrium test (TOT) was introduced by Spielman et al in 1993 as 
a test for linkage between a complex disease and a genetic marker. This test assesses the 
possibility of linkage between families with one or more affected offspring, where at 
least one parent is heterozygous at the marker near the candidate gene, in cases where 
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disease associations had already been found. However, even if prior evidence for 
association is absent, the TDT is valid and can be used to test any marker (or set of 
markers) for which data are available from parents of one or more affected offspring 
(Spielman and Evans 1996). Family-based association studies will detect marker/disease 
associations only if the marker and disease genes are in linkage disequilibrium, and in 
addition, are linked, in contrast to case-control studies (Evans and Spiel man 1995). 
The advantage of the TDT is that it does not require data from either multiplex families, 
affected or unaffected offspring (Spiel man et al 1993). The TDT involves analysis of the 
frequency of transmission of a designated allele from heterozygous parents to an 
affected offspring, with the knowledge of parental genotype, therefore, being mandatory. 
Each parent transmits one allele to each affected offspring, with the non-transmitted 
allele acting as the control samples. According to Mendelian law, for heterozygous 
parents there is a 50% chance for transmission of each allele to the offspring. Deviation 
from the expected 50 % transmission ratios of marker alleles from heterozygous parents 
to affected offspring can be analysed by constructing a contingency table of parental 
transmitted versus non-transmitted parental alleles (see Table 2.03). The statistic is 
calculated by application of the chi-square statistic (McNemar test) (Thomson 1995). 
The TDT is a powerful method of detection of association which will be positive only if 
the loci are linked to the disease locus. TDT analysis is a valid test for multiplex families 
studies (Ewens and Spielman 1995). 
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Table 2.03: Transmission disequilibrium test 
Transmitted 
Allele I 
Allele 2 
Allele I 
a 
c 
Not transmitted allele 
Allele 2 
b 
d 
TDT formula, x2 (I degree of freedom)= (b-c)2/ (b+c) 
This table shows TDT calculation steps and the formula for its caculation. 
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2.7 Analysis of the IFN-y gene polymorphism 
2.7.1 Oligonucleotide amplimers design and production 
A pair of oligonucleotide primers which flank a 122 bp region of interferon-y gene that 
contains (CA) 12 repeats (Awata et al 1994) were constructed (Figure 2.06). Amplimers 
used were commercially produced on an oligonuceotide synthesiser (Pharmacia Biotech, 
Herts, UK), and diluted for use to concentration of 10 J..LM. All oligonucleotide 
amplimers used in this study were obtained from the same company. 
2.7.2 5'-end labelled amplimer 
The sense amplimer (Table 2.05) was labelled with y-phosphate group ATP, e2P] dATP 
(Pharmacia Biotech, Herts, UK) using T4 Polynucleotide kinase (T4 PNK) (Pharmacia 
Biotech, Herts, UK). For 5' -end labelling the protocol was followed with a slight 
modification. 25 111 of sterile water was added to the tube containing the T4 PNK, 
incubated at room temperature for 5 minutes and then mixed. 50 f.!M of the forward 
amplimer, 1 f.! M of [ l 5P] A TP (I 0 f.!Cilf.l1) was added to the mixture. The volume was 
made up to 50 f.! I with sterile water prior to brief centrifugation followed by incubation at 
37 oc for 45 minutes. The reaction was stopped by immersing the mixture in an ice bath. 
5 f.ll of 5M NaCI, 2 f.! I of Quick-Precip® (Advanced Genetic Technologies Corp, USA), 
3x volume of ethanol (-20)(Rathburn Ltd, Walkerburn, UK) was added to the reaction 
tube to precipitate the oligonucleotide. Centrifugation at 1300 rpm in the MSE Mistral 
1000 (MSE Scientific Instruments, Leicester, UK) pelleted the oligonucleotide from 
which the supernatant was pipetted off. The pellet was washed in 70 % ethanol prior to 
being dissolved in 50 f.ll sterile water. 
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One 11! of the labelled oligonucleotide was counted in a scintillation counter (LS6500 
multipurpose scintillation counter, BECKMAN, USA). This gave a reading around 
25,000 cpm. 
A 20 111 PCR reaction was carried out in 0.2 m! thin walled microtubes (Advanced 
Biotechnologies, Surrey, UK) containing the following (Table 2.04). 
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Table 2.04:The PCR contents for amplification of the IFNG CA repeats 
Concentration ~I 
35P radio lab led forward amplimer (I ~M) 1. 0 
Forward amplimer (10 ~M) 1.0 
Reverse amplimer (10 ~M) 1.0 
10 x Buffer 2.0 
MgCh (10mM) 1.5 
DNTP (20mM) 0.8 
Taq DNA polymerase (5 U/~1) 0.2 
*DNA (50 ng/~1) 3.0 
Sterile H20 10.5 
Total 20 
DNA was added separately to individual tubes. 
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005~M 
0.5~ 
05 ~M 
1 x Buffer 
0.75 mM 
0.8 mM 
1.0 Unit 
150 ng 
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Table 2.05: The set of amplimers and PCR condition for amplification of the IFNG CA repeats 
Amplimers PCR condition Fragment Rference 
size/bp 
1: 5'-TCA CAA TTG ATT TTA TTC TTA C-3' 95°C 5 min 122 Awata et 
2 : 5'-TGC CTT CCT GTA GGG TAT TAT T-3' 
95'C 30 "t 48°C 40 sec 35 cycles 
72°C 40 sec 
al 1994 
72°C 5 min 
I =sense amplimer and 2=antisense amplimer 
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Fig 2.06: Illustration of the IFNG CA repeats on the IFN-y gene 
TTTAAAATTT TATTGATGGT TAATGAAAAG TTTTTACATT TTAAATATTT CATTATTTGT TTAAAACTTA 
GCTGTTATAA TTATAGCTGT CATAATAATA TTCAGACATT CACAATTGAT TTTATTCTTA CAACACAAAA 
TCAAATCTCA ~ CACACACACA CACTCGCACA TGTTTGGAAC TATCTTTTAA AGCTCGTATA 
ATAATACCCT ACAGGAAGGC ACAGTAGATG TAATAGAAAC CTGTACCATT GGGGGGCAGT ATTTTATAGT 
GGGGTGGCTT TGCTGTTTTT TGTTTTTGTA TTTTTTAGCC TAGCTTGAAA ATACTTTCTT TAGCTTACTA 
TAGTTTTTGG 
The CA repeat microsatellite is located at position 1249 to 1373bp. The position of sense 
and antisense amplimers as well as CA repeat is shadowed (Hum IFNG,DNA star 1997). 
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2. 7.3 Agarose gel electrophoresis of the PCR products 
Following PCR amplification, the products were monitored for quality and quantity by 
electrophoresis of an aliquot mixed with tracking dye on a 2% agarose gel (1% w/v 
agarose in 0.5 x TBE buffer) containing 0.01% ethidium bromide. The agarose gels were 
prepared as follows. Two grams of ultra pure agarose (Life Technologies, Paisely, UK) 
was added to IOO m! of 0.5 TBE buffer. The mixture was boiled in a microwave and 
allowed to cool to about 65°C. Ten ~-tl of ethidium bromide (10 mg/ml) (Sigma-Aidrich, 
Dorset,UK) was added and the molten agarose/ethidium bromide gently mixed and 
poured into a level gel template. Two 24 well combs were inserted into the template and 
the gel allowed to set for I h at room temperature. The combs were removed and the 
gel/template submerged in an electrophoresis tank containing 0.5 TBE buffer to a depth 
of 2-3 mm above the surface of the gel. Seven ~-tl of each PCR product was combined 
with I .5 ~-tl of 5x gel loading buffer (5x GLB; 50 mM Tris, pH 7.6, 50 mM EDT A, pH 
8.0, 0. I bromophenol blue (Sigma-Aldrich, Dorset, UK), 40% sucrose (Promega, 
Southampton, UK) was loaded into the appropriate gel well. In addition, 5 ~-tl of I23 bp 
DNA size marker (Life Technologies, Paisely, UK) was loaded in the first well 
associated with each row of samples. 
The samples then underwent electrophoresis at 200 V (constant voltage) for 45 minutes 
(Biorad Power Pac, BioRad,Herts, UK). After electrophoresis, the PCR products were 
viewed under UV transillumination (A.302 nm) and photographed using Syngene 
Genesnap (Genetic research Instrumentation (GRI) Ltd., Essex, UK) loaded with type IV 
UPP- I I -HA film (Sony Corporation, Tokyo, Japan). 
During each run a positive and a negative control samples were run on each gel. 
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2. 7.4 Microsatellite analysis of the PCR products 
Following gel electrophoresis of the PCR products, genotyping was performed for the 
microsatellites (Weber and May, 1989) on an ABI Prism™377 DNA sequencer (Perkin 
Elmer Applied Biosystems, Warrington, UK) as described below. 
2. 7 .4.1 Gel preparation 
Two sequi-Gen ™ GT Electrophoresis Cells, (one front, one back) were washed 
thoroughly with detergent solution, rinsed well with warm water and then allowed to air 
dry. The outside of the cells were cleaned with ddH20 using clean white tissue. The 
sequi-Gen ™ cells were reversed and the inside of the cells sequentially washed with 
ddH20 followed by 70% isopropanol (Rathburn Ltd, Walkerburn, UK) and then cleaned 
with white tissue. In order to ease detachment of the gel from the cells, inside of the top 
cell was introduced to Rapel-saline (Pharmacia Biotech, Herts, UK) and left to dry at 
room temperature to form a fine silicon film. The cells were assembled in a sequagel ™ 
cassette separated by two 0.2 mm gel spacer aligned along their length. The plates were 
firmly clamped with a cassette support to aid gel pouring. 
A 6%, 6M urea/formamide, polyacrylamide gel mix was performed using 36 ml of 
sequagel concentrated 1 , 99 ml sequagel diluent2, 15 ml sequagel buffer3, 12 ml sequagel 
formamide4, 65 ~-tl ofTEMED5, and I ml freshly prepared 10% ammonium persulphate 
(APS) 6 (Sigma-Aldrich, Dorset, UK 1•5 ) in a 250 ml conical flask. The gel mix was 
drawn into a syringe and carefully injected into the space between the plates. The flat 
edge of a 48 well sharks tooth comb was inserted into the top of the gel left for 2 h to 
allow complete polarisation. Alternatively, the gel was wrapped in a Saran Wrap™ and 
left overnight at room temperature. 
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2. 7.4.2 Pre-run 
The shark's tooth comb was carefully removed from the gel, rinsed with warm water, 
dried and reinserted, teeth first, into the gel to a depth of approximately 3mm. The drip 
tray was removed. The cassette was then placed in the bottom tank and connected to a 
powerpack (Biorad-Powepac, BioRad, Herts., UK). The top buffer tank attached to the 
back of the back sequi-Gen TM cell and the bottom tank were filled with 1 x TBE buffer. 
A constant current 1600-2000 V was run through I x TBE buffer and the gel was allowed 
to reach and maintain a temperature of 50 oc. 
2.7.4.3 Sample loading and electrophoresis 
Prior to the loading of samples, the gel temperature was checked to ensure that it was at 
50°C. The instrument was paused and a mixture of 3 J..ll of stop solution (Promega, UK) 
and 6J..ll ofPCR product was loaded in the appropriate well number. The run module was 
initiated and the samples electrophored for 3 hours. 
By completion of the electrophoresis process the current was disconnected and the 
buffer tanks were discharged from 1 x TBE buffer. The sequi-Gen ™ cells were gently 
separated. The gel was detached and washed in a 5% Acetic acid, IS% Methanol 
solution (Rathburn Ltd, Walkerburn, UK). The gel was supported by a 50 x 30 cm filter 
paper (Heto Laboratory Equipment, Surrey, UK) and dried. The dried gel was exposed 
to a Kodak XLSS X-ray film (Scientific Imaging Systems, Cambridge, UK) and 
incubated at -85 oc for 4h. 
DNA samples with known genotype were incorporated as controls in each microsatellite 
analysis 
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Analysis of the IL-4 gene polymorphisms 
2.8.1 The C (-285) T polymorphism 
2.8.1.1 Analysis of the C (-285) T polymorphism 
DNA samples were taken from the DNA bank in the Molecular Medicine Laboratory. 
Briefly, a pair of oligonucleotide amplimers, amplimer 1 and 2 of Table 2.07, was 
constructed which flanks the position of C (-285) T counting from the first ATG codon 
(Arai et al., 1989). A 20 IJ.I PCR reaction consisted of (Table 2.06) was used. 
2.8.1.2 Agarose gel electrophoresis of the PCR products 
Following the PCR amplification of 289 bp fragment of the IL-4 gene containing the C 
( -285) T polymorphism, the efficiency and size of the products were measured prior to 
endonuclease digestion process. The agarose gel was prepared in exactly the same 
manner that described in section 2. 8. 3 with the exception that the gel concentration was 
I%. 
2.8.1.3 Precipitation of DNA 
Since the IL-4 C ( -285) T polymorphism PCR product did not digest straight after the 
PCR reaction, the product was then precipitated aiming to maximise the chance of 
endonuclease digestion: 
Ill 0 of the total volume of sample of3.2 M NaCOOH was added to the sample, 
2 x vol of absolute ethanol was added and mixed thoroughly, 
Snap frozen in liquid N2 for I 0 min, 
Spun in a centrifuge for 15 minutes ( 13000/min), 
The supernatant was decanted and the tube was air dried for 15 min, 
The pellet was dissolved in 20 IJ.I TE. 
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Table 2.06: The PCR contents for amplification of the IL-4 gene polymorph isms 
Concentration J.ll Final Concentration 
Forward amplimer (I 0 J.1M) 1.0 0. 5 J.1M 
Reverse amplimer (I 0 J.1M) 1.0 O.SJ.1M 
!Ox Buffer 2.0 lx Buffer 
MgCb (10 mM) 6.0 3mM 
DNTP (20 mM) 0.5 O.SmM 
Taq DNA polymerase (5 U/J.ll) 0.2 1.0 Unit 
Sterile H20 4.3 
---------
DNA (50 ng/J.ll) 3.0 150 ng 
Total 20 
DNA was added separately to individual tube. 
122 
CHAPTER 2: MATERIALS AND METHODS 
Table 2. 07: The set of amplimers and PCR conditions for amplification of the IL-4 loci 
Amplimers PCR condition Fragment Restriction endonuclease Reference 
Sense and antisense = I and 2 for C (-285) T; 
3 and 4 for C (-590) T Size/bp 
95°C 5 min 
1: 5'- GAG TCT GCC TGT TAT TCT GCC TC- 3' 95"C30=} 258 Nhel I C ( -285) T 
55°C 40 sec 35 cycles 
2: 5'-AAT CAG CAC CTC TCT TCC AGG AG-3' 72°C 40 sec 5' ... G ... CTAG C ... 3' Song et al. 1996 
72°C 5 min 3' ... C GATC""G ... 5' 
95°C 5 min 
3: 5'-ACT AGG CCT CAC CTG ATA CG-3' 
95"C30 "'} 
BsmFI I C (-590) T 
55°C 40 sec 35 cycles 
252 4: 5'-GTT GTA ATG CAG TCC TCC TG-3' noc 40 sec 5' ... GGGAC (N)10 ...... 3' Walley and 
72°C 5 min 3' ... CCCTG (N)I4 ........ 5' Cookson, 1996 
This table shows the set ofamplimers, PCR condition, size of the fragmentas, well as restriction enzymes implemented for amplification ofthe IL-4 loci. 
References are also quoted. 
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2.8.1.4 The C (-285) T digestion via Nhel endonuclease enzyme 
The PCR products were digested using Nhel endonuclease restriction enzyme (New 
England Biolabs, Hertfordshire, UK). 5 J..d of enzyme mix [2.0 J-ll of Buffer B, provided 
by the supplier, 0.5J-ll (5 units) of Nhel and 2.5J-ll of sterile H20 (Baxter Healthcare, 
Thetford, UK)] was combined with l5J-ll of each one of PCR products and incubated at 
37 °C, the optimal temperature for Nhel endonuclease activity. 
However, the reaction did not take place even by using excess amount (5-25 U) of Nhel 
enzyme. 
2.8.1.5 Agarose gel electrophoresis of the PCR products following digestion 
Following endonuclease digestion of PCR products, the resulting fragments were 
resolved using a 2% agarose gel as described in section 2.8.3.However, the 
electrophoresis was carried out by running a constant current of 70 V for 1.5 hour after 
which the gel was visualised and photographed as described above. 
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Figure 2.07: Illustration of the IL-4 C (-285) T and C (-590) T polymorphisms on 
the IL-4 gene 
C (-590) T 
289 bp 
NRE-1 
C (-285) T 
NRE-2 
+I 
PRE TATAbox 
This figure illustrates position ofthe IL-4 C (-285) T and C (-590) Ton the IL-4 gene 
(Adapted from Cookson and Walley, 1996 with slight modifications). 
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2.8.2 The C (-590) T polymorphism 
2.8.2.1 Analysis of the C (-590) T polymorphism 
DNA samples were taken from the DNA bank in the Molecular Medicine Laboratory. 
Briefly, a pair of amplimers, amplimers 3 and 4 of Table 2.07, were constructed which 
flank the position ofthe C (-590) T counting from the ATG codon (Arai et al., 1989). A 
20 Jll PCR reaction as Table 2.06 was used. 
The PCR conditions for the C ( -590) T polymorphism in the IL-4 region was the same 
as above. 
2.8.2.2 Agarose gel electrophoresis of the PCR products 
Following PCR amplification of252 bp spanning positions 522 to 774 in the interleukin-
4 promoter sequence (Genebank accession number M23442), the efficiency and size of 
the products were measured prior to the endonuclease digestion process. The agarose gel 
was prepared in exactly the same way as described in section 2.8.3, with the exception 
that gel concentration was I %. 
2.8.2.3 The C (-590) T digestion via BsmFI endonuclease enzyme 
A total of 15 Jll of PCR product was added to 2. 5 111 of sterile water (Baxter Healthcare, 
Thetford, UK) together with 2.0Jll of Buffer 4 and 0.5 Jll of BsmFI (5 unit) (New 
England Biolabs™, Hertfordshire, UK) to give a final volume of 20 111. The restriction 
digest mixture was then incubated at 37°C for an hour. The reaction was stopped by the 
addition of 5J.1l of agarose gel loading buffer (5xTBE, 0.5 mol/1 EDTA, 10% v/v 
glycerol, 0.05 % w/v Bromophenol Blue). The restriction digest was carried out at 37°C 
rather than the optimum temperature for BsmFI activity, 65°C, because of undesirable 
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Taq DNA polymerase activity at this temperature. At 37°C the restriction enzyme 
retained 50% of its activity. 
I 5 111 of the restriction digest mixture was loaded onto a 2% w/v agarose gel and 
electrophoresed at a constant current of I SO V for 90 minutes. DNA molecular weight 
markers were also loaded on the gel for reference (Boehringer Mannheim Marker VIII). 
Fragments of DNA were then visualised by UV transillumination and photographed 
using video image capture system and thermal printer as described in above 
Genotypes were assigned on the basis of the pattern of fragments of different s1ze 
obtained following restriction endonuclease digestion ofPCR products. 
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2.9 Analysis of the IL-6 gene polymorphism 
2.9.1 The G (-174) C polymorphism 
DNA samples were taken from the DNA bank in the Molecular Medicine Laboratory. 
The G ( -174) C polymorphism of the IL-6 promoter region was amplified by PCR 
(Table 2.08) using a pair of appropriate amplimers (Table 2.09). 
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Table 2.08: The PCR contents for amplification of the IL-6 G (-174) C 
Concentration Ill Final Concentration 
Forward amplimer (10 JlM) 1.0 O.S JlM 
Reverse amplimer (10 JlM) 1.0 O.SJ.lM 
!Ox Buffer 2.0 I x Buffer 
MgCh (10 mM) 6.0 JmM 
DNTP (20 mM) O.S O.SmM 
Taq DNA polymerase (S U/Jll) 0.2 1.0 Unit 
Sterile H20 4.3 _.., _______ 
*DNA (SO ng/Jll) 3.0 ISO ng 
Total 20 
*DNA was added to individual tube separately to individual tube. 
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Table: 2. 09: The set ofamplimers and PCR condition for amplification of the JL-6 G (-174) C 
A~,P-lime_r_s ____ _ 
1 : 5 '-TTG TCA AGA CAT GCC AAA GTG C- 3 ' 
2 :5'-GGG AAA ATC CCA CAT TTG ATA A-3 ' 
PCR conditio_n ___ F_r_a_,g,_m_e_n_t_s_iz_e/.~bp...__R_e_st_n_· c_ti_o_n_e_n_d_o_nu_c_l_ea_s_e 
95°C 5 min 
95°C 60 se1 
55°C 60 sec 
72°C 60 sec 
243 
30 cycles 
Nla lli 
S' ... CATG .... .. . 3' 
3' ... .... GTAC ... S' 
Reference 
Fishman et al. 1998 
lltis table shows the set of amplimers, PCR condition, size of the fragment, as well as implemented restriction enzymes. The reference is quoted. 
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2.9.2 Agarose gel electrophoresis of the PCR products 
Following PCR amplification of the 243 bp fragment of the IL-6 gene spanning the C (-
28S) T polymorphism, the efficiency and size of the products were measured before the 
restriction site digestion process by Nla Ill. The agarose gel was prepared in exactly the 
same way as described in section 2.8.3, with the exception that the gel concentration was 
1%. 
2.9.3 The G (-174) C digestion via Nlaill endonuclease enzyme 
The PCR products were digested using Nlaiii endonuclease restriction enzyme (New 
England Biolabs, Hertfordshire, UK). S J..ll of enzyme mix [2.0 J..ll of Buffer B, provided 
by the supplier, O.SJ..ll (S units) of Nlaiii and 2.SJ..ll of sterile H20 (Baxter Healthcare, 
Thetford, UK)] was combined with 1SJ1l of each one ofthe PCR products and incubated 
at 3 7 oc for 16 h, overnight. The reaction was stopped by the addition of S J..l] of agarose 
gel loading buffer (SXTBE, O.S mol!! EDT A, 10% v/v glycerol, O.OS % w/v 
Bromophenol Blue). The restriction digest was carried out at 37°C rather than the 
optimum temperature for Nla Ill activity, 6S°C, because of undesirable Taq DNA 
polymerase activity at this temperature. At 3 7°C the restriction enzyme retained SO% of 
its activity. 
1 S J..ll of the restriction digest mixture was loaded onto a 2% w/v agarose gel and 
electrophoresed at a constant current of 1 SO V for 90 minutes. DNA molecular weight 
markers were also loaded on the gel for reference (Boehringer Mannheim Marker VIII). 
Fragments of DNA were then visualised by UV transillumination and photographed 
using video image capture system and thermal printer as described in section 2.8.3. 
Genotypes were assigned on the basis of the pattern of fragments of different stze 
obtained following restriction endonuclease digestion ofPCR products. 
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Figure 2.08: Illustration of the D..-6 G (-174) C 
G (-174) C 
...... ttgtgtcttgcgatgctaaaggacgtcattgca .. . .. . 
c 
NF-IL-6 
NRD TATA 
This figure illustrates the location of the IL-6 G ( -17 4) on the IL-6 gene and the G~C 
sequence (Adapted from Fishman et al. , 1998 with slight modification). 
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2.10 Analysis of The TGF-Pl gene polymorphism 
2.10.1 The T (+869) C polymorphism 
DNA samples were taken from the DNA bank in the Molecular Medicine Laboratory. In 
order to investigate genetic susceptibility of the TGF-~ I gene to type I diabetes, the T 
(+869) C polymorphism at codon IO in exon I of the TGF-~1 gene was amplified using 
ARMS-PCR methodology 241 bp fragment of the TGF-~ I gene signalling region 
spunning the T (+ 869) C polymorphism in codon IO which substitute Leucine to Proline 
amino acid (Table 2.1 0). The reverse amplimers were designed such that they differred 
at their most extreme 3' terminus, C substituted toT (Table 2.II). 
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Table 2.10: The ARMS-PCR contents for amplification of the TGF-J31 T(+869)C 
Concentration Ill Final Concentration 
Forward amplimer (15 IJ.M) 1.0 0.75 IJ.M 
Reverse amplimer (9 11M) 1.0 0.451J.M 
Reverse amplimer (81J.M) 1.0 0.4 I!M 
!Ox Buffer 2.0 I x Buffer 
MgCb {10 mM) 1.5 0.75 mM 
dNTP (20 mM) 0.5 0.5 mM 
Taq DNA polymerase (5 U/111) 0.2 1.0 Unit 
Sterile H20 4.3 
---------
*DNA (50 ng/IJ.l) 3.0 150 ng 
Total 20 
*DNA was added to individual tube separately to individual tube. 
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Table 2.11: The set of amplimers and PCR condition for amplification of the TGF-[31 T (+869) C 
Ampliers 
l:S'-TCC GTG GGA TAC TGA GAC AC-3' 
2 T:S'-AGC AGC GGT AGC AGC AGC A-3' 
2 C:S'-GCA GCG GTA GCA GCA GCG-3' 
ARMS-PCR 
condition 
9S°C IS sec} 
6S°C SO sec 
72°C 40 sec 
I 0 cycles 
9S°C 20 sec} 
S8°C SO sec 20 cycles 
72°C so sec 
Fragment 
Size/ bp 
241 
Reference 
Awad et al., 1998 
This table shows a set of amplimers, ARMS-PCR condition, as well as size of the fragment. The reference is quoted. The T and C amplimers are allele 
specific amplimers (ASA-). -
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2.1 0.2 Agarose gel electrophoresis of the PCR products 
Following PCR amplification, the products were monitored for quality and quantity by 
electrophoresis of an aliquot mixed with tracking dye on a 2% agarose gel (2 % w/v 
agarose in 0.5 x TBE buffer) containing 0.01% ethidium bromide. The gel was 
electrophoresed at a constant current of 150 V for 90 minutes. DNA molecular weight 
markers were also loaded on the gel for reference (Boehringer Mannheim Marker VIII). 
Fragments of DNA were then visualised by UV transillumination and photographed 
using video image capture system and thermal printer as described in section 2.8.3. 
Genotypes were assigned on the basis of the pattern of expression of the fragments as a 
result of each allele specific reaction. 
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Figure 2.09: Illustration ofthe TGF-fH T (+869) C 
Exon 1 2 3 4 5 6 7 
ARMS-PCR 
-
~ -----------------
-
-
T ( + 869) C cod on 10 (Leu~ Pro ) 
ASA-C 
ASA-T 
This figure illustrates the position of the TGF-~1 T (+869) C in the TGF-~1 gene and its 
amplification using ARMS-PCR technique. 
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.2.11 Statistical analysis 
2.11.1 Allele and genotype frequencies 
The frequency of allele and distribution of genotype of the studied cytokines in patients 
and healthy controls were calculated using l with Yates' correction with significance 
level set at p< 0.05, as appropriate. The p values were corrected for the number of 
comparisons made (Pc) was applied where appropriate using the Bonferroni inequality 
method (Tiwari and Terasaki, 1985). 
2.11.2 Hardy-Weinberg principle 
According to Hardy-Weinberg, principal allele frequencies remam constant from 
generation to generation (Hardy, 1908; Hart! and Jones, 1998). The genotype frequency 
of a gene with two alleles can be derived from known allelic frequencies which pairs in 
random mating. Considering a gene with two alleles, C and T, that have frequencies p 
and q, respectively. With random mating, the frequencies of genotypes CC, CT, and TT 
among zygotes expected: 
~pC 
pC----.qr 
CC:p2 CT: 2pq TT:q2 
p2CC 
pqCT 
pqTC 
q2TT 
The expected genotype frequency can be derived from the above formula and compared 
to the observed genotype frequencies using chi square test. Hardy-Weinberg equilibrium 
occurs if the observed frequency is not significantly different from the expected 
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frequency (p value> 0.05). This equation can be modified for polymorphisms consisting 
of 2+n alleles (Strachan and Read, 1996). 
2.11.3 Genetic profile 
In addition to analysing the genotypes for each gene, the genotypes of different genes 
were combined to give cytokine profile and analysed to determine whether the genes 
were linked and hence influence each other's expression. Individuals were considered 
for genetic pro file analysis provided they were not heterozygous at more than I locus. 
The double heterozygotes were omitted from the study. The subjective removal of the 
heterozygotes may introduce a bias if a large number of double heterozygotes are 
present, however, since this bias is likely to be consistent in both controls and patients 
the "error" is not significant. 
TDT was applied to Transmission of pathogenic alleles to offspring. Genetic profile 
frequencies were estimated using gene counting. All analyses were performed in an 
Excel spreadsheet (Microsoft, UK) using EPI-Info (EPI-Info version 6, Centres for 
Disease Control and Prevention, Atlanta, Georgia, USA). 
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3 RESULTS 
3.1 Analysis of the IFN-y locus 
3.1.1 Genotype frequency of the IFNG CA repeats 
A total of eight different sized IFNG CA repeat alleles were identified. Each of these 
alleles differed in a CA repeat (Table 3.01) and corresponded to 10-17 CA repeat 
respectively. From a total of 29 CA repeats genotypes the 3 I 3 genotype was 
significantly increased in the patients compared to the normal controls (33.6% vs 13.1% 
respectively, x.2=15.0, p= 0.0001, and Pc= 0.02) (Table 3.02). There was a significant 
decrease in the I I 2 in the patients compared to the normal controls (0% vs 6.5% 
respectively, p= 0.0002, and Pc= 0.006, Fisher exact test). A significant decrease also 
was found in the 2 I 4 and the 4 I 5 genotypes in the patients compared to the normal 
controls (0% vs 5.9% respectively with p=0.0007, and 0.4% vs 4.7% respectively with 
p= 0.0 I, Fisher exact test). There were no other significant differences between the 
patients and the normal controls (Table 3.02). To avoid complications the 3 I 3, 3 I 5, 
and 51 5 genotypes which occurred more frequently in the patients and normal controls 
were considered in the following analyses. 
3.1.2 Allelic frequency of the IFNG CA repeats 
The allelic frequency of the IFNG CA repeats were calculated using l and p values 
were corrected to the number of variables (Table 3.03). The allele 3, 122 bp, which 
consists of 12 CA repeats compared to the normal controls (51.4 % vs 31.3 % 
respectively, l= 23.61, p= 0.000001, and Pc= 0.00007). There was a significant 
decrease in the frequency of the allele 2 in the patients compared to the normal controls 
(6.7 % vs 14.0% respectively, x.2= 8.40, p= 0.004, and Pc= 0.03). There was no other 
significant differences between the patients and the normal controls. 
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Figure 3.01: Photographic presentation of the IFNG CA repeats 
2 3 4 5 6 7 
In this photo lanel= 122 I 122, lane 2= 126 I 120, lane 3= 126 I 122, lane 4= 120 I 120, 
lane 5= 120 I 120, lane 6= 126 I 122, and lane 7= 126 I 122. 
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Table 3.01: Different allele size and their CA repeat position 
Allele Size (bp) CA repeat position 
118 10 
2 120 11 
3 122 12 
4 124 13 
5 126 14 
6 128 15 
7 130 16 
8 132 17 
8 different alle1es of IFNG whose sizes differ by a CA repeat unit. 
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Table 3.02: The genotype frequency of the IFNG CA repeats in the patients and the 
normal controls 
Patients NC 
Genotype (n= 247) (n= 107) x2 p value Pc value 
n % n % 
83 33.6 14 13.1 15.0 0.0001 0.002 
3/3 
I I 2 0 0 7 6.5 0.0002 0.006 
214 0 0 6 5.9 0.0007 0.02 
415 1 0.4 5 4.7 0.01 ns 
I I 5 2 0.8 2 1.9 ns ns 
212 8 3.2 5 4.7 0.4 ns ns 
213 15 6.1 4 3.9 ns ns 
215 2 0.8 3 2.8 ns ns 
216 1 0.4 0 0 ns ns 
314 17 6.9 3 2.8 ns ns 
315 35 14.2 18 17.1 0.2 ns ns 
316 4 1.6 4· 3.9 ns ns 
317 6 2.4 3 2.8 ns ns 
318 3 1.2 4 3.9 ns ns 
414 8 3.2 3 2.8 ns ns 
416 I 0.4 2 1.9 ns ns 
4/7 0 0 1 0.9 ns ns 
418 2 0.8 0 0 ns ns 
515 27 10.9 8 7.5 1.0 ns ns 
516 3 1.2 2 1.9 ns ns 
517 6 2.4 4 3.7 ns ns 
518 I 0.4 0 0 ns ns 
616 I 0.4 I 0.9 ns ns 
617 I 0.4 1 0.9 ns ns 
618 0 0 1 0.9 ns ns 
7/7 0 0 I 0.9 ns ns 
Where 'n' for the patients and the normal controls (NC) is less than 5 Fisher exact test 
was used. 
'ns'= not significant which stands p and Pc values more than 0.05. 
The 3 I 3 was significantly increased in the patients compared to the NC, x2= 15.0, p= 
0.0001, and Pc= =0.002. 
The I I 2, the 2 I 4, and the 4 I 5 were significantly decreased in the patients compared to 
the NC, p= 0.0007, and Pc= 0.002; p= 0.0007 and Pc= 0.02; p= 0.01 and Pc= ns. 
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Table 3.03: The allelic frequency ofiFNG CA repeat in the patients and the normal 
controls 
Patients NC 
Alleles (n=494) (n=214) ·/ p value Pc value 
% % 
3 51.4 31.3 23.61 0.000001 0.00007 
(254) (67) 
2 6.7 14.0 8.40 0.004 0.03 
(34) (30) 
4 7.7 10.7 1.8 ns ns 
(38) (23) 
5 21.3 23.4 1.4 ns ns 
(105) (50) 
6 2.8 5.1 1.7 ns ns 
( 14) (11) 
7 2.6 3.7 0.3 ns ns 
(13) (8) 
8 1.6 2.8 0.6 ns ns 
(8) (6) 
NC= normal controls 
'ns'= not significant which stands p and Pc values more than 0.05. 
The allele 3 was significantly increased in the patients compared to the NC, /= 8.4, p= 
0.004 and Pc= 0.003. 
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3.1.3 The impact of gender of patients on the genetic susceptibility of the IFNG 
CA repeats 
The relationship of gender of the patients to the IFNG genotype and allelic frequencies 
was calculated (Table 3.04,3.05 respectively). No significant association was found 
between the genotype or allelic frequencies of the IFNG CA repeats and gender of the 
patients compared to the normal controls. 
3.1.4 The impact of age at onset on the genetic susceptibility of the IFNG CA 
repeats 
In order to find out the relationship of the age at onset of type 1 diabetes to the IFNG 
CA repeat polymorphism the patients were grouped according to the age at onset (that is, 
those under I 0 years, between 10-20 years, and over 20 years). There was a significant 
increase in the frequency of the 3 I 3 of the IFNG in the patients with <10 and 10-20 
compared to >20 years age at onset (37.0% vs 24.0% respectively, x2= 3.75, p= 0.05; 
38.5 % vs 24.0% respectively, x2= 7.10, p= 0.008). No other significant association was 
found between age at onset of type 1 diabetes and the IFNG CA repeats genotype 
frequency (Table 3.06). No significant association was found between the allelic 
frequency of the IFNG and the long term complications of diabetes (Table 3.07). 
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Table 3.04: The genotype frequency of the IFNG CA repeats with respect to gender 
of the patients and the normal controls 
Male Female 
Genotype Patients NC Patients NC 
(n=117) (n=47) (n=130) (n=60) 
% % % % 
3 I 3 34.2 12.8 33.1 13.3 
(40) (6) (43) (8) 
3 I 5 12.8 17.0 15.4 16.7 
(15) (8) (20) (I 0) 
5 I 5 12.0 8.5 10.0 6.7 
(14) (4) (13) (4) 
XIX 41.0 61.7 41.5 63.3 
(48) (29) (54) (38) 
No significant association was found between the IFNG CA repeats and gender of the 
patients. 
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Figure 3.05: The allelic frequency of the IFNG CA repeats with respect to gender of 
the patients and the normal controls 
Male Female 
Allele Patients NC Patients NC 
(n= 234) (n= 58) (n= 262) (n= 76) 
% % % % 
3 46.6 21.3 55.3 21.7 
(109) (20) (145) (26) 
5 23.5 17.0 19.1 15.0 
(50) {16) (50) (18) 
X 29.9 61.7 25.6 63.3 
(70) (58) (67) (76) 
x2 4.13 
p value ns 
No significant association was found between the frequency of the IFNG CA repeats and 
gender of the patients with type 1 diabetes. 
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Table 3.06: The genotype frequency of the IFNG CA repeats with respect to age at 
onset of type 1 diabetes 
Age at onset Genotype 
3/3 3/5 515 XIX 
(n= 83) (n= 35) (n= 27) (n= 102) 
% % % % 
< 10 years 36.1 28.6 25.9 33.3 
(30) (I 0) (7) (34) 
10-20 years 42.3 37.1 44.4 30.4 
(35) ( 13) (12) (31) 
> 20 years 21.8 34.3 29.6 36.3 
(18) ( 12) (8) (37) 
x2 3.31 
value ns 
No significant association was found between the distribution of the IFNG CA repeats 
genotypes and age at onset of patients with type I diabetes. 
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Table 3.07: The allelic frequency of the IFNG CA repeats with respect to age at 
onset of type 1 diabetes 
Age at onset Allele 
3 5 X 
(n= 254) (n= 105) (n= 135) 
% % % 
< 10 years 35.4 40.0 33.3 
(90) (42) (45) 
10-20 years 38.6 36.2 41.5 
(98) (38) (56) 
> 20 years 26.1 23.8 25.2 
(66) (25) (34) 
x2 0.60 
p value ns 
No significant association was found between age at onset of type I diabetes and 
distribution of the IFNG alleles. 
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3.1.5 The role of the IFNG CA repeats in the long term complications of diabetes 
To study the possible effects of the IFNG CA repeats polymorphism on the long term 
complications of diabetes, the genotype and allelic frequencies of the IFNG CA repeats 
were studied with respect to long term complications of diabetes. No significant 
association was found between the genotype or allelic frequencies of the IFNG CA 
repeats and long term complications of diabetes (Table 3.08, 3.09 respectively). 
3.1.6 The familial clustering analysis for the 3 I 3 genotype of the IFNG CA 
repeats 
In order to study the chance of familial clustering of the linked genotype of the IFNG 
CA repeats, the 3 I 3, 53 trios from the BDA-Warren family collection were genotyped 
for the IFNG CA repeats polymorphism. Forty one families were found to have at least 
one heterozygous parent for the allele 3 of the IFNG CA repeats. From 60 cases of allele 
3, 38 cases were transmitted to the offspring (Table 3.10). The TDT analysis showed a 
slight trend for preferential transmission of the allele 3 (63.3% vs 36.7%, x2= 
1.66,p=ns). 
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Table 3.08: The genotype frequency of the IFNG CA repeats with respect to the 
long term complications of diabetes 
IFNG CA repeat genotype 
Long term 3 I 3 3/5 5 I 5 
complications (n=47) (n=l8) (n=20) 
of diabetes % % % 
DC 17.8 22.2 15.0 
(7) (4) (3) 
DN 28.6 33.3 30.0 
(14) (6) (6) 
DNu 25.0 16.7 30.0 
(12) (3) (6) 
DR 28.6 27.8 25.0 
(14) (5) (5) 
DC= patients who have had diabetes for at least 20 years but remain free of retinopathy 
and proteinuria. 
DN= patients with nephropathy defined as patients who had diabetes for more than I 0 
years with persistent proteinoria over "12 months in the absence or haematoria or 
infection. 
DNU= patients with overt neuropathy defined as loss of ankle jerks, sensations of pain, 
foot ulcer and/or autonomic neuropathy. 
DR= patients with retinopathy defined as more than 5 blots or blots per eye. Hard or soft 
exudates, new vessels or flourescein angiographic evidence of maculopathy or previous 
laser treatment for preproliferative or proliferative retinopathy. 
No significant association was found between the IFNG genotype 3 I 3, 3 I 5, and 5 I 5 
distribution among different patients with long term complications of diabetes. 
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Table 3.09: The allelic frequency of the IFNG CA repeats with respect to the long 
term complications of diabetes 
IFNG CA repeat allele 
Long term 3 5 
complications (n=173) (n=76) 
of diabetes % % 
DC 22.0 21.1 
(38) (16) 
DN 9.1 22.4 
(45) ( 16) 
DNu 8.5 27.6 
(42) (21) 
DR 9.7 28.9 
(47) (22) 
DC= patients who have had diabetes for at least 20 years but remain free of retinopathy 
and proteinuria. 
DN= patients with nephropathy defined as patients who had diabetes for more than I 0 
years with persistent proteinoria over 12 months in the absence or haematoria or 
infection. 
DNU= patients with overt neuropathy defined as loss of ankle jerks, sensations of pain, 
foot ulcer and/or autonomic neuropathy. 
DR= patients with retinopathy defined as more than 5 blots or blots per eye. Hard or soft 
exudates, new vessels or flourescein angiographic evidence of maculopathy or previous 
laser treatment for preproliferative or proliferative retinopathy. 
No significant association was found between the IFNG alleles 3 and 5 and patients with 
long term long term complications of diabetes. 
152 
CHAPTER 3: RESULTS 
Table 3.10: TDT for the linkage analysis of the 3 I 3 of the IFNG CA repeats 
Transmitted Non-transmitted 
38 22 
30 30 
·l= 1.66 
p=ns 
The TDT result showed that out of 60 alleles transmitted from parents to offspring 38 
(63 %) were allele 3 which means there is a slight trend towards transmission of allele 3 
from parents tO offspring, slight preferential transmission, 38/60 VS 22/60, x2= 1.66 and 
P= ns. 
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3.2 Analysis of the IL-4 loci 
3.2.1 The C (-285) T polymorphism 
Forty five DNA samples were analysed for the C (-285) T polymorphism. Several 
different assay conditions were used in an attempt to identify the polymorphism. For 
instance, samples were incubated with the restriction endonuclease Nhel for between 1 
and 16 hours with increasing amounts of enzyme (5-25 units). No digestion was found 
and this it appears that this is a cloning defect. 
3.2.2 C (-590) T polymorphism 
3.2.2.1 Genotype and allelic frequencies of the IL-4 C (-590) T polymorphism 
The DNA samples (Table 2.01), after amplification of the PCR for the IL-4 gene 
polymorphism, were analysed for C (-590) T polymorphism. Samples were subjected to 
incubation at 37°C due to undesirable Taq DNA polymerase activity at 65°C, the 
optimum temperature for BsmFI activity. 
After 90 minutes incubation, 252 bp fragments of the IL-4 PCR product resulted in two 
fragments of 193 and 60 bp as a result of cleavage with BsmFI. The 60 bp fragment 
could not be detected due to slow rate of electrophoresis. 
As a result of cleavage of the 252 bp fragment of the ll...-4 gene, flanking the C ( -590) T 
polymorphism, with BsmFI restriction enzyme three genotypes were obtained: CC, 252 
bp; TT, 193bp; and CT, 252 bp/193 bp (Fig 3.02). 
The expected and observed genotypes of the IL-4 C (-590) T meet Hardy-Weinberg 
principle (Table 3 .12). 
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Allelic and genotype and allelic frequencies of the IL-4 C (-590) T polymorphism in the 
patients with type 1 diabetes were compared to normal controls (Table 3.11). 
No significant association was found between allelic and genotype distribution of the IL-
4 C (-590) T gene polymorphism and type 1 diabetes (Table 3.11). 
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Figure 3.02: Photographic presentation of the IL-4 C (-590) T 
1 2 3 4 5 6 7 
In this photograph lanel =DNA ladder, lane 2= CT, lane 3= TT, lane 4= CT, lane 5= TT, 
lane 6= CT, and lane 7= CC. 
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Table 3.11: The genotype and allelic frequencies of_ the IL-4 C (-590) T in the 
patients and the normal controls 
Patients NC 
Genotypes (n= 261) (n= 120) x2 p value 
% % 
cc 20.7 20.3 1.31 ns 
(54) (27) 
CT 31.8 31.6 0.25 ns 
(83) (42) 
TT 47.5 42.5 0.64 ns 
(124) (51) 
Alleles (n= 522) (n= 240) 
c 36.6 40.0 
(191) (96) 0.02 ns 
T 63.5 60.0 
(331) (144) 
No significant differences were found between the genotype or allelic frequencies of the 
patients and the normal controls. 
!57 
CHAPTER3:RESULTS 
Table 3.12: Comparison between the expected and the observed genotypes of the 
IIA C (-590) T according to Hardy-Weinberg principle 
IL-4 C (-590) T 
Hardy-Weinberg 
principle NC C (n=96) Patients C(n=191) 
T (n=144) T(n=331) 
p2+2pq+q2=1 
cc TC TT cc TC TT 
Expected Genotype 28 48 44 40 103 118 
Observed Genotype 27 42 51 54 83 124 
"/ 0.93 3.68 
p value ns ns 
The expected and observed genotypes of the IL-4 C (-590) T polymorphism in healthy 
controls and patients with type 1 diabetes meet Hardy-Weinberg principle. 
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3.2.2.2 The impact of gender of patients on the genetic susceptibility of the IL-4 C (-
590) T polymorphism 
The genotype and allelic frequencies of the IL-4 C ( -590) T were calculated among 
gender of the patients. No considerable association was found between the IL-4 C ( -590) 
T genotype or allelic frequencies and gender of the patients (Table 3.13 and Table 3.14 
respectively). 
3.2.2.3 The impact of age at onset of type 1 diabetes on the genetic susceptibility of 
the IL-4 C (-590) T polymorphism 
In order to find out the relationship of age at onset of type 1 diabetes to the IL-4 C( -590) 
T polymorphism the patients were categorised according to section 3.1.4. No significant 
association was found between the age at onset and either of genotype or allelic 
frequencies (Table 3.15 and 3.16 respectively). 
3.2.2.4 The role of the IL-4 C (-590) T polymorphism in the long term 
complications of diabetes 
To study the possible effects of the IL-4 C ( -590) T on the long term complications of 
diabetes the frequencies of the IL-4 C ( -590) T genotype as well as alleles were 
calculated (Table 3.17, 3.18 respectively). No significant association was found between 
the genotype or allelic frequencies of the IL-4 C ( -590) T polymorphism. 
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Table 3.13: The genotype frequency of the IL-4 C (-590) T with respect to gender of 
the patients and the normal controls 
Genotype Male 
Gender 
Female 
Patients 
% 
p value 
cc 
CT 
TT 
Patients 
% 
19.7 
(25) 
31.5 
(40) 
48.8 
(62) 
NC 
% 
17.6 
(9) 
35.3 
(18) 
46.6 
(24) 
20.9 
(28) 
32.8 
(44) 
46.3 
(62) 
NC 
% 
27.5 
(19) 
31.9 
(22) 
40.6 
(28) 
1.14 
0.01 
0.09 
No significant association was found between the IL-4 C (-590) T polymorphism 
genotype and genders of patients with type 1 diabetes. 
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Table 3. 14: The allelic frequency of the IL-4 C (-590) T with respect to gender of 
the patients and the normal controls 
Gender 
Male Female x2 p value 
Allele Patients NC Patients NC 
(n= 253) (n= 102) (n= 268) (n= 139) 
% % % % 
c 35.6 39.2 37.3 40.3 1.45 ns 
(90) (40) (lOO) (56) 
T 
64.4 60.8 62.7 59.7 0.15 ns 
(164) (62) (168) (83) 
No significant association was found between the allelic distribution of the IL-4C( -590) 
T polymorphism and gender of patients with type I diabetes. 
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Table 3.15: The genotype frequency of the IL-4 C (-590) T with respect to age at 
onset of type 1 diabetes 
Age at onset Genotype 
cc CT TT 
(n= 54) (n= 83) (n= 124) 
% % % 
< 10 years 35.2 33.7 33.9 
( 19) (28) (42) 
10-20 years 33.3 36: I 35.5 
(18) (30) (44) 
> 20 years 31.5 30.1 30.6 
(17) (25) (38) 
x! <0.01 
ns 
value 
No significant association was found between genotypes of the IL-4 C (-590) T 
polymorphism and age at onset of the patients with type l diabetes. 
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Table 3.16: The allelic frequency of the IL-4 C (-590) T with respect to age at onset 
of type 1 diabetes 
Allele 
Age at onset c T 
(n= 191) (n= 331) 
% % 
< 10 years 35.6 33.8 
(66) ( 112) 
10-20 years 35.6 35.6 
(66) ( 118) 
> 20 years 28.8 30.6 
(59) (I 01) 
x2 0.01 
p value ns 
No significant association was found between allelic distribution of the IL-4 C (-590) T 
polymorphism and age at onset of patients with type I diabetes 
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Table 3.17: The genotype frequency of the IIA C ( -590) T with respect to the long 
term complications of diabetes 
Long term 
complications of 
diabetes 
DC 
DN 
DNu 
DR 
cc 
(n= 31) 
% 
9.7 
(3) 
22.6 
(7) 
29.0 
(9) 
38.7 
(12) 
IL-4 C (-590) T genotype 
er 
(n= 44) 
% 
15.9 
(7) 
25.0 
(11) 
31.8 
(14) 
27.3 
(12) 
TT 
(n= 52) 
% 
15.4 
(8) 
26.9 
(14) 
25.0 
(13) 
32.7 
(17) 
DC= patients who have had diabetes for at least 20 years but remain free of retinopathy 
and proteinuria. 
DN= patients with nephropathy defined as patients who had diabetes for more than I 0 
years with persistent proteinoria over 12 months in the absence or haematoria or 
infection. 
DNU= patients with overt neuropathy defined as loss of ankle jerks, sensations of pain, 
foot ulcer and/or autonomic neuropathy. 
DR= patients with retinopathy defined as more than 5 blots or blots per eye. Hard or soft 
exudates, new vessels or flourescein angiographic evidence of maculopathy or previous 
laser treatment for preproliferative or proliferative retinopathy. 
No significant association was found between the IL-4 C (-590) T and patients with long 
term complications of diabetes. 
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Table 3.18: The allelic frequency of the IL-4 C (-590) T with respect to the long 
term complications of diabetes 
Long tenn IL-4 C (-590) T allele 
complications T c 
of diabetes (n= 106) (n= 158) 
% % 
DC 12.3 14.6 
(13) (23) 
DN 23.6 24.7 
(25) (39) 
DNu 30.2 31.6 
(32) (50) 
DR 33.9 29.1 
(36) (46) 
DC= patients who have had diabetes for at least 20 years but remain free of retinopathy 
and proteinuria. 
DN= patients with nephropathy defined as patients who had diabetes for more than 1 0 
years with persistent proteinoria over 12 months in the absence or haematoria or 
infection. 
DNU= patients with overt neuropathy defined as loss of ankle jerks, sensations of pain, 
foot ulcer and/or autonomic neuropathy. 
DR= patients with retinopathy defined as more than 5 blots or blots per eye. Hard or soft 
exudates, new vessels or flourescein angiographic evidence of maculopathy or previous 
laser treatment for preproliferative or proliferative retinopathy. · 
No significant association was found between allelic distribution of the IL-4 C ( -590) T 
with respect to the patients with long tenn complications ofdiabetes. 
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3.3 Analysis of the IL-6 Locus 
3.3.1 Genotype and allelic frequencies of the IL-6 G (-174) C polymorphism 
The DNA samples (Table 2.01) after amplification for the IL-6 gene polymorphism, the 
243 bp fragment of the PCR product was analysed for the G (-174) C polymorphism. 
After an overnight incubation, the 243 bp fragment of the IL-6 5' flanking resulted in 
fragments of 119 and Ill and a 13 bp as a result of cleavage with Nla Ill. Obviously 13 
bp could not be detected due to rate of electrophoresis and both of 119 and Ill bp 
fragments were represented as a single band due to 8 bp difference in length. 
As a result of cleavage of 243 bp fragment of the 5' flanking polymorphism of the IL-6 
gene with Nla III three possible genotypes were resulted. The GG as a homozygous for 
wild type allele, the CC as a homozygous for the lower allele, and the GC as a 
hetrozygout for both wild type and the lower.allele (Fig 3.03). 
The GG genotype was significantly increased in the patients comparing to the normal 
controls (50.6 % vs 33.3 % respectively , x2= 9.83, p= 0.002, and Pc=0.004). The CC 
genotype frequency was decreased in the patients comparing to the normal controls 
(12.5% vs 24.2% respectively, x2= 8.28, p= 0.004, and Pc= 0.008) (Table 3.19). 
The allelic frequencies of the IL-6 G ( -174) C polymorphism was calculated (Table 
3.20). The G (-174) was significantly increased in the patients while the C (-174) was 
decreased compared to the normal controls (69.1 % vs 54.6 %, and 30.9 % vs 45.4 % 
respectively, x2= 14.98, p= 0.0001). The allelic distribution of the IL-6 G (-174) C 
polymorphism showed to be significantly associated with type I diabetes. 
The expected and the observed genotypes of the IIL-6 G (-174) C polymorphism meet 
Hardy-Weinberg principle (Table 3.20). 
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3.3.2 The impact of gender of patients on the genetic susceptibility of the IL-6 G (-
174) C polymorphism 
Association of the IL-6 gene G ( -174) C polymorphism to gender was investigated. 
Gender of the patients was compared to normal controls with regard to the genotype and 
allelic frequencies of the IL-6 G ( -174) C (Table 3.21, 3.22). No significant association 
was found between either of the genotype frequency of the IL-6 G ( -174) C and gender 
of patients with type I diabetes. However, there was a significant decrease in the 
frequency of the C ( -174) in female patients compared to male (36.0 % vs 30.5 %, x2= 
5.80, p= 0.02). No other significant association was found (Table 3.22). 
3.3.3 The impact of age at onset on the genetic susceptibility of the IL-6 G (-174) 
C polymorphism 
In order to find out relationship of age at onset to the IL-6 G ( -174) C polymorphism the 
patients were grouped according to section 3.1.3. No considerable association was found 
between the IL-6 G ( -174) C genotype or allelic frequency and age at onset of type I 
diabetes (Table 3.25, 3.26 respectively 
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Figure 3.03: Photographic presentation of the IL-6 G (-174) C 
--
-- . 
-- ------
1 2 3 4 5 6 7 8 9 
In this photo lane 1 = CC, lane 2= CC, lane 3= GC, lane 4= GO, lane 5= GO, lane 6= 
GC, lane 7= GO, lane 8= GC, and lane 9= DNA ladder 
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Table 3.19: The genotype and allelic frequencies of the IL-6 G (-174) C 
polymorphism 
Patients NC 
Genotype (n= 258) (n= 120) x2 p value 
% % 
GG 50.6 33.3 9.83 0.002 
(130) (40) 
GC 37.0 42.5 1.06 ns 
(96) (51) 
12.5 24.2 8.28 0.004 
cc (32) (29) 
Allele (n=516) (n= 240) 
G 69.1 54.6 14.98 0.0001 
(356) ( 131) 
c 30.9 45.4 
(160) (109) 
A significant difference between the patients with type 1 diabetes and the normal 
controls. The GG genotype is considerably increases in the patients whereas the CC 
genotype is favoured, to an important degree, in the normal controls. 
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Table 3.20: Comparison of the expected and observed genotypes of the IL-6 G (-
174) C according to Hardy-Weinberg principle 
IL-6G(-174)C 
Hardy-Weinberg 
principle NC G(n=l31) Patients G (n=356) 
C(n=l09) C(n=l60) 
p2+2pq+q2=1 
GG GC cc GG GC cc 
Expected Genotype 36 59 25 125 110 25 
Observed Genotype 40 51 29 130 96 32 
l 1.09 ns 
p value 0.58 ns 
Both the expected and observed genotypes for the IL-6 G ( -174) C for healthy controls 
and patients with type 1 diabetes meet Hardy-Weinberg principle. 
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Table 3.21: The IL-6 genotype frequency of the IL-6 G (-174) C with respect to 
gender of the patients and the normal controls 
Male Female 
Genotype Patients NC Patients NC x2 p value 
(n= 117) (n= 45) (n=l41) (n= 75) 
% % % % 
51.3 35.6 49.6 32.0 
GG (60) (16) (70) (24) 0.3 
GC 34.2 42.2 39.7 42.7 0.1 
(40) (19) (56) (32) 
cc 14.5 22.2 10.7 25.3 1.4 
(17) (10) (IS) (19) 
No significant association was found between the IL-6 G ( -174) C and genders of 
patients with type 1 diabetes. 
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Table 3.22: The allelic frequency of the IL-6 G (-174) C with respect to gender of 
the patients and the normal controls 
Gender 
Allele Male Female x2 p value 
Patients NC Patients NC 
(n= 250) (n= 90) (n= 282) (n= ISO) 
% % % % 
G 64.0 56.7 69.5 53.3 1.18 ns 
(160) (51) (196) (80) 
c 36.0 43.3 30.5 46.7 5.80 0.02 
(90) (39) (86) (70) 
There was a considerable decrease in the C ( -174) in female patients compared to female 
normal control. 
No other significant association was found between the IL-6 G (-174) C polymorphism 
alleles and genders of patients with type I diabetes. 
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Table 3.23: The genotype frequency of the IL-6 G (-174) C with respect to age at 
onset of type 1 diabetes 
Age at onset Genotype 
GG GC cc 
(n= 130) (n= 96) (n= 36) 
% % % 
< 10 years 41.5 31.3 25.0 
(54) (30) (8) 
10-20 years 28.5 41.7 46.9 
(37) (40) (15) 
> 20 years 30.0 27.0 28.1 
(39) (26) (9) 
x2 0.82 
p value ns 
No significant association was found between the genotype frequency of the IL-6 G (-
17 4) C and age at onset of type I diabetes. 
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Table 3. 24: The allelic frequency of the IL-6 G (-174) C with respect to age at onset 
of type 1 diabetes 
Allele 
Age at onset G c 
(n= 356) (n= 160) 
% % 
< 10 years 38.8 28.8 
(138) (46) 
10-20 years 32.0 43.8 
(114) (70) 
> 20 years 29.7 27.5 
(104) (44) 
x2 0.70 
p value ns 
No significant association was found between allelic frequency of the IL-6 G ( -174) C 
polymorphism and aga at onset of type I diabetes. 
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3.3.4 The role of the IL-6 G ( -174) C polymorphism on the long term 
complications of diabetes 
To study the possible effects of the IL-6 G ( -174) C in the long term complications of 
diabetes the genotype and allelic frequencies of the IL-6 G ( -174) polymorphism among 
diabetes long term complications were calculated (Table 3.25, 3.36 respectively). 
No significant differences was found between the genotype or allelic frequency of the 
IL-6 G (-174) C in the patients with diabetes long term complications (Table 3.25, 3.26 
respectively). 
3.3.5 The familial clustering of the GG of the IL-6 G (-174) C polymorphism 
In order to study the chance of the familial clustering of the GG genotype of the IL-6 G 
( -174) C 53 trios from the BDA-Warren family collection were genotyped for the IL-6 G 
( -174) C polymorphism. Forty one families had at least one parent as heterozygous for 
the IL-6 G (-174) C polymorphism. Out of 55 cases of the G allele 32 were transmitted 
to the offspring (Table 3.30). The TDT analysis showed a trend towards the transmission 
of the G ( -174) (58.2% vs 41.8% respectively, x2= 0.44, p= ns). 
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Table 3.25: The genotype frequency of the IL-6 G (-174) C with respect to the long 
term complications of diabetes 
Longtenn IL-6 G (-174) C genotype 
complications GG GC cc 
of diabetes (n= 66) (n= 58) (n= 20) 
% % % 
DC 12.1 12.1 10.0 
(8) (7) (2) 
DN 
30.3 32.8 25.0 
(20) ( 19) (5) 
DNU 
25.8 24.1 20.0 
(17) (14) (4) 
DR 
31.8 31.0 45.0 
(21) ( 18) (9) 
DC= patients who have had diabetes for at least 20 years but remain free of retinopathy 
and proteinuria. 
DN= patients with nephropathy defined as patients who had diabetes for more than 10 
years with persistent proteinoria over 12 months in the absence or haematoria or 
infection. 
DNU= patients with overt neuropathy defined as loss of ankle jerks, sensations of pain, 
foot ulcer and/or autonomic neuropathy. 
DR= patients with retinopathy defined as more than 5 blots or blots per eye. Hard or soft 
exudates, new vessels or flourescein angiographic evidence of maculopathy or previous 
laser treatment for preproliferative or proliferative retinopathy. 
No significant association was found between the IL-6 G ( -175) C genotype and diabetic 
long tenn complications 
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Table 3.26: The allelic frequency of the IL-6 G ( -174) C polymorphism with respect 
to the long term complications of diabetes 
Long term IL-6 G (-174) C allele 
complications G c 
of diabetes (n= 170) (n= 98) 
% % 
DC 13.5 11.9 
(23) ( 11) 
DN 22.9 29.6 
(39) (29) 
DNU 28.2 22.4 
(48) (22) 
DR 35.3 36.7 
(60) (36) 
DC= patients who have had diabetes for at least 20 years but remain free of retinopathy 
and proteinuria. 
DN= patients with nephropathy defined as patients who had diabetes for more than I 0 
years with persistent proteinoria over 12 months in the absence or haematoria or 
infection. 
DNU= patients with overt neuropathy defined as loss of ankle jerks, sensations of pain, 
foot ulcer and/or autonomic neuropathy. 
DR= patients with retinopathy defined as more than 5 blots or blots per eye. Hard or soft 
exudates, new vessels or flourescein angiographic evidence of maculopathy or previous 
laser treatment for preproliferative or proliferative retinopathy. 
No significant association was found between IL-6 G (-174) C allelic distribution with 
different diabetic long term complications. 
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Table 3.27: TDT for the linkage analysis of the GG genotype of the IL-6 G (-174) C 
TDT 
Transmitted Non-transmitted 
32 23 
27 27 
p = ns 
Out of 55 cases of the G ( -174), 32 (58.2 %) cases was transmitted from parents to the 
offspring. There was a trend for preferential transmission of the G ( -174), x.2= 0.67 and 
p= ns. 
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3.4 Analysis of the TGF -~1 locus 
3.4.1 The genotype and allelic frequencies of the TGF-131 (+869) C 
The T (+869) C in the polymorphic region in exon 1 of the TGF-131 gene that results in a 
transitions of Leucine to Proline in codon 10 was accurately detected using the ARMS-
PCR methodology (Fig 3.04). The frequencies of the TT, the TC, and the CC in the 
patients with type 1 diabetes were 26.0 %, 56.0 %, and 17.5% respectively (Table 3.28). 
The expected and observed genotypes of the normal controls and the patients with type I 
diabetes meet Hardy-Weinberg principle (Table 3.29). 
The genotype and allelic distribution of the T (+869) C in the TGF-131gene were 
calculated. The frequency ofTC was significantly increased in the patients comparing to 
the normal controls (56.3% vs 39.8% respectively, x2= 8.71, p= 0.003, and Pc= 0.006). 
No other significant differences were found between the frequency of the IL-6 genotype 
in the patients as well as the normal controls (Table 3.28). No significant difference was 
found between the allelic frequency of the TGF-131 T (+869) C in the patients and the 
normal controls (Table 3.28). 
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Figure 3.04: Photographic presentation of the TGF-~1 C (+869) T 
.- T allele 
¥ C allele 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 
In this photo lane 1 represents the CC, lane 2= TC, lane 3= TT, lane 4= TC, lane 5= TT, 
lane 6= TC, lane 7= CC, lane 8= TC, lane 9= TT, lane 10= TT, lane 11= TT, lane 12= 
TC, lane 13= CC, lane 14= TC, lane 15= CC, lane 16= TT, lane 17= TT. 
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Table 3.28: The genotype and allelic frequencies of the TGF-~1 T (+869) C 
polymorphism 
Patients NC 
Genotype (n= 229) (n= 123) 
"/ p value 
% % 
TT (60) 26.2 (44) 35.8 3.52 ns 
TC 56.3 39.8 8.71 0.003 
(129) (49) 
cc 26.2 24.4 2.41 ns 
(40) (30) 
Alleles (n= 458) (n= 256) 
T 54.4 55.7 0.07 ns 
(249) (137) 
c 45.6 44.3 
(209) (109) 
The TC genotype show a significant association with type I diabetes (p=0.003). 
Although the TT genotype frequency is more in the patients than the normal controls but 
was not significant. Allelic distribution of the T (+869) C polymorphism in codon I 0 of 
TGF-~ does not show a significant association with type I diabetes. 
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Table 3.29: Comparison between the expected and observed genotypes of the TGF-
131 T (+869) C according to Hardy-Weinberg principle 
TGF-Pl T (+869) C 
Hardy-Weinberg 
principle NC T (n=137) Patients T (n=249) 
p2+2pq+q2=1 
C (n=l09) C (n=209) 
TT TC cc TT TC cc 
Expected genotype 38 60 25 67 114 48 
Observed genotype 44 49 30 60 129 40 
x2 2.00 2.00 
p value ns ns 
The expected and observed genotypes of the TGF-P 1 T (+869) C for the healthy controls 
and the patients with type 1 diabetes meet Hardy-Weinberg principle. 
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3.4.2 The impact of gender of patients on the genetic susceptibility of the TGF-Pl 
T (+869) C polymorphism 
The relationship of gender of the patients to the genotype and allelic frequencies of the 
TGF-P I T (+869) C polymorphism was calculated (Table 3. 30, 3.31 respectively). No 
significant association was found between gender of the patients and the genotype or 
allelic frequencies of the TGF-P I T (+869) C polymorphism (Table 3.30, 3.31 
respectively). 
3.4.3 The impact of age at onset of type 1 diabetes on the genetic susceptibility of 
the TGF-Pl T (+869) C polymorphism 
In order to find out the relationship of the age at onset of type I diabetes to the TGF-P I 
T (+869) C polymorphism, the patients were grouped according to the age at onset 
according to section 3.1.3. No significant association was found between the genotype 
and allelic frequencies of the TGF-PI T (+869) C polymorphism and age at onset (Table 
3.32, 3.33 respectively). 
The correlation between genotype frequency of the T ( +869) C polymorphism in exon I 
of the TGF-P I gene and gender of the study subject was studied. There has been no 
significant difference between the genotype frequencies of the T ( +869) C polymorphism 
in the TGF-plgene with regard to the gender of patients with type I diabetes (Table 
3.32). 
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Table 3.30: The genotype frequency of the TGF-JH T (+869) C with respect to 
gender of the patients and the normal controls 
Male Female 
Genotype Patients NC Patients NC x2 p value 
(n= 93) (n= 55) (n= 136) (n= 68) 
% % % % 
TT 20.4 34.5 30.1 36.8 1.00 ns 
(19) (19) (41) (25) 
TC 61.3 40.0 53.0 39.7 0.01 ns 
(57) (22) (72) (27) 
cc 18.3 25.5 16.9 23.5 0.01 ns 
(17) (14) (23) (16) 
No significant association was found between the frequency of the TGF-P1 T (+869) C 
genotype with respect to gender of the patients with type 1 diabetes. 
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Table 3.31: The allelic frequency of the TGF-~1 T (+869) C with respect to gender 
of the patients and the normal controls 
Gender 
Allele Male Female r! p value 
Patients NC Patients NC 
(n= 186) (n= 100) (n= 272) (n= 136) 
% % % % 
T 51. I 60.0 56.6 56.6 0.95 ns 
(95) (60) (154) (77) 
c 49.9 40.0 43.3 43.3 0.16 ns 
(91) (40) (118) (59) 
No significant association was found between the allelic frequency of the TGF-~ I T 
+8629) C with respect to gender of the patients with type I diabetes. 
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Table 3.32: The genotype frequency of the TGF-131 T (+869) C with respect to age 
at onset of type 1 diabetes 
Genotype 
Age at onset TT TC cc 
(n= 60) (n= 129) (n= 40) 
< 10 years 31.7 33.3 32.5 
( 19) (43) (13) 
10-20 years 41.7 37.2 40.0 
(25) (48) (16) 
> 20 years 26.6 29.5 27.5 
( 16) (38) ( 11) 
l 0.02 
value ns 
No significant association was found between genotype frequencies of the TGF-131 T 
( +869) C with respect to age at onset of the patients with type 1 diabetes. 
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Table 3.33: The allelic frequency of the TGF-131 T (+869) C with respect to age at 
onset of type I diabetes 
Allele 
Age at onset T c 
(n= 249) (n= 209) 
% % 
< I 0 years 32.5 33.0 
(81) (69) 
10-20 years 39.4 38.3 
(98) (80) 
> 20 years 28.1 58.7 
(70) (60) 
x2 0.01 
p value ns 
No significant association was found between the allelic frequency of the TGF-131 T 
(+869) C with respect to age at onset of type I diabetes. 
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3.4.4 The role of the TGF-Pl T (+869) C polymorphism on the long term 
complications of diabetes 
To study the possible effects of the TGF-PI T (+869) Con the long term complications 
of diabetes, the genotype and allelic frequencies of the TGF-PI T (+869) C were 
calculated (Table 3. 34, 3. 35 respectively). 
There was a significant decrease in the frequency of the TC in the patients with diabetic 
nephropathy compared to the diabetic control patients (17.9% vs 29.9% respectively, 
x
2
= 3.89, p= 0.05). No other significant association was found between the genotype of 
the TGF-P1 T (+869) C and the long term complications of diabetes (Table 3.34). 
No significant association was found between the allelic distribution of the TGF-P 1 ,T 
(+869) C and the diabetes long term complications (Table 3. 35). 
3.4.5 The familial clustering of the TGF-Pl T (+869) C polymorphism 
In order to study the chance offamilial clustering of the TC of the TGF-P1 T (+869) C, 
53 trios from BDA-Warren family collection were genotyped for the TGF-P1 
polymorphism Out of 58 transmitted alleles from heterozygous parents the T (+869) 
transmitted 35 times and the C (+869) transmitted 23 times. The TDT analysis show a 
significant increase in the T (29) comparing to the C (29) (60.3 % vs 39.7 % 
respectively,x2=4.17,p=0.04). 
3.5 Association of individual cytokine gene polymorphisms 
In order to aid studying individual cytokine gene polymorphisms with type 1 diabetes, 
genotype frequencies of the IFNG CA repeats, the IL-6 G ( -174) C, the TGF-P 1 T 
(+869) C, and the IL-4 C (-590) Twere grouped in Figure 3.05. 
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Table 3.34: The genotype frequency of the TGF-f31 T (+869) C with respect to the 
long term complications of diabetes 
Long term 
complications of 
diabetes 
DC 
DN 
DNu 
DR 
TT 
(n= 39) 
% 
20.5 
(8) 
33.3 
(13) 
20.5 
(8) 
25.7 
(I 0) 
TGF -f31 T ( +869) C 
TC 
(n= 67) 
% 
29.9 
(20) 
17.9 
(12) 
23.8 
(16) 
28.4 
(19) 
cc 
(n= 15) 
% 
6.7 
(1) 
33.3 
(5) 
33.3 
(5) 
26.7 
(4) 
DR= patients with retinopathy defined as more than 5 blots or blots per eye. Hard or soft 
exudates, new vessels or flourescein angiographic evidence of maculopathy or previous 
laser treatment for preproliferative or proliferative retinopathy. 
DN= patients with nephropathy defined as patients who had diabetes for more than I 0 
years with persistent proteinoria over 12 months in the absence or haematoria or 
infection. 
DNU= patients with overt neuropathy defined as loss of ankle jerks, sensations of pain, 
foot ulcer and/or autonomic neuropathy. 
DC= patients who have had diabetes for at least 20 years but remain free of retinopathy 
and proteinuria. 
There was a significant decrease in the frequency of the TC of the TGF -f31 T ( +869) C 
in the patients with nephropathy compared to the diabetic control patients (x2= 3. 92, p= 
0.04). No other significant association was found. 
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Table 3.35: The allelic frequency of the TGF-Bl T (+869) C with respect to the long 
term complications of diabetes 
Long term complications 
of diabetes 
DC 
DN 
DNu 
DR 
T 
(n= 145) 
% 
24.8 
(36) 
26.2 
(38) 
22.1 
(32) 
26.9 
(39) 
TGF-BI T (+869) C 
c 
(n= 97) 
% 
22.7 
(22) 
22.7 
(22) 
26.8 
(26) 
27.8 
(27) 
DR= patients with retinopathy defined as more than 5 blots or blots per eye. Hard or soft 
exudates, new vessels or flourescein angiographic evidence of maculopathy or previous 
laser treatment for preproliferative or proliferative retinopathy. 
DN= patients with nephropathy defined as patients who had diabetes for more than I 0 
years with persistent proteinuria over 12 months in the absence or haematuria or 
infection. 
DNU= patients with overt neuropathy defined as loss of ankle jerks, loss of pain 
sensation, foot ulcer and/or autonomic neuropathy. 
DC= patients who have had diabetes for at least 20 years but remam free fromof 
retinopathy and microalbuminoria. 
No significant association was found between the allelic frequency of the TGB-1 T 
( +869) C and the long term complications of diabetes. 
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Table 3.36: TDT for the linkage analysis of the TC of the TGF-f31 C (+869) T 
Transmitted Non-transmitted 
35 23 
23 35 
p= 0.04 
From 58 transmitted alleles of the TGF-f31 T (+ 869) C 35 (61.0 %) were allele T (+ 
869) and 23 were allele C (+ 869). The TDT result shows that there was significant 
preferential transmission ofthe TGF-131 T (+ 869) allele (x2= 4.17, p= 0.04). 
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Figure 3.05: Illustration of the association of the IFNG, IL-4 C (-590) T, IL-6 G (-
174) C, and TGF-JH T (+869) C polymorphisms with type 1 diabetes 
60~----------------------------------------------. 
50 1 p= o.oo2 
40 1 p= o.ooooo1 
30 
20 
10 
0~--,---~--~--~---.---r--~--~--~--~---,--~ 
,,., ,~ t,}~ & ,f-' c" ~ ~G c" c" G~ ~ ~-<:-~"' ~~"' ~·P ~,., ~,., ~ ,...&- ,...~~ ,...&- ~ ~ ~ 
..,._ IFN Pat -+- IFN Con -+-IL6 Pat -+-IL6 Con 
-+-TGFPat -+-TGFCon -+- IL4Pat -+-IL4Con 
This figure illustrates the individual association of this thesis candidate genes with type 
1 diabetes 
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3.6 Analysis of genetic profile 
In order to determine the relationship between cytokine gene polymorphisms with 
respect to each other, the incidence the genotypes in the patients as well as the normal 
controls were correlated. 
3.6.1 The IL-4 C (-590) T vs The IFNG CA repeats 
There was a significant increase in the frequency of the patients with the TT of the IL-4 
C (-590) T and the 3 I 3 of the IFNG CA repeats compared to the normal controls (37.2 
% vs 19.5 % respectively, x2=3.86, p= 0.05). On the other hand, there was a significant 
decrease in the frequency of the patients with the TT and the X I X compared to the 
normal controls (36.4 %vs 61.0% respectively, x2= 6.41, p= 0.0 I). No other significant 
association was found (Table 3.37). 
The IL-4 C ( -590) T and the IFNG CA repeats were analysed with respect to gender of 
the patients and the normal controls. No significant difference was found (Table 3.38). 
The IL-4 C ( -590) T and the IFNG CA repeats were analysed with respect to age at onset 
of type I diabetes. There was a significant increase in the frequency of the patients with 
the TT and the 3 I 3 genotype in the patients with < I 0 and I 0-20 years compared to > 
20 years age at onset (48.6% and 45.8% vs 22.2 %, x2= 5.81, p= 0.05). No other 
significant association was found (Table 3.39). 
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Table 3.37: Correlation between the IL-4 C (-590) T and the IFNG CA repeats 
genotypes 
IL-4 C (-590) T genotype 
IFNGCA cc CT TT 
Genotype Patients NC Patients NC Patients NC 
(n= 46) (n= 26) (n= 75) (n= 26) (n= 110) (n= 41) 
% % % % % % 
313 32.7 11.7 33.3 15.4 37.2 19.5 
(15) (3) (25) (4) (41) (8) 
3 I 5 13.0 15.4 10.7 23.1 15.5 12.2 
(6) (4) (8) (6) (17) (5) 
5 I 5 15.2 7.8 9.3 7.8 10.9 7.3 
(7) (2) (7) (2) (12) (3) 
XIX 69.1 65.3 46.7 53.7 36.4 61.0 
(18) (17) (35) (12) (40) (25) 
There was a slight increase in the frequency of the TT ofthe IL-4 C (-590) T with the 3 
13 of the IFNG CA repeats. 
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Table 3. 38: Association of the IL-4 C (-590) T and the IFNG genotype frequency with respect to gender of patients with type 1 diabetes 
IL-4 C(-590) T genotype 
IFNGCA cc CT TT 
repeat Male Female Male Female Male Female 
Patients NC Patients NC Patients NC Patients NC Patients NC Patients NC 
(n= 23) (n= 12) (n= 23) (n= 14) (n= 34) (n= 14) (n= 41) (n= 13) (n=51) (n=22) (n= 59) (n= 19) 
% % % % % % % % % % % % 
3/3 30.4 8.3 34.8 14.3 32.4 21.4 34.1 7.6 39.2 18.2 35.6 21.1 
(7) (1) (8) (2) (11) (3) (14) (1) (20) (4) (21) (4) 
3/5 17.4 16.7 8.6 14.3 11.8 14.3 9.8 30.8 15.7 13.6 15.3 10.5 
(4) (2) (2) (2) (4) (2) (4) (4) (8) (3) (9) (2) 
5/5 17.4 13.0 14.3 8.8 21.4 9.8 15.4 11.8 9.1 10.2 5.3 
(4) (0) (3) (2) (3) (3) (4) (2) (6) (2) (6) (1) 
XIX 34.8 75.0 43.6 57.1 47.1 42.9 46.3 46.2 33.3 59.1 38.9 63.1 
(8) (9) (10) (8) (16) (6) (19) (6) (17) (13) (23) (12) 
No Significant association was found. 
195 
CHAPTER 3: RESULTS 
Table 3. 39: Association of the IL-4 C (-590) T and the IFNG genotype frequency with respect to age at onset of patients with type 1 diabetes 
IFNGCA IT..,-4 C (-590) T 
repeat cc CT TT 
< 10 years 10-20 years > 20 years < 10 years 10-20 years > 20 years < 10 years 10-20 years > 20 years 
% % % % % % % % .. % 
313 46.7 27.7 21.4 33.3 39.1 28.6 48.6 40.58 22.2 
(7) (5) (3) (8) (9) (8) (18) (15) (8) 
3 I 5 6.7 16.7 14.3 12.5 8.7 10.7 16.2 13.5 16.7 
(I) (3) (2) (3) (2) (3) (6) (5) (6) 
515 13.3 16.7 21.4 12.5 14.3 8.1 10.8 13.9 
(2) (3) (3) (3) (0) (4) (3) (4) (5) 
XIX 33.3 28.9 42.9 41.7 52.2 46.6 27.1 35.2 47.2 
(5) (7) (6) (10) (12) (28) (10) (13) (I 7) 
There was a significant increase in the frequency ofthe TT and the 3 I 3 in <10 and 10-20 years compared to the patients with >20 years age at onset (48.6 
%and 45.8% vs 22.2 %, x.2= 5.81, p= 0.05). No other significant association was found. 
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3.6.2 The IL-6 G (-174) C vs the IFNG CA repeats 
The IL-6 G (-174) C genotype frequency was analysed with respect to the IFNG CA 
repeats genotype. There was a significant increase in the frequency of the patients with 
the GG of the IL-6 G (-174) C and the 3 I 3 of the IFNG CA repeats compared to the 
normal controls (41.6 % vs 18.9 % respectively, x2= 4.99, p= 0.02. This was 
accompanied by a significant decrease in the frequency of the patients with GG and the 
X I X in the patients compared to the normal controls (28.0 % vs 54.1 % respectively, 
x
2
= 8.25, p= 0.004). In addition, there was a significant increase in the frequency of the 
patients with GC and the 3 I 3 genotype in the patients compared to the normal controls 
(39.4 % vs 10.0 % respectively, x2= 9.21, p= 0.002). Finally, there was a significant 
decrease in the frequency of the patients with the GC and the X I X genotype in the 
patients compared to the normal controls (34.9 % vs 72.5% respectively, x2= 11.64, p= 
0.0006) (Table 3.40). 
The IL-6 G (-174) C and the IFNG CA repeats genotypes were analysed with respect to 
gender. No significant association was found between the frequencies of the IL-6 G (-
147) C and the IFNG in the patients and the normal controls with respect to gedender 
(Table 3.41 ). 
The IL-6 G ( -1 7 4) C and the IFNG CA repeats genotype were analysed with respect to 
age at onset of type I diabetes. There was a significant increase in the frequency ofthe 
patients with the GG and the 3 I 3 with <10 and 10-20 compared to >20 years age at 
onset (50.9% and 43.9% vs 22.6% respectively, x2= 6.61, p= 0.03). No other 
significant association was found (Table= 3 .42). 
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Table 3.40: Correlation between the IL-6 G (-174) C and the IFNG CA repeats 
genotypes 
IL-6 G (-174) C 
IFNG CA repeat GG GC cc 
genotype Patients NC Patients NC Patients NC 
(n=125) (n= 36) (n= 66) (n= 40) (n= 31) (n= 17) 
% % % % % % 
313 
41.6 18.9 39.4 10.0 29.0 18.8 
(52) (7) (26) (4) (9) (3) 
3 I 5 
15.2 16.2 13.6 12.5 9.7 25.0 
(19) (6) (9) (5) (3) (4) 
5 I 5 15.2 10.8 12.1 5.0 9.7 6.3 
(19) (4) (8) (2) (3) (1) 
XIX 28.0 54.1 34.9 22.5 51.6 49.9 
(35) (19) (23) (29) ( 16) (8) 
There is a significant association between the GG of the IL-6 G ( -17 4) C and the 3 I 3 of 
the IFNG CA repeat (x2= 4. 99, p= 0.02); there was a significant increase in the patients 
with the GC and the 3 I 3 genotype compared to the normal controls (x2= 9.21, p= 
0.002). The majority of the GG genotyped patients had the 3 I 3 of the IFNG CA 
genotype. 
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Table 3. 41: Association of the IL-6 G (-174) C and the IFNG genotype frequency with respect to gender of patients with type 1 diabetes 
IL-6 G (-174) C 
IFNGCA GG GC cc 
repeat Male Female Male Female Male Female 
Patients NC Patients NC Patients NC Patients NC Patients NC Patients NC 
(n= 60) (n= 20) (n= 65) (n= 17) (n= 33) (n= 20) (n= 33) (n= 20) (n= 16) (n= 8) (n= IS) (n= 8) 
% % % % % % % % % % % % 
313 41.7 20.0 41.5 17.6 36.4 10.0 42.4 10.0 31.3 37.5 26.7 
(25) (4) (27) (3) (12) (2) (14) (2) (S) (3) (4) (0) 
3 IS 16.7 15.0 13.8 17.6 15.2 10.0 12.1 15.0 6.3 25.0 13.3 25.0 
(10) (3) (9) (3) (S) (2) (4) (3) (1) (2) (2) (2) 
5 IS 13.3 10.0 16.0 11.8 12.1 10.0 12.1 12.5 6.7 12.5 
(8) (2) (11) (2) (4) (2) (4) (0) (2) (0) (1) (1) 
XIX 28.3 55.0 27.8 53.0 36.4 70.0 33.4 75.0 49.9 37.5 53.3 74.9 
(17) (11) (18) (9) (12) (14) ( 11) (1 S) (8) (3) (8) (S) 
No significant association was found. 
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Table 3. 42: Association of the IL-6 G (-174) C and the IFNG genotypes frequency with respect to age at onset of patients with type 1 diabetes 
IFNGCA IL-6 G (-174) C 
repeat GG GC cc 
< 10 years 10-20 years > 20 years < 10 years 10-20 years > 20 years < 10 years 10-20 years > 20 years 
(n= 53) (n= 41) (n= 31) (n= 22) (n= 23) (n= 21) (n= 7) (n= 1 0) (n= 14) 
% % % % % % % % % 
313 50.9 43.9 22.6 40.9 39.1 38.1 28.6 30.0 28.6 
(27) (18) (7) (9) (9) (8) (2) (3) (4) 
315 13.2 14.6 19.4 13.6 17.4 9.5 10.0 14.3 
(7) (6) (6) (3) (4) (2) (0) (1) (2) 
515 11.3 12.2 25.8 9.4 13.1 14.3 14.3 10.0 7.1 
(6) (5) (8) (2) (3) (3) (1) (1) (1)_ 
XIX 24.6 29.3 32.2 ·36.4 30.4 38.1 57.1 50.0 50.0 
(132 ~12) (10) (8) (7) (8) ~42 (5) ~7) 
There was asignificant increase in the frequency of the patients with the GG and the 3 I 3 in <1 0 and 10-20 years compared to the patients with age at 
onset of>20 years ( 50.9% and 43.9% vs 22.6% repectively, "!!= 6.61, p=O 03). No other significant association was found. 
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3.6.3 The IL-6 G (-174) T vs IL-4 C (-590) T 
The IL-6 G (-174) C genotype was analysed with respect of the IL-4 C (-590) T 
genotype. No significant difference was found between the frequencies of the patients 
and the normal controls (Table 3 43). 
The IL-6 G ( -174) C and the IL-4 C ( -590) T were analysed with respect to gender of the 
patients and the normal controls. No significant difference was found (Table 3.44). 
The IL-6 G (-174) C and the IL-4 C ( -590) T genotype were analysed with respect to age 
at onset of the patients. No significant association was found (Table 3.45). 
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Table 3.43: Correlation between the IL-6 G (-174) C and the IL-4 C (-590) T 
genotypes 
IL-4 C (-590) T 
Genotype 
cc 
CT 
TT 
GG 
Patients 
(n= 60) 
13.1 
(17) 
30.0 
(39) 
56.9 
(74) 
NC 
(n= 36) 
18.4 
(7) 
31.6 
(12) 
50.0 
(19) 
IL-6 G ( -17 4) C genotype 
GC 
Patients 
(n= 129) 
29;2 
(28) 
36.5 
(35) 
34.3 
(33) 
NC 
(n= 42) 
23.5 
(12) 
39.2 
(20) 
37.3 
(19) 
Patients 
(n= 40) 
25.0 
(8) 
28.1 
(9) 
46.9 
(15) 
cc 
NC 
(n= 27) 
27.6 
(8) 
34.5 
(10) 
37.9 
( 11) 
No significant association was found between the frequency oftheiL-6 G ( -174) C with 
respect tci the IL-4 C (-590) T genotype. 
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Table 3. 44: Association of the IL-6 G (-174) C and the IL-4 (-590) T genotype frequency with respect to gender of patients with type 1 diabetes 
fL-6 G (-174) C genotype 
fL-4 C (-590) T GG GC cc 
genotype Male Female Male Female Male Female 
Patients NC Patients NC Patients NC Patients NC Patients NC Patients NC 
(n= 62) (n= 18) (n= 68) (n= 20) (n= 45) (n= 24) (n= 51) (n= 27) (n= 14) (n= 16) (n= 18) (n=13) 
cc 14.5 16.7 11.8 20.0 22.2 25.6 35.3 22.2 21.4 31.3 27.8 23.1 
(9) (3) {8) (4) {10) (6) {18) (6) (3) (5) (5) (3) 
CT 29.0 38.9 30.8 25.0 40.0 37.5 33.3 40.7 28.6 37.5 27.8 30.7 
(18) (7) {21) (5) ( 18) (9) (17) (11) (4) (6) (5) (4) 
TT 56.5 44.4 57.4 55.0 37.8 37.5 31.4 37.1 50.0 31.2 44.4 46.2 
(35) (8) (39) (11) ( 17) (9) (16) (10) (7) (5) (8) (6) 
No significant association was found. 
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Table 3. 45: Association of the IL-6 G ( -174) C and the IL-4 C (-590) T genotype frequency with respect to age at onset of type 1 diabetes 
IL-6 G (-174) C genotype 
IL-4 C (-590) T GG GC cc 
genotype <10 years 10-20 years >20 years <10 years 10-20 years >20 years <10 years 10-20 years >20 years 
(n=5 1) (n= 45) (n=34) (n= 31) (n= 31) (n= 34) (n= 11) (n= 12) (n= 11) 
% % % % % % % % % 
cc 9.8 13.3 17.6 32.3 35.4 20.6 18.2 16.7 36.5 
(5) (6) (6) (10) (11) (7) (2) (2) (4) 
CT 23.5 28.9 41.2 38.7 32.3 38.2 27.3 33.3 18.2 
(12) (13) (14) (12) (10) (13) (3) (4) (2) 
TT 66.7 57.8 41.2 29.0 32.3 41.2 54.5 50.0 27.3 
(34) (26) (14) (9) (10) (14) (6) (6) (3) 
No significant association was found. 
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3.6.4 The TGF-lH vs the IFNG CA repeats 
The TGF-131 T (+869) C genotype frequency was analysed with respect to the IFNG 
genotype. There was a significant increase in the frequency of the TC in the patients 
weth the 3 I 3 genotype compared to the normal controls ( 44.7 % vs 17 .I % respectively, 
x2= 10.60, p= 0.001). This was accompanied with a significant decrease in the patients 
with the TC and the X I X genotype compared to the normal controls (29.0% vs 57.2% 
respectively, x2= 14.37, p= 0.0001). No other significant association was found (Table 
3.46). 
The TGF-131 and the IFNG genotypes were analysed with respect to gender. No 
significant association was found (Table 3. 47). 
The TGF-131 and the IFNG genotypes were analysed with respect to age at onset of the 
patients. No significant association was found (Table 3. 48). 
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Table 3.46: Correlation between the TGF-f31 T (+869) C and the IFNG CA repeats 
genotypes 
TGF-f3I T (+869) C genotype 
IFNG CA repeat TT TC cc 
Genotype Patients NC Patients NC Patients NC 
(n= 60) (n= 30) (n= I28) (n=4I) (n= 36) (n= 20) 
% % "% % % % 
3 13 30.6 I3.9 44.5 17.1 I9.4 I8.2 
(I9) (5) (57) (6) (7) (2) 
3 I 5 I6.I I9.4 IS.6 I7.I 13.9 27.3 
(10) (7) (20) (6) (5) (3) 
51 5 8.I 8.3 I0.9 8.6 I9.4 I9.I 
(5) (3) (14) (3) (7) (I) 
XIX 45.2 58.4 29.0. 57.2 47.3 45.4 
(26) (IS) (37) (26) (I6) (5) 
There was a significant association between the TC ofthe TGF-f3I T (+ 869) C and the 3 
13 ofthe IFNG CA repeat genotypes (x?= I0.60, p= O.OOI). This was accompanied by a 
significant decrease in the CA and the X I X genotypes (x2= I4.37, p= O.OOOI). No other 
significant association was found. 
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Table 3. 47: Association the TGF-131 T (+869) C and the IFNG genotype frequency with respect to gender of patients with type 1 diabetes 
IFNGCA 
repeat 
TT 
TGF-131 T ( +869) C genotype 
TC 
Female Male Female Male 
Patients NC Patients NC Patients NC Patients NC 
Male 
Patients NC 
29) (n= IS) 
% % 
(n= 31) (n= IS) (n= 62) (n= 20) (n= 66) (n= 21) (n= 17) (n= 9) 
3/3 
3/S 
S/S 
XIX 
30.0 
(9) 
16.7 
(S) 
10.0 
(3) 
43.3 
(12) 
1S.8 
(3) 
21.1 
(4) 
S.3 
(1) 
S7.8 
(7) 
No significant association was found. 
% % %% %% % 
32.3 
(10) 
16.1 
(S) 
6.S 
(2) 
4S.I 
(14) 
IO.S 43.S 
(2) (27) 
IS.8 14.S 
(3) (9) 
10.S 14.S 
( 2) (9) 
63.2 27.S 
(8) (17) 
IO.S 4S.S 
(2) (30) 
21.1 16.7 
(4) (11) 
S.3 7.6 
(1) (S) 
63.1 30.2 
(12) (20) 
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17.6 33.3 
(3) (3) 
11.8 33.3 
(2) (3) 
11.8 11.8 
(2) (2) 
S8.8 21.6 
(14) (9) 
cc 
Female 
Patients NC (n= 
(n=l9) (n=ll) 
% 
(0) 
40.0 
(2) 
(0) 
% 
21.1 
(4) 
IO.S 
(2) 
26.3 
(S) 
60,0 42.1 
(7) (8) 
% 
40.0 
(2) 
20.0 
(I) 
(0) 
40.0 
(8) 
CHAPTER 3: RESULTS 
Table 3. 48: Association of the TGF-J3l T (+869) C and the IFNG genotype frequency with respect to age at onset of patients with type 1 diabetes 
TGF-J31 T (+869) C genotype 
IFNGCA TT TC cc 
repeat < 10 years 10-20 years > 20 years < 10 years 10-20 years > 20 years < 10 years 10-20 years > 20 years 
(n= 21) (n= 17) (n= 22) (n=41) (n= 48) (n= 39) (n= 12) (n= 12) (n= 12) 
% % % % % % % % % 
3/3 31.8 38.9 20.8 40.0 49.0 33.3 16.7 23.1 15.4 
(7) (7) (5) (18) (25) (14) (2) (3) (2) 
3/5 9.1 16.7 20.8 26.7 15.7 23.8 8.3 23.1 7.7 
(2) (3) (5) (8) (5) (7) (1) (3) (1) 
5/5 9.1 12.5 8.9 9.8 11.9 25.0 7.7 23.1 
(2) (0) (3) (4) (5) (5) (3) (!) (3) 
XIX 50.0 44.4 45.9 24.4 25.5 31.0 50.0 46.1 53.8 
(10) (7) (9) (11) (13) (13) (6) (5) (7) 
No significant association was found. 
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3.6.5 The TGF-131 T (+869) C vs the IL-4 C (-590) T 
The TGF-~1 T (+869) C genotype was analysed with respect to the IL-4 C (-590) 
genotype. No significant association was found (Table 3.49). 
The TGF-~1 T (+869) C and IL-4 C (-590) T genotypes were analyse with respect to 
gender. No significant association was found (Table 3.51). 
The TGF-~1 T (+869) C and the IL-4 C (-590) genotypes were analysed with respect to 
age at onset ofthe patients. No significant association was found Table 3.52). 
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Table 3.49: Correlation between the TGF-~1 T (+869) C and the IL-4 C (-590) T 
genotypes 
TGF-~ 1 T (29) C genotype 
ll.-4 C (-590) T TT TC cc 
Genotype Patients NC Patients NC Patients NC 
(n= 60) (n= 38) (n= 129) (n= 46) (n= 40) (n= 30) 
% % % % % % 
cc 21.7 18.4 22.5 25.0 27.5 20.7 
(13) (7) (29) ( 11) (11) (6) 
CT 25.0 28.9 37.2 31.8 25.0 37.9 
(15) (11) (48) (14) (10) ( 11) 
TT 53.3 52.7 40.3 43.2 47.5 41.4 
(32) (20) (52) (19) (19) (12) 
No significant association was found between the TGF-~1 T (+869) C and the IL-4 C (-
590) T genotype frequencies. 
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Table 3. 50: Association of the TGF-131 T (+869) C and the IL-4 (-590) genotype frequency with respect to gender of patients with type 1 diabetes 
TGF-P I T (+869) C genotype 
ITA C (-590) T TT TC cc 
Genotype Male Female Male Female Male Female 
Patients NC Patients NC Patients NC Patients NC Patients NC Patients NC 
(n= 26) (n= 17) (n= 34) (n= 21) (n= 62) (n= 19) (n= 67) (n= 25) (n= 19) (n= 13) (n= 21) (n=16) 
cc 19.2 17.6 23.5 19.1 24.2 26.3 20.9 24.0 26.3 15.4 28.6 25.0 
(5) (3) (8) (4) (15) (5) (14) (6) (5) (2) (6) (4) 
CT 26.9 35.3 23.5 23.8 35.5 31.6 38.8 32.0 21.1 38.5 28.6 37.5 
(7) (6) (8) (5) (22) (6) (26) (8) (4) (5) (6) (6) 
TT 53.9 47.1 53.8 57.1 40.3 42.1 40.3 44.0 52.6 48.1 42.8 37.5 
(14) (8) (18) (12) (25) (8) (27) (11) (10) (6) (9) (6) 
No significant association was found. 
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Table 3. 51: Association of the TGF-131 T (+869) C and the IL-4 C (-590) T genotype frequency with. respect to age at onset of type 1 diabetes 
TGF-I3I T (+869) C genotype 
IL-4 C (-590) T TT TC cc 
genotype <IO years I 0-20 years >20 years <IO years I0-20 years >20 years <10 years I 0-20 years >20 years 
(n= 20) (n= I8) (n= 22) (n= 32) (n= 44) (n= 43) (n= 13) (n= 14) (n= 13) 
% % % % % % % % % 
cc 25.0 22_2 18.2 28_1 22.8 23_3 27.1 28.6 30.8 
(5) (4) (4) (9) (IO) (10) (3) (4) (4) 
CT 25.0 27.8 22.7 43.8 38.6 39.5 30.8 21.4 23.1 
(5) (5) (5) (14) (17) (17) (4) (3) (3) 
TT 50.0 50.0 59.1 28.1 38.6 37.2 46.1 50.0 46.1 
(10) (9) (13) (9) (17) (16) (6) (7) (6) 
No significant association was found. 
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3.6.6 The TGF-rH T (+869) C vs IL-6 G (-174) C 
The TGF-~1 T (+869) C genotype was analysed with respect to the IL-6 G (-I74) C 
genotype. There was a significant increase in the frequency of the TC in the patients 
with the GG compared to the normal controls (64.3 %vs 40.5% respectively, x2= 6.48, 
p= O.OI). This was accompanied by a significant decrease in the frequency of the TC 
genotype in the patients with the CC genotype comparing to the normal controls (6.2 %, 
vs 23.8% respectively, x2= 8.64, p= 0.003). No other significant association was found 
(Table 3.52). 
The TGF-~ I and the IL-6 G ( -I74) C genotypes were analysed with respect to gender. 
No significant association was found (Table 3.53). 
The TGF -~I and the IL-6 G ( -I7 4) C genotypes were analysed with respect to age at 
onset of the patients. There was a significant increase in the frequency ofthe TC and GG 
in the patients with <IO years compared to I0-20 and >20 years age at onset (70.7%vs 
63.2% and 54.5% respectively, x2= 5.90, p=0.05). No significant association was found 
(Table 3 .54). 
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Table 3.52: Correlation between the TGF-~1 T (+869) C and the IL-6 G (-174) C 
genotypes 
TGF-~1 T (+869) C 
IL-6 G (-174) C TT TC cc 
Genotype Patients NC Patients NC Patients NC 
(n= 60) (n= 36) (n= 129) (n= 42) (n= 40) (n= 27) 
GG 36.7 33.3 64.3 40.5 22.5 22.2 
(22) (12) (83) (17) (9) (6) 
GC 42.4 36.1 29.5 35.7 62.5 44.5 
(28) (13) (38) (IS) (25) (12) 
cc 20.9 30.6 6.2 23.8 15.0 33.3 
(10) ( 11) (8) ( 1 0) (6) (9) 
·There was a significant increase of the TC genotype of the TGF-~1 T (+ 869)C in the 
patients with the GG of the IL-6 G (-174) C compared to normal controls (x2= 6.48, p= 
0.0 I). There was a significant decrease in the frequency of the TC genotype in the 
patients with the CC genotype of the IL-6 comparing to the normal controls (6.2 %, vs 
23.8 %respectively, x2= 8.64, p= 0.003). No other significant association was found. No 
other significant association was found. 
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Table 3. 53: Association of the TGF-131 T (+869) C and the IL-6 G (-174) C genotype frequency with respect to gender of patients with type 1 
diabetes 
TGF-131 T (+869) C genotype 
IL-6 G (-174) C TT TC cc 
genotype Male Female Male Female Male Female 
Patients NC Patients NC Patients NC Patients NC Patients NC Patients NC 
(n= 30) (n= 18) (n= 30) (n= 18) (n= 57) (n= 19) (n= 68) (n= 22) (n=21) (n= 13) (n= 19) (n=14) 
GG 33.3 33.3 40.0 33.3 63.2 42.1 69.1 40.9 19.0 23.1 26.3 21.4 
(10) (6) (12) (6) (36) (8) (47) (9) (4) (3) (5) (3) 
GC 53.3 44.4 40.0 27.8 28.1 36.8 26.5 36.4 66.7 38.5 57.9 50.0 
(16) (8) (12) (5) (16) (7) (18) (8) (14) (5) (11) (7) 
cc 13.4 22.3 20.0 38.9 8.7 21.1 4.4 22.7 14.3 38.4 15.8 28.6 
(4) (4) (6) (7) (5) (4) (3) (5) (3) (5) (3) (4) 
No significant association was found. 
215 
CHAPTER3:RESULTS 
Table 3. 54: Association of the TGF-131 T (+869) C and the IL-6 G (-174) C genotype frequency with respect to age at onset of type 1 diabetes 
TGF-131 T ( +869) C genotype 
IL-6 G (-174) C TT TC cc 
genotype <10 years 10-20 years >20 years <10 years 10-20 years >20 years <10 years 10-20 years >20 years 
(n=22) (n= 21) (n=17) (n= 58) (n= 38) (n= 33) (n= 16) (n= 11) (n= 13) 
% % % % % % % % % 
GG 45.5 33.3 29.4 70.7 63.2 54.5 18.8 18.2 30.8 
(10) (7) (5) (41) (24) (18) (3) (2) (4) 
GC 40.9 47.6 52.9 24.1 28.9 39.4 62.4 72.7 53.8 
(9) (10) (9) (8) (11) (13) (10) (8) (7) 
cc 13.6 19.1 17.7 5.2 7.9 6.1 18.8 9.1 15.4 
(3) (4) (32 (3) (3) (2) (3) (1) (2) 
No significant association was found. 
216 
CHAPTER 4: DISCUSSION 
4 DISCUSSION 
Type I diabetes is a chronic autoimmune disease caused by the complete destruction of 
pancreatic ~ cells, resulting in an absolute lack of insulin. Both genetic and 
environmental factors might be involved in the pathogenesis of type I diabetes (Buzzetti 
et al., 1998;Rabinovitch, 1998; Kida, 1998; Friday et al., 1999). 
Several environmental factors such as infectious agents, dietary components, e.g. cow's 
milk, viruses and others exert their action on the genetically susceptible individuals and 
promote diabetes. It seems that environmental factors are associated with a large number 
of diseases. This is certainly the case for infectious diseases, even if the genetic 
background can strongly influence disease expression. The situation is very different in 
the case of diseases in which the environmental factors essentially modulate the 
expression of predisposing genes, either positively (predisposing factors) or negatively 
(protective factors). In the case of triggering factors, the disease onset is directly related 
to the encounter with the environmental factor, which can then be considered as the 
cause of the disease. In the modulation hypothesis, the disease appears only in the 
fraction of the population at genetic risk and it is on this population that environmental 
factors exert their positive or negative effects. According to the available data type 
diabetes is of the second category (Songini and Mountoni, 1991 ). 
In addition, evidence has been collected which suggests that genetic factors may play a 
primary role in the onset of diabetes and its progression (Buzzetti et al., 
1998;Rabinovitch, 1998; Kida, 1998; Friday et al. 1999): Twin studies, familial 
clustering, HLA association, and novel non-MHC susceptible genes for the disease all 
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provide evidence for a genetic background to the disease by investigating the whole 
genome approach. It is well recognised that type I diabetes is a polygenic disease and 
the disease cannot be classified according to specific model of recessive, dominant, or 
intennediate inheritance (see also chapter one, 1.6.4). In addition, the disease-
susceptibility genes are highly polymorphic, with a number of different allelic variants 
that are associated with the disease. 
Genome-wide scans leading for linkage of certain chromosome regions with type I 
diabetes in affected sib-pair families have revealed that the major susceptibility locus 
resides within the major histocompatibility complex (MHC) or the HLA on chromosome 
6p21. It is recognised that the HLA contains multiple susceptibility loci- IDDM 1, 
including the class II genes, which control the major pathological features of the disease: 
T cells mediated autoimmune destruction of the insulin producing pancreatic ~-cells . 
. However, a second locus, the insulin gene minisatellite VNTR, on chromosome 11 p 15 
known as !DDM2 also offers susceptibility. Although the association of certain HLA 
alleles with type I diabetes is very strong, this genetic locus is estimated to account for 
less than 50 % of genetic contributions to the disease susceptibility (Todd,2000). The 
search for non-HLA susceptibility genes has received great attention in recent years. 
Although genome wide searches are frought with controversy, such studies have 
suggested the association of numerous non-MHC loci with type I diabetes that will 
require careful follow-up investigation (Todd, 1998; Todd, 2000; Pugliese and 
Eisenbarth, 2000). 
Non-MHC polymorphisms have been shown to override the susceptibility to an 
autoimmune disease provided by pathogenic HLA haplotypes (Verdaguer et al., 1999). 
218 X 
CHAPTER 4: DISCUSSION 
Cytokines, due to their role in the immune system, are thought to be an important in the 
destruction of pancreatic islet P cells and immune regulation (Rabinovitch, 1998). There 
is now clear evidence that cytokine gene polymorphisms may alter the production of that 
particular cytokine. 
Consequently polymorphisms can alter the functions of these genes. As cytokines play 
an important role in the pathogenesis of type I diabetes, given the relative position of 
type I diabetes susceptibility towards cytokine gene polymorphism, major hurdles in 
understanding the role of the identified genes in defining genetic susceptibility, as well 
as their function, lie a head. 
Further, as cytokines form part of a signalling network and gene polymorphisms can 
alter their function, it can be postulated that genetic polymorphism in one cytokine can 
alter the function of that cytokine which may lead to interruption of the immune system, 
hence the disease susceptibility. 
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4.1 Amplification of cytokine gene polymorphism 
Signalling between cells of the immune system takes place both by direct cell-cell 
interactions involving surface molecules on the interacting cells and by cytokines. In 
association with hormones and neurotransmitters, cytokines form a chemical signalling 
system that regulates development, tissue repair, and the immune response (Thompson, 
1998). In parallel with other signals arising from cell-cell or cell-antigen contacts 
cytokines provide a network controlling both innate or specific immune responses, 
including inflammation, defence against virus infection, proliferation of specific T- orB-
cell clones, and regulation of their functions. 
More than thirty years ago investigations were stated into finding polymorphisms in the 
genetic structure of cytokines (Rabinovitch, 1998; Thompson, 1998). To date there are 
many repeats of cytokine gene polymorphisms. Some of these gene polymorphisms have 
been shown to influence genetic susceptibility and progression of diseases. It is well 
documented that cytokines may play a great role in the onset of type I diabetes and its 
progression. The role of ILl p and a, IL-l ra, and TNF-aJP is well documented, section 
1.7. In this study the genetic susceptibility of the IFN-y CA repeat, the IL-4 C (-590) T, 
the IL-6 G (-174) C, and the TGF-PI T (+869) C polymorphisms in patients with type I 
diabetes were investigated. 
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4.2 Cytokines as the immunogenetic markers for type 1 diabetes 
4.2.1 IFN-y, the THl cytokines profile inducer 
In the present study a strong association within the first intron of the IFN-y gene and 
type 1 diabetes was found . The association between the IFN-y gene and type 1 diabetes 
had previously been studied by Awata and colleagues (1994). 
Evidence was found for an association of the CA repeat polymorphism within the first 
intron of the IFN-y gene and type 1 diabetes. Of 3 different studies investigating the 
association of the IFNG CA repeat and type 1 diabetes, only one, Pociot and colleagues 
have reported positive association in a Finnish, but no association in a Danish population 
(Pociot et al., 1997). This study confirmed that the IFNG CA repeat is an octa allelic 
polymorphism. The allele 3 showed a significant association with type I diabetes. 
This was in contrast to the original report describing the polymorphism (Ruiz-Linares, 
1993), where 6 alleles were reported with the apparent lack of the allele numbers 5 and 
8, according to the present nomenclature. The study was based on analysis of 54 
chromosomes of unrelated individuals of African, Asian, and European origin (Ruiz-
Linares, 1993). In the Japanese population the presence of 8 alleles were reported 
(Awata et al., 1994). However, the exact length of PCR-identified alleles, or the number 
of CA repeats of different alleles were not reported, and comparison of data, including 
evaluation of the type 1 diabetes association, from different studies is, therefore, 
difficult. In Danish and Finnish populations 5 alleles were reported where alleles number 
I, 7, and 8 (of the present nomenclature) were not identified (Pociot et al., 1997). Pociot 
and his eo-workers have reported a significant association between allelic and genotype 
frequencies of the IFNG CA repeats polymorphism and type 1 diabetes in Finnish 
population. However, they claimed no association between the IFNG CA repeat 
polymorphism and type I diabetes in Danish population. Further, they have concluded 
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that this CA repeat polymorphism can differ according to ethnic groups. In Spanish 
population 8 alleles were identified and this polymorphism was associated with type I 
diabetes (Gallart et al., 1998). Recently the IFNG has been studied in British patients 
with pancreatitis and 8 alleles were identified. The allele 3 and 5 has been associated 
with the disease (O'Reilley et al., 2000). 
Although Awata and colleagues reported a significant association of the IFNG CA 
repeat with type I diabetes in young-onset patients (<10 years) no significant difference 
was found between the age at onset of the patients with type I diabetes and the IFNG 
CA repeat polymorphism. The results may reflect differences in the incidence of long 
term complications. 
The TDT result from the 3 I 3 genotype of the IFNG CA repeats showed a trend of 
transmission of the allele 3 from the parents to the offspring. However, a larger study is 
required to draw a familial clustering conclusion. 
Further, the presence of IFN-y in diabetes is well documented and it is believed that 
IFN-y plays a role in the pathogenesis of type I diabetes. This genetic susceptibility 
confirms the existed reports on the genetic susceptibility of the IFNG CA repeat and 
attest that the 3 I 3 genotype and the allele 3 is significantly associated with the disease. 
One should be cautious about the positive association, since multiple factors could give 
erroneous associations. However, a sufficient number of patients with type I diabetes 
and healthy controls were analysed. 
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The IFN-y production was associated with the IFNG CA repeat polymorphism (Pravica 
et al., 1999). Pravica and colleagues studied this microsatellite region of the IFN-y gene 
in 164 healthy individuals and showed that IFN-y production was significantly 
associated with allele 3. 
4.2.2 IL-4, the TH2 cytokine profile inducer 
There was no Nhel restriction endonuclease site in the PCR products at -285 bp. 
Arai and colleagues have previously reported that the 5' -flanking sequence plays a 
pivotal role in regulated expression of IL-4 during T cell activation. Since -285 bp 
position is in this region, any polymorphisms here could effect the expression of the IL-4 
gene (Arai et al., 1989). The results presented here suggests that there is no 
polymorphism at -285 bp. It has been suggested by other groups that this is due to a 
cloning artefact (Professor P Mathesien, University of Bristol, 1997). 
There has been no prevoius studies between the IL-4 C ( -590) T polymorphism and type 
I diabetes. Since the IL-4 C ( -590) T has been reported to be linked to the IL-4 function 
it suggests that IL-4 may not have a significant role in the pathogenesis of type 1 
diabetes. However, IL-4 has been implicated in the pathogenesis of experimental 
diabetes (Rapport et al., 1993; Mueller et al., 1996; Mueller et al., 1997; Rabinovitch, 
1998). This can be explained by the cross regulatory effect of TH1/TH2 phenomenon 
where TH2 or IL-4 and IL-10 production would be initiated as a result of the increase in 
TH I cytokine profile. Recently, Leech and colleagues have studied in vivo activated 
circulating T cells in type I diabetes. They reported the lack of TH2 cytokines in type I 
diabetes and concluded that IL-4 and IL-l 0 production in newly diagnosed type 1 
diabetic patients may represent an attempt at immunoregulation of active insulitis (Leech 
et al., 1999). 
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Although several earlier studies (Copeman et al., 1995; Pociot et al.,l992; Pociot et al., 
1993; Pociot et al., 19941; Mandrup-Poulsen et al., 1994; Metcalfe et al.,l995) reported 
possible association ofTNF-aJP, IL-Ia and p, IL-l ra, and IFN-y gene polymorphisms, 
this is the first report about the IL-4 C ( -590) T polymorphism in patients with type I 
diabetes. No significant association was found between the IL-4 C ( -590) T 
polymorphism and type I diabetes. 
4.2.3 IL-6, a multifunctional cytokine released by macrophages 
These results suggest that the IL-6 gene may be involved in the susceptibility to type I 
diabetes. This is the first study investigating the IL-6 gene in this disease. The in vitro 
production of IL-6 protein following the stimulation of monocytes from patients with 
type I diabetes with lipopolysaccharide has been found together with low levels of IL-l. 
It has been suggested that this may be due to an immunological defect (Ohno et al., 
1993). In the NOD/Wehi mouse model of type I diabetes the disease can be prevented 
by treatment with anti-IL-6 antibodies whilst IL-6 can be detected in the islets of the 
animals (Campbell et al., 1991 ). 
The G ( -174) C polymorphism has been studied in patients with juvenile chronic arthritis 
where an increase in the frequency of the GC genotype was found compared to normal 
controls (Fishman et al., 1998). Functional studies using luciferase reporter assays with 
the IL-6 promoter containing either the G ( -174) or C ( -174) allele showed that the G (-
I 74) was far more efficient than the C (-1 74) construct. This was reflected in the plasma 
levels of IL-6 in normal controls where those individuals with the CC genotype had the 
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lowest level whilst those with the GG genotype had the highest. In this study it was not 
possible to measure plasma levels of IL-6 in either the patients or nonnal controls. Also, 
there is a suggestion that hyperglycaemia may stimulate IL-6 release and consequently 
measuring the levels of this cytokine in plasma is difficult (Kato et al., 1997). In 
conclusion, in this thesis the results suggest rthat the IL-6 G ( -174) C may be implicated 
in the genetic susceptibility to type I diabetes. 
4.2.4 TGF-~1, the immunosuppressor cytok.ine 
TGF-~1 is a multifunctional cytokine that regulates the proliferation and differentiation 
of a variety of cell types in vitro. The importance of TGF-~ 1 in immune regulation and 
tolerance has been increasingly recognised. It is now proposed that there are populations 
of regulatory T cells (T-reg) which are also categorised as TH3 that exert their action 
primarily by secreting this cytokine. 
Type 1 diabetes is an immune derived disorder which is caused by the destruction of 
pancreatic ~ cells. It is well documented that diabetes is a cell mediated disease in which 
THI cells are dominant. TH3 or immunosuppressive cytokine, namely TGF-~1, is a 
possible cytokine to play its role in the maintenance of TH I I TH2 cytokine profile. 
The possible genetic association of the TGF-~ 1 T (+869) C polymorphism in the intron 
I of the gene was studied by screening the patients with type I diabetes and the nonnal 
control subjects for the latter polymorphism. There was a significant association between 
the TC genotype with type I diabetes. Allelic frequencies of the TGF-~1 T (+869) C 
polymorphism showed no considerable association with type 1 diabetes. The TDT result 
for the TC genotype of the TGF-~1 T (+869) C showed a significant increase in the 
transmission of the T (+869) than the C (+869). However, a larger study is required to 
draw a familial linkage conclusion. 
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Pociot et al., 1998 have studied the association of the C (76) T and 713-8delC 
polymorphism in the TGF-P I gene with type I diabetes. These researchers have shown 
that there has been no genetic association between the latter polymorphisms and type I 
diabetes in general. However, they have reported a weak but significant association of 
the C (76) T polymorphism in the TGF-P I gene with diabetes nephropathy (Pociot et al., 
1998). 
In order to examine the strength of the susceptibility of the T (+869) C polymorphism of 
the TGF-P I gene with long-term diabetic complications, this polymorphism has been 
studied in patients with diabetic nephropathy, retinopathy and neuropathy. Meanwhile, a 
group of patients with type I diabetes who show no complications after 20 years of the 
disease, was also studied. A significant decrease was found in the frequency of the TC in 
the patients with diabetic nephropathy compared with the diabetic controls. This 
decrease was counteracted with a slight increase in the frequency of the TT. No other 
significant association was found between the T (+869) C polymorphism in the TGF-PI 
diabetes long term complications. These findings reflect the a possible role of the TGF-
p I T ( +869) C gene polymorphism in the diabetic nephropathy that confirms the 
available expression studies. However, a large scale study is required to draw such 
conclusion. 
TGF-P I is synthesised as a latent protein composed of 390 amino acids (Derynck et al., 
1985; Lyons et al., 1990). The amino acid sequence of the active TGF-P I is highly 
conserved across mammalian species, indicating a strong selection against variant forms 
of the protein. However, variations in the constitutive or induced expression of the 
protein as a consequence of variability with different effects of TGF-P I on cellular 
functions (Cambien et al., 1996). The Leu (+869) Pro polymorphism of TGF-PI is 
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located in the 29-residue signal peptide sequence which functions to translocate newly 
synthesised proteins (Vemer, 1988). An increase in glucose serum level, which is the 
hallmark of diabetes, would enhance TGF-~ I production in order to stimulate glucose 
uptake. However, the T (+869) C polymorphism in the signal sequence of the TGF-~1 
gene which results in a Leu~Pro substitution in amino acid I 0 possibly affects the 
function of the signal peptide in the TGF-~ I gene, hence, TGF-~ I protein synthesis. 
To date there has been no association study on the TGF-~ I gene polymorphism with 
type I diabetes except the C (73) T and 713-8del C polymorph isms in the TGF-~ I gene 
(Pociot et al., 1998). Since the CT genotype of the T ( +869) C polymorphism in ex on I 
of the TGF-~ I gene is significantly associated with type I diabetes it is unlikely that 
there is a linkage disequilibrium between the T (+869) C polymorphism and either 713-
. 8del C or C (76) T. 
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4.3 Correlation studies between cytokine gene polymorphisms 
studied in this thesis 
The function of cytokines in the immune system is a complex process. Although several 
studies provided evidence for the influence of gene polymorphism in cytokine genes and 
their function (Cookson and Walley, 1996; Fishman et al., 1998; Awad et al., 1998; 
Pravica et al., I 999) genetic profile in this thesis provide evidence where the production 
and function of an individual cytokine may not be only influenced by their genetic 
structure. However, cytokines are a complex network which seem to influence one 
another function. 
The frequency of the TT of the IL-4 C ( -590) T showed a significant increase in the 
patients with the 3 I 3 of the IFNG CA repeats compared to the normal controls, and a 
remarkable decrease in the TT with the X I X. The frequency of the patients with the GG 
and the GC of the IL-6 G (-I 74) C was increased significantly in the patients with the 3 I 
3 compared to the normal controls; a remarkable decrease was found in the frequency of 
the GG and the GC in the patients with the X I X. There was also a significant increase 
in the frequency of the TC of the TGF-~1 T (+869) C in the patients with the 3 I 3; and a 
remarkable decrease in the frequency of the TC in the patients with the X I X compared 
to the normal controls. No significant association was found between the IL-6 G (-1 74) 
C and the TGF-PI T (+869) C with the IL-4 C (-590) T gene polymorphisms genotype. 
A significant increase was found between the TC of the TGF-~ I and the GG of the IL-6. 
On the other hand, the frequency of the TC decreased significantly in the patients with 
the CC of the IL-6. A significant increase was found in the frequency of the patients 
with the GG of the IL-6 and the 3 I 3 of the IFNG with <10 and 10-20 compared to >20 
years age at onset. A significant association was found between the frequency of TC of 
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the TGF-P I in the patients with the GG of the IL-6 with <I 0 compared to I 0-20 and >20 
years age at onset. No significant association was found between the genotypes of the 
TGF-J31 and the IFNG, the TGF-p I and the IL-4, and the IL-6 and the IL-4 genotype 
frequencies according to age at onset. 
The results of the correlation studies signify that the genetic susceptibility of cytokines 
to the disease might be influenced by age at the onset of type I diabetes of the patients. 
The factor of age which were reported by Japanese (Awata et al., 1994; Kida et al., 
I 999) showed to influence the genetic susceptibility of cytokine gene polymorphism in 
this study as well, though it did not show a significant association in individual cytokine 
gene polymorphism studies in this thesis. 
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4.4 Type 1 diabetes pathogenesis model based on this thesis findings 
Based on the results of this study and the evidence reviewed in this thesis a model for 
the pathogenesis of type I diabetes is depicted (Figure 4.0 I). 
The process of destruction of P-cells which results in type 1 diabetes is believed to be 
the result of a disorder of immunoregulation. It is hypothesised that the environmental 
factors trigger the pathogenetic process by causing a restricted and focal beta-cell 
damage leading to the release of either modified or previously secluded beta-cell 
antigen. These antigens are taken up by APC recruited to the islets and accordingly the 
antigen is introduced to the THO which according to the immunogenic signals provided 
by the APC would deviate the TH 1 I TH2 cytokine profile towards TH 1 cytokines 
production. Accordingly, THI cytokines-IFN-y, TNF-p, dominate over TH2 cytokines 
IL-4 and IL-l 0. This allows TH 1 cytokines to initiate a cascade of 
immune/inflammatory processes in the islet (insulitis). Upon the interruption of the TH 1 
I TH2 balance TH3 or regulatory T cells are recruited to produce the immunosuppressive 
cytokine, TGF-PI. Association of the TC genotype of TGF-P1 T (+869) C 
polymorphism with type I diabetes and its association with low production of TGF-P1 
could give a clue for this deviation of the TH 1 I TH2 cytokine profile. IFN-y activates 
cytotoxic T cells that interact specifically with P-cells and destroy them, and initiates the 
production of IL-l, TNF-a, and IL-6 as well as oxygen and nitrogen free radicals by 
macrophages that are highly toxic to islet P-cells. 
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Figure 4.01: Presentation of the immunogenetic of cytokines in the pathogenesis of 
type 1 diabetes 
..---
/ '\ \. J_. 
' / -
Type 1 Diabetes 
Modifications of the existing model for type 1 diabetes pathogenesis. fl-Ag: the fl-
cell antigen is presented through APC: antigen presenting cells via the MHC class 
11 to THO: the precursor T -helper cells which would be producing THl or TH2: T-
helper 1 and T -helper 2 subsets. The immunogenic signals produced by the fl-cell 
antigens induce production of THl which lead to production of THl cytokine 
profile and deviation of the TH1 I TH2 cytokine profile balance. This deviation 
initiates THO to produce regulatory T subset, TH3. TH3 produce mainly TGF-fl1 
cytokine which acts as the immunosuppressor or regulator cytokine. Meanwhile 
THl cytokines, IFN""Y, TNF-fl would be released. IFN-y initiates macrophages to 
produce its cytotoxic activity by production of IL-l, TNF-a, and IL-6. At the same 
time, produce o-, NO- which are highly toxic to the islets fl-cells. IFN-yalso initiates 
cytotoxic T -cells, CDS+, which attacks fl-Ag via the MHC class I. All of these factors 
contribute to the destruction of pancreatic fl-cells and progression of type 1 
diabetes (Rabinovitch, 1994 with modification). 
231 
CHAPTER 4: DISCUSSION 
4.5 Conclusion 
Type I diabetes is associated with altered humoral and cellular immunity. This is 
demonstrated by the presence of autoreactive antibodies targeting ~-cell constituents and 
other autoantigens, circular autoreactive T cells, and expression of adhesion molecules. 
In particular, type I diabetes was associated with altered regulation of cytokine 
expression manifested in part by reduced levels of serum cytokine inhibitors coupled 
with sustained expression of proinflammtory and immunoregulatory cytokines. The 
development of hyperglycaemia, a hallmark of type 1 diabetes, appears later in the 
course of the disease, frequently following months or years of the initiation ofthe T cell-
targeted autoimmune destruction of islet ~ cells. 
The exact role ofT cell and macrophages derived cytokines play in the pathogenesis of 
type 1 diabetes remain the subject of intense investigation. Conclusions reached were 
largely based on studies on the genetically type 1 diabetes-predispose animals: Based on 
these and other studies, cytokines were shown to induce or exacerbate type I diabetes 
through direct and indirect mechanisms. 
Although it is accepted that type I diabetes resulted from altered balance between TH1 I 
TH2 cells, the exact roles of TH I and TH2 as well as TH3 subsets play in type I 
diabetes pathogenesis remain to be established. 
In this study, association of human TH1-, TH2-, macrophage-, as well as TH3-derived 
cytokines gene polymorphisms with type 1 diabetes were studied. The CA repeat 
polymorphism in the first intron of IFN-y has shown a significant association with type 1 
diabetes. The IL-4 C (-590) T polymorphism showed no association with type I 
diabetes. The G ( -174) C polymorphism in the IL-6 gene has also shown to be 
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significantly linked to type I diabetes. The T (+869) C gene polymorphism in the TGF-~ 
gene has shown to be significantly associated with type I diabetes. 
IFN-y is the initiator of TH I cytokine profile and also it inhibits TH2 cytokine profile. 
The association of the CA repeat in the IFN-y gene with type I diabetes defines the role 
of TH I in the onset of type I diabetes. The IL-4 C ( -590) T gene polymorphism did not 
show a significant association with type I diabetes. From the point that IL-4 plays an 
important role in the initiation of TH2 cytokine profile and inhibition of THI cytokines, 
it seems that TH2 has hardly to do anything in the type I diabetes. However, due to the 
cross regulatory effect of THI I TH2 cytokine profile it seems that IL-4, which is the 
initiator of TH2 cytokines and induces TH I cytokine, could be released to maintain the 
balance during the early phases of type I diabetes, which would be suppressed later in 
the course of the disease1• The IL-6 G ( -174) C gene polymorphism was significantly 
associated with type I diabetes. Last but not least, the T (+869) C polymorphism in the 
TGF-~ I gene also showed a significant association with type I diabetes. According to 
the mentioned hypothesis, TGF-~ I which is a regulatory or a immunosuppressor 
cytokine produced by TH3 may get into action when the cross regulatory effects of IL-4 
is suppressed. 
Although familial clustering towards the transmission of the linked cytokine gene 
polymorphisms studied in this thesis suggest a relative association with the susceptibility 
to type I diabetes in order to draw a conclusion a larger scale study is required. 
Genetic profile studies showed to be significantly valid to verify genetic linkage between 
genes located on different chromosomes. The correlation of the TT genotype of the IL-4 
1 A proposal was submined to DrAG Demaine in June 1999 referred to the postulated issue. 
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C ( -590) T with the 3 I 3 genotype of the IFNG but not with the IL-6 G ( -174) C and the 
TGF-~1 T (+869) C suggests that, in spite of lack of association between the IL-4 C (-
590) T polymorphism with type 1 diabetes, its genotype is correlated to the IFNG 
polymorphism. The lack of correlation between the IL-4 C ( -590) T and the IL-6 G (-
174) Cas well as the TGF-~1 T (+869) C may be due to some immunological processes 
which must be investigated. 
Age at onset of type I diabetes was not related to individual cytokine gene 
polymorphisms. it may be related to certain cytokine gene profile. 
No association was found between cytokine gene po1ymorphisms and gender of the 
patients. 
Cytokine gene polymorphisms, which were studied in this thesis, were shown to have a 
functional impact on their expression (Cookson and Walley, 1996; Fishman et al., 1998; 
A wad et al., 1998; Pravica et al., 1999). However, genetic profile results of this thesis 
provide evidence for the impact of age at onset on the frequency of cytokine gene 
polymorphism genotype, hence cytokine function. Gender of the patients did not show 
any impact on the frequency of individual cytokine gene polymorphism in the patients 
apart from a significant increase of the C ( -174) of the IL-6 in the females normal 
controls. The correlation studies in this thesis provide further evidence of the impact of 
cytokine gene polymorphism on each other, ie the TT of the IL-4 C ( -590) T and the 3 I 
3 of the 1FNG CA repeats. This may explain cytokine network system. These results 
could add a new edition to the impact of cytokines in type 1 diabetes pathogenesis. 
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These results provide a human case evidence for the role of TH 1-, TH2-, TH3-, and 
macrophages-derived cytokines in the onset of type I diabetes and its progression. The 
association of the IFN-y CA repeat gene polymorphism with type 1 diabetes was under 
debate, this data could confirm the association of the IFNG with type I diabetes and the 
lack of ethnicity which was raised by Pociot and colleagues (Pociot et al., 1997). 
The association studies of the IL-4 C (-590) T, the IL-6 G (-174) C, and the TGF-P1 T 
(+869) C gene polymorphisms with type 1 diabetes are the first case study reports. One 
should be cautious about the positive association, since multiple factors could give 
erroneous associations. However, enough normal controls and patients with type I 
diabetes were analysed. 
"If we stop asking the question 'what breaks tolerance' and begin to focus on the vast 
array of possibilities for each disease, we may begin to understand their multigenic 
nature" (Matzinger, 1998). 
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4.6 Future considerations 
It is well known that type I diabetes is caused by an immune-mediated destruction of 
pancreatic islet P-cells. Recent studies have shown that genes outside of the HLA region 
are involved in determining susceptibility to type I diabetes. It is now known that 
polymorphisms in the coding and non-coding regions of the genes encoding cytokines 
may contribute to the susceptibility to autoimmune diseases as well as influencing the 
immune response to foreign antigens. There are few studies on the role of cytokines in 
. human type I diabetes. Candidate genes implicated in the susceptibility to type I 
diabetes have been selected on the basis of our knowledge of the pathogenesis of type I 
diabetes and its long term complications. 
Investigating the role of cytokine gene polymorphisms of TH I, TH2, TH3, and 
macrophages origin in the understanding of the pathogenesis of type I diabetes and its 
long term complications is an urgent need in the understanding of the pathogenesis of 
type 1 diabetes. Single nucleotide polymorphisms (SNPs) are major contributors to 
genetic variation as they comprise more than 80 % of all known polymorphisms and 
their density in the human genome is about one in every 300 to 500 base pairs (Wang et 
al., 1998; Collins, 1999). They are mostly biallilic and consequently less informative 
than mocrosatellite markers, although they are more frequent and mutationally more 
stable which makes them suitable for association studies. Some SNPs may contribute 
directly to a trait or disease phenotype by altering gene expression or protein function. 
The susceptibility ofthe IFNG CA repeats, the IL-4 C (-590) T, IL-6 G (-174) C, and the 
TGF -PI T ( +869) C have been accomplished using case control and family based parent 
offspring trios studies. 
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Interleukin- I 2 seems to play important role in initiating the cytokine network in type I 
diabetes. Recently a polymorphism is reported in the promoter region of the IL-12 gene 
(Pravica et al., 2000). Investigating the association of this polymorphism with type 
diabetes can help in better understanding of type I diabetes pathogenesis. 
To correlate the cytokines gene polymorphism association to type I diabetes and its 
complications it seems necessary to investigate the latter genetic association to cytokines 
protein secretion. To determine the role of cytokines in type I diabetes the elevation in 
bioactivity of each cytokine at different stages of the disease ie newly diagnosed, 
patients with history and each of complications could be defined by measuring their 
protein levels in serum. 
To accomplish such a project the following is require: 
• Peripheral blood of the follwing. 
a) newly diagnosed patients 
b) patients with Nephropathy 
c) patients with Retinopathy 
d) patients with Neuropathy 
• Immunoassays to measure IL-4, IL-6, IL-12, IL-l, TGF-~, and IFN-y. 
Further, to fulfil this study it seems necessary to find out how the cytokine network is 
initiated and how antigen switches on Th I mediated cytokine profile in type I diabetes. 
For example, the role of IL-12 in initiation of Th I cytokine network or the role of IL-6 
in preceding insulitis by measuring NFKB. 
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